日本臨牀　68/増刊10　新時代の脳腫瘍学

出版社： 日本臨牀社
発行日： 2010-12-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 新時代の脳腫瘍学―診断・治療の最前線―
電子書籍版： 2010-12-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

15,400 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

15,400 円(税込)

購入する

目次

  • 日本臨牀　68/増刊10　新時代の脳腫瘍学

    ―目次―

    特集　新時代の脳腫瘍学―診断・治療の最前線―

    ?．脳腫瘍の疫学：
    　　　我が国および世界における脳腫瘍の発生に関する疫学的動向

    II．脳腫瘍の生物学 　 　
    　１． 脳腫瘍の発生機序 　 　
    　２． 脳腫瘍の生物学 　 　

    III．脳腫瘍の病理 　 　
    　１． 概論 　 　
    　２． 各論 　 　

    IV． 脳腫瘍の診断 　 　
    　１． 脳腫瘍の画像診断 　 　
    　２． 脳腫瘍の腫瘍マーカー 　 　
    　３． 脳腫瘍の遺伝子診断―現状と未来― 　

    V．脳腫瘍の治療 　 　
    　１． 概論 　 　
    　２． 脳腫瘍の外科療法 　 　
    　３． 脳腫瘍の放射線療法 　 　
    　４． 脳腫瘍の化学療法 　 　
    　５． 脳腫瘍の遺伝子・ウイルス療法 　 　
    　６． 脳腫瘍の分子標的治療 　 　
    　７． 脳腫瘍の免疫療法 　 　

    VI．小児脳腫瘍の治療 　 　
    　１． 小児脳腫瘍の特性および治療上の問題点 　
    　２． 髄芽腫の標準治療と治療開発の動向　
    　３． 上衣腫治療の問題点 　
    　４． 小児頭蓋内胚細胞性腫瘍治療の最新知見 　

    VII．高齢者脳腫瘍の治療 　 　
    　１． 高齢者脳腫瘍の特性 　
    　２． 高齢者における悪性神経膠腫の治療 　
    　３． 高齢者頭蓋底腫瘍の治療 　
    　４． 高齢者髄膜腫の手術と予後 　

    VIII．転移性脳腫瘍 　 　
    　１． 転移性脳腫瘍：概論 　
    　２． 転移性脳腫瘍に対するガンマナイフ治療　
    　３． 傍鞍部腫瘍に対するサイバーナイフ治療　
    　４． 転移性脳腫瘍に対する化学療法 　
    　５． 髄膜がん腫症の診断と治療 　

    IX．多施設共同試験 　 　
    　１． 我が国における悪性神経膠腫多施設共同試験の問題点 　
    　２． 膠芽腫の多施設共同試験―世界における動向― 　
    　３． 退形成性神経膠腫の多施設共同試験―世界における動向―
    　４． 低悪性度神経膠腫の多施設共同試験―世界における動向―
    　５． 小児脳腫瘍の多施設共同試験―世界における動向― 　
    　６． 悪性リンパ腫の多施設共同試験―世界における動向― 　
    　７． 転移性脳腫瘍の多施設共同試験―世界における動向―

    X．特論 　 　
    　１． 脳腫瘍における高次脳機能障害 　
    　２． 小児脳腫瘍患者のQOL
    　３． 脳腫瘍患者および家族への告知の現状と諸問題 　
    　４． 脳腫瘍のサイコオンコロジー 　

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 脳腫瘍の疫学

P.13 掲載の参考文献
1) The Committee of Brain Tumor Registry of Japan : Report of brain tumor registry of Japan (1984-2000), 12th ed. Neurol Med Chir 49 (Suppl) : 2009.
 
2) CBTRUS : CBTRUS Statistical Report : Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006. 2010.
 
3) CBTRUS : Statistical Report : Primary Brain Tumors in the United States, 1992-1997. 2000.
 
4) CBTRUS : Statistical Report : Primary Brain Tumors in the United States, 2000-2004. 2008.
 
5) Kleihues P, et al : Glioblastoma. In : WHO Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), p 33-49, International Agency for Research on Cancer, Lyon, 2007.
 
6) Yan H, et al : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 : 765-773, 2009.
PubMed
7) Wrensch M, et al : Epidemiology of primary brain tumors : Current concepts and review of the literature. Neuro Oncol 4 : 278-299, 2002.
PubMed
8) Kan P, et al : Cellular phone use and brain tumor : a meta-analysis. J Neurooncol 86 : 71-78, 2008.
PubMed

II 脳腫瘍の生物学

P.22 掲載の参考文献
1) Bailey P, Cushing H : A Classification of the Tumors of the Glioma Group on a Histogenetic Basis with a Correlated Study of Prognosis, Lippincott, Philadelphia, 1926.
 
2) Louis DN, et al (eds) : WHO Classification of tumours of the central nervous system, IARC, Lyon, 2007.
 
3) Singh SK et al : Identhication of human brain tumour initiating cells, Nature 432 : 396-401, 2004.
PubMed
4) Oppermann H, et al : Uninfected vertebrate cells contain a protein that is closely related to the product of the avian sarcoma virus transforming gene (src). Proc Natl Acad Sci USA 76 : 1804-1808, 1979.
 
5) Hanahan D, Weinberg RA : The hallmarks of cancer Cell 100 : 57-70, 2000.
PubMed
6) Parsons DW, et al : An integrated genomic analysis of human glioblastoma multiforme. Science 321 : 1807-1812, 2008.
PubMed
7) Yan H, et al : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 : 765-773, 2009.
PubMed
8) Zhao S, et al : Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324 : 261-265, 2009.
PubMed
9) Hegi ME, et al : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005.
PubMed
10) Noushmehr H, et al : Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17 : 510-522, 2010.
PubMed
11) Cancer Genome Atlas Research Network : Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 : 1061-1068, 2008.
 
12) Verhaak RG, et al : Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17 : 98-110, 2010.
PubMed
13) Axelrod R, et al : Evolution of cooperation among tumor cells. Proc Natl Acad Sci USA 103 : 13474-13479, 2006.
PubMed
14) Berger F, et al : Development of gliomas : potential role of asymmetrical cell division of neural stem cells. Lancet Oncol 5 : 511-514, 2004.
PubMed
15) Stiles CD, Rowitch DH : Glioma stem cells : a midterm exam. Neuron 58 : 832-846, 2008.
PubMed
P.27 掲載の参考文献
1) Singh SK et al : Identification of human brain tumour initiating cells. Nature 432 : 396-401, 2004.
PubMed
2) Read TA et al : Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 15 : 135-147, 2009.
 
3) Son MJ, et al : SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4 : 440-452, 2009.
PubMed
4) Ward RJ, et al : Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma Cancer Res 69 : 4682-4690, 2009.
PubMed
5) Goodell MA, et al : Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183 : 1797-1806, 1996.
PubMed
6) Kondo T, et al : Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101 : 781-786, 2004.
PubMed
7) Bachoo RM, et al : Epidermal growth factor receptor and Ink4a/Arf : convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1 : 267-277, 2002.
 
8) Dai C, et al : PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15 : 1913-1925, 2001.
PubMed
9) Nishide K, et al : Glioblastoma formation from cell population depleted of Prominin1-expressing cells. PLoS One 4 : e6869, 2009.
PubMed
10) Hide T, et al : Soxll prevents tumorigenesis of glioma-initiating cells by inducing neuronal differentiation. Cancer Res 69 : 7953-7959, 2009.
 
11) Kondo T : Epigenetic alchemy for cell fate conversion. Curr Opin Genet Dev 16 : 502-507, 2006.
PubMed
12) Sell S : Potential gene therapy strategies for cancer stem cells. Curr Gene Ther 6 : 579-591, 2006.
PubMed
13) Massard C, et al : Tumour stem cell-targeted treatment : elimination or differentiation. Ann Oncol 17 : 1620-1624, 2006.
PubMed
14) Calabrese C, et al : A perivascular niche for brain tumor stem cells. Cancer Cell 11 : 69-82, 2007.
 
15) Li Z, et al : Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15 : 501-513, 2009.
PubMed
P.33 掲載の参考文献
1) Garber K : Energy deregulation : licensing tumors to grow. Science 312 : 1158-1159, 2006.
PubMed
2) Tomiyama A, et al : Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors Bax and Bak. J Natl Cancer Inst 98 : 1462-1473, 2006.
 
3) Youle RJ, Strasser A : The BCL-2 protein family : opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9 : 47-59, 2008.
PubMed
4) Hanahan D, Weinberg RA : The hallmarks of cancer. Cell 100 : 57-70, 2000.
PubMed
5) Pelicano H, et al : Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol 175 : 913-923, 2006.
PubMed
6) Vander Heiden MG, et al : Understanding the Warburg effect : the metabolic requirements of cell proliferation. Science 324 : 1029-1033, 2009.
PubMed
7) Gogvadze V, et al : Mitochondria as targets for cancer chemotherapy. Semin Cancer Biol 19 : 57-66, 2009.
 
8) Rhodes CG, et al : In vivo disturbance of the oxidative metabolism of glucose in human cerebral glioma. Ann Neurol 14 : 614-626, 1983.
PubMed
9) Mineura K, et al : Perfusion and metabolism in predicting survival of patients with cerebral gliomas. Cancer 73 : 2386-2394, 1994.
PubMed
10) Tyler JL, et al : Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nuc Med 28 : 1123-1133, 1987.
 
P.38 掲載の参考文献
1) Ye ZC, Sontheimer H : Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 59 : 4383-4391, 1999.
PubMed
2) Ishiuchi S, et al : Ca2+ -permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci 27 : 7987-8001, 2007.
PubMed
3) Takano T, et al : Glutamate release promotes growth of malignant gliomas. Nat Med 7 : 1010-1015, 2001.
PubMed
4) Ye ZC, et al : Compromised glutamate transport in human glioma cells : reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci 19 : 10767-10777, 1999.
 
5) Chung WJ, Sontheimer H : Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. J Neurochem 110 : 182-193, 2009.
PubMed
6) Vanhoutte N, Hermans E : Glutamate-induced glioma cell proliferation is prevented by functional expression of the glutamate transporter GLT-1. FEBS Lett 582 : 1847-1852, 2008.
PubMed
7) de Groot JF, et al : The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res 65 : 1934-1940, 2005.
PubMed
8) Labrakis C, et al : Glutamate receptor activation can trigger electrical acivity in human glioma cells. Eur J Neurosci 10 : 2153-2162, 1998.
 
9) Markert JM, et al : Differential gene expression profiling in human brain tumors. Physiol Genomics 5 : 21-33, 2001.
PubMed
10) Ishiuchi S, et al : Blockage of Ca2+ -permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 8 : 971-978, 2002.
 
11) Maas S, et al : Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci USA 98 : 14687-14692, 2001.
PubMed
12) Sontheimer H : Malignant gliomas : perverting glutamate and ion homeostasis for selective advantage. Trends Neurosci 26 : 543-549, 2003.
PubMed
13) Smith JS, et al : PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93 : 1246-1256, 2001.
PubMed
14) Lokker NA, et al : Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells : evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62 : 3729-3735, 2002.
PubMed
15) Shawver LK, et al : Smart drugs : tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1 : 117-123, 2002.
 
16) Datta SR, et al : Cellular survival : a play in three Akts. Genes Dev 13 : 2905-2927, 1999.
PubMed
17) Alessi DR, Cohen P : Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 8 : 55-62, 1998.
PubMed
18) Osaki M, et al : PI3K-Akt pathway : its functions and alterations in human cancer. Apoptosis 9 : 667-676, 2004.
PubMed
19) Cantley LC, Neel BG : New insights into tumor suppression : PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96 : 4240-4245, 1999.
PubMed
20) Li J, et al : PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 : 1943-1947, 1997.
PubMed
21) Maehama T, Dixon JE : The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem 273 : 13375-13378, 1998.
PubMed
22) Choe G, et al : Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63 : 2742-2746, 2003.
PubMed
23) Toker A, et al : Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 275 : 8271-8274, 2000.
 
24) Vanhaesebroeck B, et al : The PI3K-PDK1 connection : more than just a road to PKB. Biochem J 346 : 561-576, 2000.
PubMed
25) Mellinghoff IK, et al : Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 : 2012-2024, 2005.
PubMed
26) Kohara A, et al : In vitro characterization of YM872, a selective, potent and highly water-soluble α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist. J pharm Pharmacol 50 : 795-801, 1998.
 
27) Yamashita H, et al : Effect of YM928, a novel AMPA receptor antagonist, on seizures in EL mice and kainate-induced seizures in rats. Naunyn Schmiedebergs Arch Pharmacol 370 : 99-105, 2004.
PubMed
28) Langan YM, et al : Talampanel, a new antiepileptic drug : single-and multi-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia 44 : 46-53, 2003.
 
29) Grossman SA, et al : Phase II trial of talampanel in conjunction with standard radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM). J Clin Oncol 26 : Suppl ; Abstr 2014, 2008.
 
30) Grossman SA, et al : Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma : a multicenter phase II trial. J Clin Oncol 27 : 4155-4161, 2009.
PubMed
P.44 掲載の参考文献
1) Petricoin EF, et al : Chnical proteomics : translating benchside promise into bedside reality. Nat Rev Drug Discov 1 : 683-695, 2002.
 
2) Hanash S, et al : Disease proteomics. Nature 422 : 226-232, 2003.
PubMed
3) Celis JE, et al : Human 2-D PAGE databases for proteome analysis in health and disease : http://biobase.dk/cgi-bin/celis. FEBS Lett 398 : 129-134, 1996.
PubMed
4) Iwadate Y : Clinical proteomics in cancer research-promises and limitation of current two-dimensional gel electrophoresis. Curr Med Chem 15 : 2393-2400, 2008.
 
5) Diamandis EP : Mass spectrometry as a diagnostic and a cancer biomarker discovery tool. Mol Cell Proteomics 3 : 367-378, 2004.
 
6) Aebersold R, Mann M : Mass spectrometry-based proteomics. Nature 422 : 198-207, 2003.
PubMed
7) Iwadate Y, et al : Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 64 : 2496-2501, 2004.
PubMed
8) Deighton RF, et al : Glioma pathophysiology : insights emerging from proteomics. Brain Pathol 20 : 691-703. 2010.
PubMed
9) Fukuda EM, et al : Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res 65 : 5190-5194, 2005.
 
10) Iwadate Y, et al : High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. Anticancer Res 28 : 415-418, 2008.
PubMed
11) Ueda R, et al : Identification of human glioma antigen, SOX6, recognized by patients'sera. Oncogene 23 : 1420-1427, 2004.
PubMed
P.50 掲載の参考文献
1) Larsen F, et al : CpG islands as gene markers in the human genome. Genomics 13 : 1095-1107, 1992.
PubMed
2) Kondo Y, et al : Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 23 : 206-215, 2003.
PubMed
3) Kondo Y, et al : Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc Natl Acad Sci USA 101 : 7398-7403, 2004.
PubMed
4) Mtiller J, et al : Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 111 : 197-208, 2002.
 
5) Kuzmichev A, et al : Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 16 : 2893-2905, 2002.
PubMed
6) Cao R, et al : Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298 : 1039-1043, 2002.
PubMed
7) Czermin B, et al : Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 111 : 185-196, 2002.
PubMed
8) Oi S, et al : Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells. J Neurooncol 92 : 15-22, 2009.
 
9) Widschwendter M, et al : Epigenetic stem cell signature in cancer. Nat Genet 39 : 157-158, 2007.
PubMed
10) Kantarjian H, et al : Decitabine improves patient outcomes in myelodysplastic syndromes : results of a phase III randomized study. Cancer 106 : 1794-1803, 2006.
PubMed
11) Natsume A, et al : The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 122 : 2542-2553, 2008.
PubMed
P.55 掲載の参考文献
1) Parsons DW, et al : An integrated genomic analysis of human glioblastoma multiforme. Science 321 : 1807-1812, 2008.
PubMed
2) Yan H, et al : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 : 765-773, 2009.
PubMed
3) Cancer Genome Atlas Research Network : Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 : 1061-1068, 2008.
 
4) Dupuy A, Simon RM : Critical review of published microarray studies for cancer outcome and guide-lines on statistical analysis and reporting. J Natl Cancer Inst 99 : 147-157, 2007.
 
5) Verhaak RG, et al : Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17 : 98-110, 2010.
PubMed
6) Phillips HS, et al : Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9 : 157-173, 2006.
PubMed
7) Noushmehr H, et al : Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17 : 510-522, 2010.
PubMed
P.60 掲載の参考文献
1) The International Cancer Genome Consortium : International network of cancer genome projects. Nature 464 (7291) : 993-998, 2010.
PubMed
2) The Cancer Genome Atlas Research Network : Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (7216) : 1061-1068, 2008.
 
3) Reilly KM, et al : Nf1 ; Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 26 (1) : 109-113, 2000.
PubMed
4) Hunter C, et al : A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66 (8) : 3987-3991, 2006.
 
5) Parsons DW, et al : An integrated genomic analysis of human glioblastoma multiforme. Science 321 (5897) : 1807-1812, 2008.
PubMed
6) Yan H, et al : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 (8) : 765-773, 2009.
PubMed
7) Ward PS, et al : The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17 (3) : 225-234, 2010.
PubMed
8) Verhaak RG, et al : Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17 (1) : 98-110, 2010.
PubMed
9) Noushmehr H, et al : Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17 (5) : 510-522, 2010.
PubMed
P.64 掲載の参考文献
1) Chan JA, et al : MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65 : 6029-6033, 2005.
PubMed
2) Ciafre SA, et al : Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334 : 1351-1358, 2005.
PubMed
3) Gabriely G, et al : MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 28 : 5369-5380, 2008.
PubMed
4) Papagiannakopoulos T, et al : MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 68 : 8164-8172, 2008.
PubMed
5) Chen Y, et al : MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett 272 : 197-205, 2008.
PubMed
6) Ohno M, et al : The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma. Mol Cancer Res 7 : 2022-2030, 2009.
PubMed
7) Conti A, et al : miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol 93 : 325-332, 2009.
PubMed
8) Gillies JK, Lorimer IA : Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 6 : 2005-2009, 2007.
PubMed
9) Kefas B, et al : microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma, Cancer Res 68 : 3566-3572, 2008.
PubMed
10) Zhang Y, et al : MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J Mol Med 87 : 43-51, 2009.
PubMed
11) Godlewski J, et al : Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68 : 9125-9130, 2008.
PubMed
12) Silber J, et al : miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6 : 14, 2008.
PubMed
13) Pierson J, et al : Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol 90 : 1-7, 2008.
PubMed
14) Ferretti E, et al : Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J 27 : 2616-2627, 2008.
PubMed
15) Uziel T, et al : The miR-17～92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci USA 106 : 2812-2817, 2009.
 
P.68 掲載の参考文献
1) Collins VP : Mechanisms of disease : genetic predictors of response to treatment in brain tumors. Nat Clin Pract Oncol 4 : 362-374, 2007.
PubMed
2) Ichimura K, et al : Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60 : 417-424, 2000.
PubMed
3) Kruse JP, Gu W : Modes of p53 regulation. Cell 137 : 609-622, 2009.
PubMed
4) Liu L, et al : Clinical signhicance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 83 : 917-926, 2005.
PubMed
5) Lee JC, et al : Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3 : e485, 2006.
PubMed
6) McLendon R, et al : Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 : 1061-1068, 2008.
PubMed
7) Jones DT, et al : Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68 : 8673-8677, 2008.
PubMed
8) Jones DT, et al : Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549 : BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 28 : 2119-2123, 2009.
 
9) Parsons DW, et al : An integrated genomic analysis of human glioblastoma multiforme. Science 321 : 1807-1812, 2008.
PubMed
10) Ichimura K, et al : IDH1 mutations are present in the majority of common adult gliomas but are rare in primary glioblastomas. Neuro Oncol 11 : 341-347, 2009.
PubMed
11) Dang L, et al : Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462 : 739-744, 2009.
PubMed
12) Jenkins RB, et al : At (1 ; 19) (q10 ; p10) mediates the combined deletions of 1p and 19q and predicts abetter prognosis of patients with oligodendroglioma. Cancer Res 66 : 9852-9861, 2006.
 
13) Vogazianou AP, et al : Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro Oncol 12 : 664-678, 2010.
PubMed
14) Cairncross G, et al : Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma : Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24 : 2707-2714, 2006.
PubMed
15) Watanabe T, et al : IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174 : 1149-1153, 2009.
PubMed
P.74 掲載の参考文献
1) Singh SK, et al : Identification of a cancer stem cell in human brain tumors. Cancer Res 63 : 5821-5828, 2003.
PubMed
2) Singh SK, et al : Identification of human brain tumour initiating cells. Nature 432 : 396-401, 2004.
PubMed
3) Chen R, et al : A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17 : 362-375, 2010.
 
4) Shih AH, Holland EC : Notch signaling enhances nestin expression in gliomas. Neoplasia 8 : 1072-1082, 2006.
PubMed
5) Bhattacharya S, et al : Maintenance of retinal stem cells by Abcg2 is regulated by notch signaling. J Cell Sci 120 : 2652-2662, 2007.
PubMed
6) Dahmane N, et al : The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development 128 : 5201-5212, 2001.
PubMed
7) Clement V, et al : HEDGEHOG-GLI1 signaling regulates human glioma growth. cancer stem cell self-renewal and tumorigenicity. Curr Biol 17 : 165-172, 2007.
PubMed
8) Hambardzumyan D, et al : PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 22 : 436-448, 2008.
PubMed
9) Bleau AM, et al : PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4 : 226-235, 2009.
PubMed
10) Heddleston JM, et al : The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8 : 3274-3284, 2009.
PubMed
11) Li Z, et al : Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15 : 501-513, 2009.
PubMed
12) Piccirillo SG, et al : Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumor-initiating cells. Nature 444 : 761-765, 2006.
PubMed
13) Charles N, et al : Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 6 : 141-152, 2010.
PubMed
14) Calabrese C, et al : A perivascular niche for brain tumor stem cells. Cancer Cell 11 : 69-82, 2007.
 
15) Bao S, et al : Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66 : 7843-7848, 2006.
PubMed
16) Becher OJ, et al : Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res 68 : 2241-2249, 2008.
PubMed
17) Llaguno SA, et al : Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15 : 45-56, 2009.
 
18) Hambardzumyan D, et al : Modeling Adult Gliomas Using RCAS/t-va Technology. Transl Oncol 2 : 89-95, 2009.
PubMed
19) Zhu H, et al : Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci USA 106 : 2712-2716, 2009.
PubMed
P.79 掲載の参考文献
1) Osoba D, et al : Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18 : 1481-1491, 2000.
PubMed
2) Gerson SL : MGMT : its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4 : 296-307, 2004.
PubMed
3) Hegi ME, et al : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005.
PubMed
4) Wick W, et al : NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27 : 5874-5880, 2009.
 
5) Hirose Y, et al : Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg 98 : 591-598, 2003.
PubMed
6) Hirose Y, et al : The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol 23 : 8306-8315, 2003.
 
7) Alonso M, et al : Microsatellite instability occurs in distinct subtypes of pediatric but not adult central nervous system tumors. Cancer Res 61 : 2124-2128, 2001.
 
8) Cahill DP, et al : Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13 : 2038-2045, 2007.
PubMed
9) Kinsella TJ : Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin Cancer Res 15 : 1853-1859, 2009.
PubMed
10) Hirose Y, et al : p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61 : 1957-1963, 2001.
PubMed
11) Hirose Y, et al : Abrogation of the Chk1-mediated G2 checkpoint pathway potentiates temozolomideinduced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 61 : 5843-5849, 2001.
 
12) O'Connell MJ, et al : The G2-phase DNA-damage checkpoint. Trends Cell Biol 10 : 296-303, 2000.
 
13) Ichimura K, et al : Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60 : 417-424, 2000.
PubMed
14) Hirose Y, et al : Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide. J Neurosurg 100 : 1060-1065, 2004.
PubMed
15) Hirose Y, et al : Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res 65 : 4861-4869, 2005.
PubMed
P.86 掲載の参考文献
1) Du C, et al : Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102 : 33-42, 2000.
PubMed
2) Yip KW, Reed JC : Bcl-2 family proteins and cancer. Oncogene 27 : 6398-6406, 2008.
PubMed
3) Cimmino A, et al : miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102 : 13944-13949, 2005.
PubMed
4) Younes A, Kadin ME : Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 21 : 3526-3534, 2003.
PubMed
5) Frank S, et al : Expression of TRAIL and its receptors in human brain tumors. Biochem Biophys Res Commun 257 : 454-459, 1999.
PubMed
6) Okada H, Mak TW : Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 4 : 592-603, 2004.
PubMed
7) Ziegler DS, et al : Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 26 : 493-500, 2008.
PubMed
8) Nagane M, et al : The potential of TRAIL for cancer chemotherapy. Apoptosis 6 : 191-197, 2001.
PubMed
9) O'Brien S, et al : Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 25 : 1114-1120, 2007.
 
10) Gajewski TF : On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol 25 : 1305-1307, 2007.
PubMed
11) Nagane M, et al : Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro Oncol 12 : 687-700, 2010.
PubMed
12) Sun H, et al : Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. J Med Chem 49 : 7916-7920, 2006.
PubMed
13) Shingu T, et al : Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells. Cancer Res 63 : 4044-4047, 2003.
PubMed
14) Galanis E, et al : Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme : a North Central Cancer Treatment Group Study. J Clin Oncol 23 : 5294-5304, 2005.
 
15) Doherty L, et al : Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67 : 156-158, 2006.
PubMed
16) Lum JJ, et al : Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120 : 237-248, 2005.
PubMed
17) Lefranc F, et al : Proautophagic drugs : a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 12 : 1395-1403, 2007.
PubMed
18) Lockshin RA, Zakeri Z : Apoptosis, autophagy, and more. Int J Biochem Cell Biol 36 : 2405-2419, 2004.
PubMed
19) Kondo Y, et al : The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5 : 726-734, 2005.
PubMed
20) Miracco C, et al : Protein and mRNA expression of autophagy gene Beclin 1 in human brain tumours. Int J Oncol 30 : 429-436, 2007.
PubMed
21) Crighton D, et al : DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 126 : 121-134, 2006.
PubMed
22) Kanzawa T, et al : Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11 : 448-457, 2004.
PubMed
23) Iwamaru A, et al : Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 26 : 1840-1851, 2007.
PubMed
24) 永根基雄 : 薬剤耐性関連遺伝子と個別化化学療法. 日本臨牀 63 (増刊号9) : 460-471, 2005.
Medical*Online
P.92 掲載の参考文献
1) Zagzag D, et al : Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma : implications for angiogenesis and glioma cell invasion. Lab Invest 86 : 1221-1232, 2006.
PubMed
2) Fujiwara S, et al : Silencing hypoxia-inducible factor-lalpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int J Oncol 30 : 793-802, 2007.
 
3) Takano S, et al : Molecular therapeutic targets for glioma angiogenesis. J Oncol 2010 : 351908, 2010.
PubMed
4) Esencay M, et al : HGF upregulates CXCR4 expression in gliomas via NF-kappaB : implications for glioma cell migration. J Neurooncol 99 : 33-40, 2010.
PubMed
5) Tamase A, et al : Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc Natl Acad Sci USA 106 : 17163-17168, 2009.
 
6) Watters JJ, et al : Microglia function in brain tumors. J Neurosci Res 81 : 447-455, 2005.
PubMed
7) Markovic DS, et al : Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc Natl Acad Sci USA 106 : 12530-12535, 2009.
PubMed
8) Yoshida Y, et al : Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. Int J Cancer 126 : 2341-2352, 2010.
PubMed
9) Farin A, et al : Transplanted glioma cells migrate and proliferate on host brain vasculature : a dynamic analysis. Glia 53 : 799-808, 2006.
PubMed
10) Nakada M, et al : The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells. Cancer Res 64 : 3179-3185, 2004.
PubMed
11) Nakada M, et al : Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res 66 : 8492-8500, 2006.
PubMed
12) Nakada M, et al : The phosphorylation of ephrin-B2 ligand promotes glioma cell migration and invasion. Int J Cancer 126 : 1155-1165, 2010.
PubMed
13) Nakada M, et al : The role of matrix metalloproteinases in glioma invasion. Front Biosci 8 : e261-269, 2003.
PubMed
14) Seno T, et al : Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas. Int J Oncol 34 : 707-715, 2009.
PubMed
15) Nakada M, et al : Suppression of membrane-type 1 matrix metalloproteinase (MMP) -mediated MMP-2 activation and tumor invasion by testican 3 and its splicing variant gene product, N-Tes. Cancer Res 61 : 8896-8902, 2001.
PubMed
P.97 掲載の参考文献
1) 大西丘倫, 長戸重幸 : グリオーマ浸潤の分子病態. グリオーマ : 病態と治療 (田渕和雄編), p103-112, シュプリンガー・フェアラーク, 2006.
 
2) 大西丘倫 : 神経系細胞の接着因子. 免疫学からみた神経系と神経疾患, (吉田孝人ほか編), p131-139, 日本医学館, 1999.
 
3) 大西丘倫 : 免疫グロブリンスーパーファミリー L1. 接着分子ハンドブック (宮坂昌之監), p100-102, 秀潤社, 2000.
 
4) Asou H, et al : The cell adhesion molecule LI has a specific role in neural cell migration. Neuroreport 3 : 481-484, 1992.
 
5) Duczmal A, et al : The L1 adhesion molecule supports αvβ3-mediated migration of human tumor cells and activated lymphocytes. Biochem Biophys Res Commun 232 : 236-239, 1997.
 
6) Izumoto S, et al : Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion. Cancer Res 56 : 1440-1444, 1996.
PubMed
7) Ohnishi T, et al : A novel model of glioma cell invasion using organotypic brain slice culture. Cancer Res 58 : 2935-2940, 1998.
PubMed
8) 大西丘倫 : 免疫グロブリンスーパーファミリー NCAM. 接着分子ハンドブック (宮坂昌之監), p 97-99, 秀潤社, 2000.
 
9) Seki T, Arai Y : Distribution and possible roles of the highly polysialylated neural cell adhesion molecule (NCAM-H) in the developing and adult central nervous system. Neurosci Res 17 : 265-290, 1993.
 
10) Andersson AM, et al : Characterization of NCAM expression and function in BT4C and BT4Cn glioma cells. Int J Cancer 47 : 124-129, 1991.
PubMed
11) Edvardsen K, et al : Transfection of glioma cells with the neural cell adhesion molecule NCAM : effect on glioma-cell invasion and growth in vivo. Int J Cancer 58 : 116-122, 1994.
PubMed
12) Owens GC, et al : Overexpression of a transmembrane isoform of neural cell adhesion molecule alters the invasiveness of rat CNS-1 glioma. Cancer Res 58 : 2020-2028, 1998.
 
13) Suzuki M, et al : Polysialic acid facilitates tumor invasion by glioma cells. Glycobiology 15 : 887-894, 2005.
PubMed
P.102 掲載の参考文献
1) 八尾徹ほか : システムバイオロジー-解析データ応用の第2ステージへ-. BIOINDUSTRY 25 (12) : 7-75, 2008.
 
2) Kitano H : Computational systems biology. Nature 420 (6912) : 206-210, 2002.
PubMed
3) Kitano H : Cancer robustness : tumour tactics. Nature 426 (6963) : 125, 2003.
PubMed
4) Huang SS, Fraenkel E : Integrating proteomic, transcriptional, and interactome data reveals hidden components of signaling and regulatory networks. Sci Signal 2 (81) : ra40, 2009.
PubMed
5) Goeman JJ, Buhlmann P : Analyzing gene expression data in terms of gene sets : methodological issues. Bioinformatics 23 (8) : 980-987, 2007.
PubMed
6) Borisov N, et al : Systems-level interactions between insulin-EGF networks amplify mitogenic signaling. Mol Syst Biol 5 : 256, 2009.
PubMed
7) Shiraishi T, et al : Large-scale analysis of network bistability for human cancers. PLoS Comput Biol 6 (7) : e1000851. doi : 10.1371/journaLpcbi. 1000851, 2010.
 
8) Ptashne M : A Genetic Switch ; Phage Lambda and Higher Organisms, Blackwell Science, Oxford, 1992.
 
9) 所眞理雄 (編) : オープンシステムサイエンス 原理解明の科学から問題解決の科学へ, NTT出版, 2009.
 
P.108 掲載の参考文献
1) Rascher G, et al : Extracellular matrix and the blood-brain barrier in glioblastoma multiforme : spatial segregation of tenascin and agrin. Acta Neuropathol 104 : 85-91, 2002.
PubMed
2) Galea I, et al : An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J Exp Med 204 : 2023-2030, 2007.
PubMed
3) Yamada S, et al : Albumin outflow into deep cervical lymph from different regions of rabbit brain. Am J Physiol 261 : H1197-1204, 1991.
 
4) Fecci PE, et al : Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66 : 3294-3302, 2006.
PubMed
5) Ueda R, et al : Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res 15 : 6551-6559, 2009.
PubMed
6) Lalier L, et al : Increase in PGE2 biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme. Oncogene 26 : 4999-5009, 2007.
PubMed
7) Parsa AT, et al : Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13 : 84-88, 2007.
PubMed
8) Berger R et al : Phase I saiety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14 : 3044-3051, 2008.
 
9) Takao M, et al : Increased synthesis of indoleamine-2, 3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 17 : 1333-1339, 2007.
 
10) Grauer OM, et al : CD4+ FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 121 : 95-105, 2007.
PubMed
11) Maker AV, et al : Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175 : 7746-7754, 2005.
PubMed
12) Ueda R, et al : Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci USA 106 : 10746-10751, 2009.
PubMed
13) Sasaki K, et al : miR-17-92 expression in differentiated T cells-implications for cancer immunotherapy. J Transl Med 8 : 17, 2010.
PubMed
14) Dudley ME, et al : Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 : 850-854, 2002.
PubMed

III 脳腫瘍の病理

P.117 掲載の参考文献
1) Weinberg RA : The Biology of Cancer, Garland Science, Taylor & Frabcus Group, New York, 2007.
 
2) McLendon RE, et al : Russell and Rubinstein's Pathology of Tumors of the Nervous System, 7th ed, Hodder Arnold, London, 2006.
 
3) Nagashima K, et al : Induction of brain tumors by a newly isolated JC virus (Tokyo-1 strain). Am J Pathol 116 : 455-463, 1984.
PubMed
4) Tabuchi K : Glioma : Research and Therapy, Springer, Tokyo, 2006.
 
5) Wong AJ, et al : Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84 : 6899-6903, 1987.
PubMed
6) Louis DN, et al : WHO Classification of Tumours of the Central Nervous System, 4th ed, International Agency for Research on Cancer (IARC), Lyon, 2007.
 
7) Ohgaki H, Kleihues P : Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170 : 1445-1453, 2007.
PubMed
8) Holland EC, et al : A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12 : 3675-3685, 1998.
PubMed
9) Ding H, et al : Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 61 : 3826-3836, 2001.
 
10) Holland EC, et al : Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25 : 55-57, 2000,
PubMed
11) Pardal R, et al : Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3 : 895-902, 2003.
PubMed
12) Bonnet D, Dick JE : Human acute myeloid leukemia is organized as a hierarchy that originates from aprimitive hematopoietic cell. Nat Med 3 : 730-737, 1997.
 
13) Ignatova TN, et al : Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39 : 193-206, 2002.
PubMed
14) Kondo T, et al : Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101 : 781-786, 2004.
PubMed
15) Singh SK, et al : Identification of human brain tumour initiating cells. Nature 432 : 396-401, 2004.
PubMed
16) Gupta PB, et al : Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138 : 645-659, 2009.
PubMed
17) Tabu K, et al : Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res 18 : 1037-1046, 2008.
PubMed
18) Tabu K, et al : Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks. Mol Cancer 9 : 39, 2010.
PubMed
19) Parsons DW, et al : An integrated genomic analysis of human glioblastoma multiforme. Science 321 : 1807-1812, 2008.
PubMed
20) Cancer Genome Atlas Research Network : Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 : 1061-1068, 2008.
 
21) Yan H, et al : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 : 765-773, 2009.
PubMed
22) Watanabe T, et al : IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174 : 1149-1153, 2009.
PubMed
23) Dang L, et al : Cancer-assoCiated IDH1 mutations produce 2-hydroxyglutarate. Nature 465 : 966, 2010.
PubMed
24) Phillips HS, et al : Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9 : 157-173, 2006.
PubMed
25) Carro MS, et al : The transcriptional network for mesenchymal transformation of brain tumours. Nature 463 : 318-325, 2010.
PubMed
26) Noushmehr H, et al : Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17 : 510-522, 2010.
PubMed
27) Cairncross JG, Macdonald DR : Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23 : 360-364, 1988.
PubMed
28) Ueki K, et al : Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8 : 196-201, 2002.
PubMed
29) Bagchi A, et al : CHD5 is a tumor suppressor at human 1p36. Cell 128 : 459-475, 2007.
PubMed
30) Hegi ME, et al : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005.
PubMed
31) Sasai K, et al : Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma : relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol 32 : 1220-1227, 2008.
PubMed
32) Sasai K, et al : O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells : implications for anti-glioma therapies. Mol Cancer 6 : 36, 2007.
PubMed
33) Natsume A, et al : A combination of IFN-beta and temozolomide in human glioma xenograft models : implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol 61 : 653-659, 2008.
PubMed
P.126 掲載の参考文献
1) Zulch KJ Histological Typing of Tumours of the Central Nervous System, World Health Organization, Geneva, 1979.
 
2) Zulch KJ : Historical development of the classification of brain tumours and the new proposal of the World Health Organization (WHO). Neurosurg Rev 4 : 123-127, 1981.
PubMed
3) Kleihues P, et al : Histological Typing of Tumours of the Central Nervous System, Springer-Verlag, Berlin, 1993.
 
4) Fields WS : Primary Brain Tumors. A Review of Histologic Classification, p 286, Springer-Verlag, New York, 1989.
 
5) Kleihues P, Cavenee WK : Pathology and Genetics of Tumours of the Nervous System (ed by Kleihues P, Sobin LH), p 314, IARC Press, Lyon, 2000.
 
6) Louis DN, et al : WHO Classification of Tumours of the Central Nervous System (ed by Bosman FT, et al), p 309, International Agency for Research on Cancer, Lyon, 2007.
 
7) Louis DN, et al : : The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114 : 97-109, 2007.
PubMed
8) Rousseau A, et al : The 2007 WHO classification of tumors of the central nervous system-what has changed? Curr Opin Neurol 21 : 720-727, 2008.
PubMed
9) Brat DJ, et al : Surgical neuropathology update : a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med 132 : 993-1007, 2008.
PubMed
10) 中里洋一 : 改訂された脳腫瘍WHO分類. Brain Nerve 60 : 59-77, 2008.
 
11) 中里洋一 : 脳腫瘍の新WHO分類. 脳神経外科 36 : 473-491, 2008.
 
12) Fuller GN, Scheithauer BW : The 2007 Revised World Health Organization (WHO) Classification of Tumours of the Central Nervous System : newly codified entities. Brain Pathol 17 : 304-307, 2007.
PubMed
13) Lellouch -Tubiana A, et al : Angiocentric neuroepithelial tumor (ANET) : a new epilepsy-related clinicopathological entity with distinctive MRI. Brain Pathol 15 : 281-286, 2005.
 
14) Wang M, et al : Monomorphous angiocentric glioma : a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol 64 : 875-881, 2005.
PubMed
15) Komori T, et al : A rosette-forming glioneuronal tumor of the fourth ventricle : infratentorial form of dysembryoplastic neuroepithelial tumor? Am J Surg Pathol 26 : 582-591, 2002.
 
16) Jouvet A, et al : Papillary tumor of the pineal region. Am J Surg Pathol 27 : 505-512, 2003.
PubMed
17) Roncaroli F, et al : 'Spindle cell oncocytoma' of the adenohypophysis : a tumor of folliculostellate cells? Am J Surg Pathol 26 : 1048-1055, 2002.
PubMed
18) Scheithauer BW, et al : The 2007 WHO classhication of tumors of the nervous system : controversies in surgical neuropathology. Brain Pathol 18 : 307-316, 2008.
PubMed
19) Trembath D, et al : Gray zones in brain tumor classification : evolving concepts. Adv Anat Pathol 15 : 287-297, 2008.
PubMed
20) Perry A : AGBM by any other name? Brain Pathol 18 : i-iii, 2008.
 
P.131 掲載の参考文献
1) Louis DN, et al : WHO Classification of Tumours of the Central Nervous System, IARC, Lyon, 2007.
PubMed
2) 脳腫瘍全国統計委員会 : 脳腫瘍全国・集計報告, Vol 9, 1996.
 
3) Tanaka Y, et al : Diversity of glial cell components in pilocytic astrocytoma. Neuropathology 28 : 399-407, 2008.
PubMed
4) Tihan T, et al : Pediatric astrocytomas with monomorphous pilomyxoid features and a less favorable outcome. J Neuropathol Exp Neurol 58 : 1061-1068, 1999.
 
5) Chikai K, et al : Clinico-pathological features of pilomyxoid astrocytoma of the optic pathway. Acta Neuropathol (Berl) 108 : 109-114, 2004.
PubMed
6) Yan H, et al : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 : 765-773, 2009.
PubMed
7) Giannini C, et al : Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol 58 : 46-53, 1999.
PubMed
8) Watanabe K, et al : Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6 : 217-223, 1996.
PubMed
9) Brandsma D, et al : Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9 : 453-461, 2008.
PubMed
10) Hegi ME, et al : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005.
PubMed
11) Burger PC, Vollmer RT : Histologic factors of prognostic significance in the glioblastoma multiforme. Cancer 46 : 1179-1186, 1980.
PubMed
12) Miller CR, et al : Significance of necrosis in grading of oligodendroglial neoplasms : a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24 : 5419-5426, 2006.
PubMed
13) Kros JM, et al : Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951 : assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 66 : 545-551, 2007.
PubMed
14) Perry A, et al : Malignant gliomas with primitive neuroectodermal tumor-like components : a clinicopathologic and genetic study of 53 cases. Brain Pathol 19 : 81-90, 2009.
 
P.135 掲載の参考文献
1) Bromberg JE, van den Bent MJ : Oligodendrogliomas : molecular biology and treatment. Oncologist 14 : 155-163, 2009.
PubMed
2) 近藤亨 : オリゴデンドロサイトの分化制御機構とオリゴデンドログリオーマの発生. Brain and Nerve 61 : 741-755, 2009.
 
3) Watanabe T, et al : IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174 : 1149-1153, 2009.
PubMed
4) Ohgaki H, Kleihues P : Genetic alterations and signaling pathways in the evolution of gliomas, Cancer Sci 100 : 2235-2241, 2009.
PubMed
5) 久保田紀彦 : 乏突起膠腫由来の腫瘍. 脳腫瘍の病理と臨床, 改訂第2版 (佐藤一史編), p5-15, 診断と治療社, 2008.
 
6) Giannini C, et al : Anaplastic oligodendroglial tumors : refining the correlation among histopathology, 1p 19q deletion and clinical outcome in intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18 : 360-369, 2008.
PubMed
7) Miller CR et al : Significance of necrosis in grading of oligodendroglial neoplasm : aclinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24 : 5419-5426, 2006.
 
8) Kros JM, et al : Panel review of anaplastic oligodendroglioma from European Organization for Research and Ttreatment of Cancer Trial 26951 : assessment of consensus in diagnosis, influence of 1p/13q loss, and correlations with outcome. J Neuropathol Exp Neurol 66 : 545-551, 2007.
 
9) Kleihues P, et al : Glioblastoma. In : WHO Classification of Tumors of the Central Nervous System (ed by Lois DN, et al), p 33-49, IARC, Lyon, 2007.
 
10) Rousseau A, et al : Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas : use of YKL-40, ApoE, ASCL1 and NKX2.2. J Neuropathol Exp Neurol 65 : 1149-1156, 2006.
PubMed
11) Capper D, et al : Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118 : 599-601, 2009.
PubMed
12) Report of Brain Tumor Registry of Japan, 12th ed. Neurol Med Chir 49 (Suppl) : 1-96, 2009.
 
13) Brandes AA, et al : Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response of temozolomide in anaplastic and recurrent oligodendroglioma : a retrospective GICNO study. J Clin Oncol 24 : 4746-4753, 2006.
 
P.140 掲載の参考文献
1) WHO Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), 4th ed, IARC Press, Lyon, 2007.
 
2) 脳腫瘍病理カラーアトラス (河本圭司ほか編), 第3版, 医学書院2009.
 
3) Perry A, Brat DJ (ed) : Practical Surgical Neuropathology, Churchill Livingstone, Philadelphia, 2010.
 
P.144 掲載の参考文献
1) Louis DN, et al (ed) : WHO Classification of Tumours of the Central Nervous System, 4th ed, IARC Press, Lyon, 2007.
 
2) Lehman NL : Patterns of brain infiltration and secondary structure formation in supratentorial ependymal tumors. J Neuropathol Exp Neurol 67 : 900-910, 2008.
PubMed
3) Snuderl M, et al : Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas. J Neuropathol Exp Neurol 67 : 911-920, 2008.
PubMed
4) Rodriguez FJ, et al : Ependymomas with neuronal differentiation. A morphologic and immunohistochemical spectrum. Acta Neuropathol 113 : 313-324, 2007.
PubMed
5) Ho DM, et al : A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma. J Neurooncol 54 : 77-85, 2001.
PubMed
6) Moritani S, et al : Highly anaplastic extraventricular ependymoma arising in an adult, mimicking metastatic adenocarcinoma with heavy stromal inflammation and emperipolesis. Pathol Int 53 : 539-546, 2003.
 
7) Burger PC, et al : Surgical Pathology of the Nervous System and Its Coverings, 4th ed, Churchill Livingstone, New York, 2002.
 
8) Lehman NL : Central nervous system tumors with ependymal features : abroadened spectrum of primarily ependymal differentiation? J Neuropathol Exp Neurol 67 : 177-188, 2008.
PubMed
9) Friede RL, Pollak A : The cytogenetic basis of classifying ependymomas. J Neuropathol Exp Neurol 37 : 103-118, 1978.
PubMed
10) Shintaku M, Sakamoto T : Tanycytic ependymoma of the filum terminale with pleomorphic giant cells. Brain Tumor Pathol 26 : 79-82, 2009.
PubMed
11) Shintaku M, et al : Tanycytic ependymoma of the spinal cord with anaplastic cytological features. Brain Tumor Pathol 26 : 7-10, 2009.
PubMed
12) Judkins AR, Ellison DW : Ependymoblastoma : dear, damned, distracting diagnosis, farewell! Brain Pathol 20 : 133-139, 2010.
PubMed
13) Rodriguez FJ, et al : Ependymal tumors with sarcomatous change ("ependymosarcoma") : A clinicopathologic and molecular cytogenetic study. Am J Surg Pathol 32 : 699-709, 2008.
PubMed
14) Jeibmann A, et al : Prognostic implications of atypical histologic features in choroid plexus papilloma. J Neuropathol Exp Neurol 65 : 1069-1073, 2006.
PubMed
15) Dulai MS, et al : Intramedullary papillary ependymoma with choroid plexus differentiation and cerebrospinal fluid dissemination to the brain. Case report. J Neurosurg Pediatr 5 : 511-517, 2010.
 
P.149 掲載の参考文献
1) Choux M, et al : Brainstem tumors. In : Pediatric Neurosurgery (ed by Choux M, et al), p 471-491, Churchill Livingstone, New York, 2000.
 
2) Recinos PF, et al : Brainstem tumors : where are we today? Pediatr Neurosurg 43 : 192-201, 2007.
PubMed
3) Kesari S, et al : Prognostic factors in adult brainstem glioma : a multicenter, retrospective analysis of 101 cases. J Neurooncol 88 : 175-183, 2008.
 
4) Guillamo JS, et al : Brainstem gliomas in adults : prognostic factors and classification. Brain 124 : 2528-2539, 2001.
PubMed
5) Fisher PG, et al : A clinicopathologic reappraisal of brain stem tumor classification : identification of pilocytic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer 89 : 1569-1576, 2000.
PubMed
6) Mauffrey C : Paediatric brainstem gliomas : prognostic factors and management. J Clin Neurosci 13 (4) : 431-437, 2006.
PubMed
7) Broniscer A, et al : Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol 25 : 682-689, 2007.
 
P.154 掲載の参考文献
1) Fuller GN, et al : Gliomatosis cerebri. In : Pathology & Genetics of Tumours of the Central Nervous System (ed by Louis DN, et al), p 50-52, IARC, Lyon, 2007.
 
2) Smith JS, et al : Gliomatosis cerebri. In : Textbook of Neuro-Oncology (ed by Berger MS, et al), p211-217, Elsevier, Philadelphia, 2005.
 
3) Jennings MT, et al : Gliomatosis cerebri presenting as intractable epilepsy during early childhood. J Child Neurol 10 : 37-45, 1995.
PubMed
4) Vates GE, et al : Gliomatosis cerebri : a review of 22 cases. Neurosurgery 53 : 261-271, 2003.
PubMed
5) Nevin S : Gliomatosis cerebri. Brain 61 : 170-191, 1938.
 
6) Rubinstein IJ : Gliomatosis cerebri. In : Tumors of the Central Nervous System, p 42, AFIP, Washington DC, 1972.
 
7) Galanaud D, et al : Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg 98 : 269-276, 2003.
PubMed
8) Glas M, et al : Procarbazine and CCNU as initial treatment in gliomatosis cerebri. Oncology 75 : 182-185, 2008.
PubMed
9) Herrlinger U, et al : Gliomatosis cerebri : molecular pathology and clinical course. Ann Neurol 52 : 390-399, 2002.
PubMed
10) Deramecourt V, et al : Bilateral temporal glioma presenting as a paraneoplastic limbic encephalitis with pure cognitive impairment. Neurologist 15 : 208-211, 2009.
PubMed
11) Osborn AG, et al : Gliomatosis cerebri. In : Diagnostic Imagings, Brain, p I : 6-27-1 : 6-29, AMIRSYS, Salt Lake City, 2004.
 
12) Mohana-Borges AV, et al : Role of proton magnetic resonance spectroscopy in the diagnosis of gliomatosis cerebri : a unique pattern of normal choline but elevated Myo-inositol metabolite levels. J Comput Assist Tomogr 28 : 103-105, 2004.
 
13) 高野晋吾ほか : Gliomaosis cerebri大脳膠腫症. 脳腫瘍臨床病理カラーアトラス第3版 (河本圭司ほか編), p31-33, 医学書院, 2009.
 
14) Burger P, et al : Gliomatosis cerebri. In : Tumors of the Central Nervous System (ed by Burger P, et al), p 83-86, American Registry of Pathology, Washington DC, 2007.
 
15) Kros JM, et al : Genetic aberrations in gliomatosis cerebri support monoclonal tumorigenesis. J Neuropathol Exp Neurol 61 : 806-814, 2002.
PubMed
P.158 掲載の参考文献
1) The committee of brain tumor registry of Japan : Report of brain tumor registry of Japan (1984-2000). Neurol med-chir 49 (Suppl) : 5-38, 2009.
 
2) Perry A, et al : Meningiomas. In : WHO Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), p 164-177, International Agency for Research on Cancer, Lyon, 2007.
 
3) Perry A, et al : 'Malignancy' in meningiomas : a clinicopathological study of 116 patients, with grading implications. Cancer 85 : 2046-2056, 1999.
 
4) Simpson D : The recurrence of intracranial meningiomas after surgical treatment J Neurol Neurosurg Psychiatry 20 : 22-39, 1957.
PubMed
5) Aghi MK, et al : Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 64 : 56-60, 2009.
PubMed
6) Rosenberg LA, et al : Long-term experience with World Health Oraganization grade III (malignant) meningiomas at a single institution. Int J Radiat Oncol Biol Phys 74 : 427-432, 2009.
 
P.162 掲載の参考文献
1) Scheithauer BW, et al : Schwannoma In : Tumors of the Peripheral Nervous System. Atlas of Tumor Pathology, 3rd Series fascicle 24, p 105-176, Armed Forces Institute of Pathology, Washington, DC, 1999.
 
2) The Committee of Brain Tumor Registry of Japan : Report of Brain Tumor Registry of Japan (1984-2000), 12th ed. Neurol Med Chir 49 (Suppl) : 2009.
 
3) Burger PC, et al : Schwannoma and melanocytic schwannoma. In : Surgical Pathology of the Nervous System and its Coverings, 4th ed, p 540-544, Churchill Livingstone, Now York, 2002.
 
4) Scheithauer BW, et al : Schwannoma. In : WHO Classification of Tumours of the Central Nervous System, 4th ed (ed by Louis DN, et al), p 152-155, International Agency for Research on Cancer, Lyon, 2007.
 
5) Casadei GP, et al : Cellular schwannoma. A clinicopathologic, DNA flow cytometric, and proliferation marker study of 70 patients. Cancer 75 : 1109-1119, 1995.
PubMed
6) Carney JA : Psammomatous melanotic schwannoma, A distinctive, heritable tumor with special associations, including cardiac myxoma and the Cushing's syndrome. Am J Surg Pathol 14 : 206-222, 1990.
 
7) Nonaka D, et al : Sox10 : a pan-schwannian and melanocytic marker. Am J Surg Pathol 32 : 1291-1298, 2008.
 
8) Erlandson RA : Schwann cell neoplasms and malignant peripheral nerve sheath tumors. In : Diagnostic Transmission Electron Microscopy of Tumors with Clinicopathological, Immunohistochemical, and Cytogenetic Correlations, p 710-717, Raven Press, New York, 1994.
 
9) Burger PC, Scheithauer BW : Tumors of intracranial and intraspinal peripheral nerves. In : Tumors of the Central Nervous System. AFIP Atlas of Tumor Pathology, 4th Series fascicle 7, p 431-452, American Registry of Pathology and Armed Forces Institute of Pathology, Washington, DC, 2007.
 
P.166 掲載の参考文献
1) Lloyd RV, et al : Tumours of the pituitary. In : World Health Organization Classification of Tumours : Pathology and Genetics of Tumours of Endocrine Organs (ed by DeLellis RA, et al), p 9-47, IARC Press, Lyon, 2004.
 
2) 竹井麻生, 長村義之 : 下垂体腫瘍の機能的病理分類 -下垂体腫瘍のすべて- (寺本明, 長村義之編), p108-115, 医学書院, 2009.
 
3) Ezzat S, et al : Basic fibroblast growth factor expression by two prolactin and thyrotropin-producing pituitary adenomas. Endocr Pathol 6 : 125-134, 1995.
PubMed
4) Matsuno A, et al : Secretion of high-molecular-weight adrenocorticotropic hormone from a pituitary adenoma in a patient without Cushing stigmata. Case report. J Neurosurg 101 : 874-877, 2004.
 
5) FeliX IA, et al : Massive Crooke's hyalinization in corticotroph cell adenomas of the human pituitary. A histological, immunocytological, and electron microscopic study of three cases. Acta Neurochir (Wien) 58 : 235-243, 1981.
 
6) George DH, et al : Crooke's cell adenoma of the pituitary : an aggressive variant of corticotroph adenoma, Am J Surg Pathol 27 : 1330-1336, 2003.
 
7) Lloyd RV, et al : Analysis of endocrine active and clinically silent corticotropic adenomas by in situ hybridization. Am J Pathol 137 : 479-488, 1990.
PubMed
8) Horvath E, Kovacs K : Folliculo-stellate cells of the human pituitary : a type of adult stem cell? Ultrastruct Pathol 26 : 219-228, 2002.
PubMed
9) Yagishita S, et al : Folliculo-stellate cell adenoma of the pituitary. A light-and electron-microscopic study. Acta Neuropathol 62 : 340-344, 1984.
PubMed
10) Tachibana O, Yamashima T : Immunohistochemical study of folliculo-stellate cells in human pituitary adenomas. Acta Neuropathol 76 : 458-464, 1988.
PubMed
11) Voit D, et al : Folliculo-stellate cells in pituitary adenomas of patients with acromegaly. Pathol Res Pract 195 : 143-147, 1999.
PubMed
12) 立花修 : Folliculo-stellate cell adenoma -下垂体腫瘍のすべて- (寺本明, 長村義之編), p 125-130, 医学書院, 2009.
 
13) Dahiya S, et al : Spindle cell oncocytoma of the adenohypophysis : report of two cases. Acta Neuropathol 110 : 97-99, 2005.
PubMed
P.170 掲載の参考文献
1) Prabbu VC, Brown HG : The pathogenesis of craniopharyngiomas. Childs Nerv Syst 21 : 622-627, 2005.
 
2) Rushing EJ, et al : Craniopharyngioma. In : WHO Classification of Tumours of the Central Nervous System, 4th ed (ed by Louis DN, et al), p 238-240, IARC Press, Lyon, 2007.
 
3) Paulus W, et al : Odontogenic classification of craniopharyngiomas : a clinicopathological study of 54 cases. Histopathology 30 : 172-177, 1997.
PubMed
4) Rodriguez FJ, et al : The spectrum of malignancy in craniopharyngioma. Am J Surg Pathol 31 : 1020-1028, 2007.
PubMed
5) Sato K, et al : Ciliated craniopharyngioma may arise from Rathke cleft cyst. Clin Neuropathol 25 : 25-28, 2006.
PubMed
6) Tateyama H, et al : Different keratin profiles in craniopharyngioma subtypes and ameloblastomas. Pathol Res Pract 197 : 735-742, 2001.
PubMed
7) Kusama K, et al : Expression of hard α-keratins in pilomatrixoma, craniopharyngioma, and calcifying odontogenic cyst Am J Clin Pathol 123 : 376-381, 2005.
 
8) Sekine S, et al : Expression of enamel proteins and LEF1 in adamantinomatous craniopharyngioma : evidence for its odontogenic epithelial differentiation. Histopathology 45 : 573-579, 2004.
PubMed
9) Buslei R, et al : Nuclear β-catenin accumulation associates with epithelial morphogenesis in craniopharyngiomas. Acta Neuropathol 113 : 585-590, 2007.
 
10) Buslei R, et al : Common mutations of β-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol 109 : 589-597, 2005.
 
11) Hofmann BM, et al : Nuclear beta-catenin accumulation as reliable marker for the differentiation between cystic craniopharyngiomas and rathke cleft cysts : aclinico-pathologic approach. Am J Surg Pathol 30 : 1595-1603, 2006.
 
12) Sekine S, et al : Beta-catenin mutations are frequent in calcifying odontogenic cysts, but rare in ameloblastomas. Am J Pathol 163 : 1707-1712, 2003.
PubMed
13) Nishioka H, et al : Endocrinological and MRI features of pituitary adenomas with marked xanthogranulomatous reaction. Neuroradiology 52 : 997-1002, 2010.
PubMed
14) Paulus W, et al : Xanthogranuloma of the sellar region : a clinicopathological entity different from adamantinomatous craniopharyngioma. Acta Neuropathol 97 : 377-382, 1999.
PubMed
15) Nishioka H, et al : Primary suprasellar malignant tumor with odontogenic features : case report. Neurosurgery 65 : E380-E382, 2009.
PubMed
P.179 掲載の参考文献
1) Rosenblum MK, et al : Germ cell tumours. In : WHO Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), p 198-204, IARC, Lyon, 2007.
 
2) Goodwin TL, et al : Incidence patterns of central nervous system germ cell tumors : ASEER study. J Pediatr Hematol Oncol 31 : 541-544, 2009.
 
3) Leroy X, et al : CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma. J Histochem Cytochem 50 (2) : 283-285, 2002.
PubMed
4) Lau SK, et al : D2-40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma : a comparative immunohistochemical study with KIT (CD117) and CD30. Mod Pathol 20 : 320-325, 2007.
PubMed
5) Ngan KW, et al : Immunohistochemical expression of OCT4 in primary central nervous system germ cell tumours. J Clin Neurosci 15 : 149-152, 2008.
PubMed
6) Santagata S, et al : Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol 31 : 836-845, 2007.
 
7) Hattab EM, et al : OCT4 immunohistochemistry is superior to placental alkaline phosphatase (PLAP) in the diagnosis of central nervous system germinoma. Am J Surg Pathol 29 : 368-371, 2005.
 
8) Mei K, et al : Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system : a study of 77 cases. Mod Pathol 22 : 1628-1636, 2009.
PubMed
9) Santagata S, et al : Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Am J Surg Pathol 30 : 1613-1618, 2006.
PubMed
10) Gopalan A, et al : Testicular mixed germ cell tumors : a morphological and immunohistochemical study using stem cell markers, Oct3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas. Mod Pathol 22 : 1066-1074, 2009.
PubMed
11) Liu A, et al : Diagnostic utility of novel stem cell markers SALL4, 0CT4, NANOG, SOX2, UTF1, and TCL1 in primary mediastinal germ cell tumors. Am J Surg Pathol 34 : 697-706, 2010.
PubMed
P.183 掲載の参考文献
1) Giangaspero F, et al : Medulloblastoma. In : WHO Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), p 132-140, IARC, Lyon, 2007.
 
2) McManamy CS, et al : Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior. Brain Pathol 17 : 151-164, 2007.
PubMed
3) Brown HG, et al : "Large cell/anaplastic" medulloblastomas : a Pediatric Oncology Group study. J Neuropathol Exp Neurol 59 : 857-865, 2000.
 
4) Pfister S, et al : Histology and molecular pathology of pediatric brain tumors. J Child Neurol 24 : 1375-1386, 2009.
PubMed
5) Fan X, Eberhart CG : Medulloblastoma stem cells. J Clin Oncol 26 : 2821-2827, 2008.
PubMed
6) Tabori U, et al : Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 28 : 1345-1350, 2010.
PubMed
7) Ellison DW, et al : β-Catenin status predicts a favorable outcome in childhood medulloblastoma : the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23 : 7951-7957, 2005.
 
8) Clifford SC, et al : Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 5 : 2666-2670, 2006.
PubMed
9) Giordana MT, et al : Anaplasia is rare and does not influence prognosis in adult medulloblastoma. J Neuropathol Exp Neurol 64 : 869-874, 2005.
 
P.187 掲載の参考文献
1) Kleihues P, Cavenee WK (ed) : Pathology and Genetics of Tumours of the Nervous System, IARC Press, Lyon, 2000.
 
2) Louis DN, et al (ed) : WHO Classification of Tumours of the Central Nervous System, IARC Press, Lyon, 2007.
 
3) Johnston DL, et al : Supratentorial primitive neuroectodermal tumors : a Canadian pediatric brain tumor consortium report. J Neurooncol 86 : 101-108, 2008.
PubMed
4) The Committee of Brain Tumor Registry of Japan : Report of Brain Tumor Registry of Japan (1984-2000), 12th ed. Neurol medico-chirurgica, Suppl Vol 49, 0ctober, 2009.
 
5) Central Brain Tumor Registry of the United States : CBTUS Statistical Report ; Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006, Hinsdale, 2010. Website : www.cbtrus.org
 
6) Hayden JT, et al : Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adult but not children. Cell Cycle 8 : 1806-1807, 2009.
 
7) Kagawa N, et al : Detection of genetic and chromosomal aberrations in medulloblastomas and primitive neuroectodermal tumors with DNA microarrays. Brain Tumor Pathol 23 : 41-47, 2006.
PubMed
8) Perry A, et al : Malignant gliomas with primitive neuroectodermal tumor-like components : a clinicopathological and genetic study of 53 cases. Brain Pathol 19 : 81-90, 2009.
 
9) Chintagumpala M, et al : A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol 11 : 33-40, 2009.
PubMed
P.191 掲載の参考文献
1) Rorke LB, et al : Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood : definition of an entity. J Neurosurg 85 : 56-65, 1996.
PubMed
2) 宇津木聡ほか : Atypical teratoid/rhabdoid tumor (AT/RT) -広範なependymal differentiationを伴った症例. 脳外誌 7 : 507-512, 1998.
 
3) Oka H, Scheithauer BW : Clinicopathological characteristics of atypical teratoid/rhabdoid tumor. Neurol Med Chir (Tokyo) 39 : 510-518, 1999.
PubMed
4) Kleihues P, Cavenee WK : World Health Organization Classification of Tumours. Pathology & Genetics, Tumours of the Nervous System, p 123-148, IARC Press, Lyon, 2000.
 
5) Judkins AR, et al : Atypical teratoid/rhabdoid tumor. In : WHO Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), p 147-149, IARC Press, Lyon, 2007.
 
6) Wong TT, et al : Primary pediatric brain tumors : statistics of Taipei VGH, Taiwan (1975-2004). Cancer 104 : 2156-2167, 2005.
PubMed
7) Biegel JA : Molecular genetics of atypical teratoid/rhabdoid tumor. Neurosurg Focus 20 : E11, 2006.
PubMed
8) Raisanen J, et al : Chromosome 22q deletions in atypical teratoid/rhabdoid tumors in adults. Brain Pathol 15 : 23-28, 2005.
PubMed
9) Hilden JM, et al : Central nervous system atypical teratoid/rhabdoid tumor : results of therapy in children enrolled in a registry. J Clin Oncol 22 : 2877-2884, 2004.
 
10) Tanizaki Y, et al : Atypical teratoid/rhabdoid tumor arising from the spinal cord : case report and review of the literature. Clin Neuropathol 25 : 81-85, 2006.
PubMed
11) Meyers SP, et al : Primary intracranial atypical teratoid/rhabdoid tumors of infancy and childhood : MRI features and patient outcomes. AJNR Am J Neuroradiol 27 : 962-971, 2006.
PubMed
12) Janson K, et al : Predisposition to atypical teratoid/rhabdoid tumor due to an inherited INI1 mutation. Pediatr Blood Cancer 47 : 279-284, 2006.
 
13) Arcaro A, et al : Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. Biochem J 406 : 57-66, 2007.
PubMed
14) Athale UH, et al : Childhood atypical teratoid rhabdoid tumor of the central nervous system : a metaanalysis of observational studies. J Pediatr Hematol Oncol 31 : 651-663, 2009.
 
15) Finkelstein-Shechter T, et al : Atypical teratoid or rhabdoid tumors : improved outcome with high-dose chemotherapy. J Pediatr Hematol Oncol 32 : e182-186, 2010.
PubMed
P.200 掲載の参考文献
1) Report of Brain Tumor Registry of Japan (1984-2000). Neurol Med Chir (Tokyo) 49 (Suppl) : 1-101, 2009.
 
2) Deckert M, Paulus W : Malignant lymphomas. In : World Health Organization Histological Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), p 188-192, IARC, Lyon, 2007.
 
3) Abrey LE, et al ; International Primary CNS Lymphoma Collaborative Group : Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23 : 5034-5043, 2005.
 
4) Ferreri Al, et al : Prognostic scoring system for primary CNS lymphomas : the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21 : 266-272, 2003.
 
5) Abrey LE, et al : Primary central nervous system lymphoma : the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24 : 5711-5715, 2006.
 
6) Ekenel M, Deangelis LM : Treatment of primary central nervous system lymphoma. Curr Treat Options Neurol 9 : 271-282, 2007.
PubMed
7) Ferreri AJ, et al : High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma : a randomised phase 2 trial. Lancet 374 : 1512-1520, 2009.
PubMed
8) Kluin PM, et al : Primary diffuse large B cell lymphoma of the CNS. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p 240-241, IARC, Lyon, 2008.
 
9) Alizadeh AA, et al : Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 : 503-511, 2000.
PubMed
10) Ding BB, et al : Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111 : 1515-1523, 2008.
 
11) Rosenwald A, et al : The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 : 1937-1947, 2002.
PubMed
12) Hans CP, et al : Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 : 275-282, 2004.
PubMed
13) Chang CC, et al : Immunohistochemical expression patterns of gemlinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 28 : 464-470, 2004.
PubMed
14) Montesinos-Rongen M, et al : Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B celL Leukemia 22 : 400-405, 2008.
PubMed
15) Camilleri-Broet S, et al : A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas : analysis of 83 cases. Blood 107 : 190-196, 2006.
PubMed
16) Lin CH, et al : Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res 12 : 1152-1156, 2006.
PubMed
17) Levy O, et al : Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer 112 : 151-156, 2008.
PubMed
18) Chang CC, et al : Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Arch Pathol Lab Med 127 : 208-212, 2003.
 
19) Nakamura M, et al : Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res 63 : 737-741, 2003.
PubMed
20) Cady FM, et al : Del (6) (q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol 26 : 4814-4819, 2008.
 
21) Courts C, et al : Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma. J Neuropathol Exp Neurol 67 : 720-727, 2008.
PubMed
22) Dent AL, et al : Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 276 : 589-592, 1997.
 
23) Riemersma SA, et al : Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 96 : 3569-3577, 2000.
 
24) Rubenstein JL, et al : Gene expression and angiotropism in primary CNS lymphoma. Blood 107 : 3716-3723, 2006.
PubMed
25) Smith JR, et al : Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 101 : 815-821, 2003.
PubMed
26) Krumbholz M, et al : BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201 : 195-200, 2005.
PubMed
27) Cobbers JM, et al : Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol 8 : 263-276, 1998.
PubMed
28) Nakamura M, et al : Frequent alterations of the p14 (ARF) and p16 (INK4a) genes in primary central nervous system lymphomas. Cancer Res 61 : 6335-6339, 2001.
PubMed
29) Ferreri AJ, et al : Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br J Haematol 126 : 657-664, 2004.
PubMed
P.206 掲載の参考文献
1) Von Recklinghausen F : Ueber die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen. Berlin : A. Hirschwald, 1882. (英訳 : Advance in Neurology, Vol 29 : Neurofibbromatosis, p259-275, Raven Press, New York, 1981.)
 
2) National Institutes of Health Consensus Development Conference. Neurofibromatosis. Conference Statement. Arch Neurol 45 : 575-578, 1988.
PubMed
3) Fountai JW, et al : Physical mapPing of a translocation breakpoint in neurofibromatosis. Science 244 : 1085-1087, 1989.
 
4) Seizinger BR, et al : Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 322 : 644-647, 1986.
PubMed
5) Cawthon RM, et al : A major segment of the neurofibromatosis type 1 gene : cDNA sequence, genomic structure, and point mutations. Cell 62 : 193-201, 1990.
 
6) Rouleau GA, et al : Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363 : 515-521, 1993,
 
7) Trofatter JA, et al : A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72 : 791-800, 1993.
PubMed
8) Niimura M : Overview and clinical aspects of neurofibromatosis 1. Gann Monogr Cancer Res 46 : 115-124, 1999.
 
9) Gardner WJ, Frazier CH : Bilateral acoustic neurofibromas : a clinical study and field survey of a family of five generations with bilateral deafness in thirty-eight members. Arch Neurol Psychiatry 23 : 266-302, 1930.
 
10) Evans DG, et al : A genetic study of type 2 neurofibromatosis in the United Kingdom. Prevalence, mutation rate, fitness, and confirmation of material transmission effect on severity. J Med Genet 29 : 841-846, 1992,
 
11) Gutmann DH, et al : The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278 : 51-57, 1997.
PubMed
12) Mautner VF, et al : Spinal tumors in patients with neurofibromatosis type 2 : MR imaging study of frequency, multiplicity and variety. Am J Roentgenol 165 : 951-955, 1995.
 
13) Aghi M, et al : Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors : clinical and molecular study of a unique phenotype. J Neurosurg 104 : 201-207, 2006.
PubMed
14) Xu GF, et al : The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 63 : 835-841, 1990.
PubMed
15) Kim HA, et al : Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. Oncogene 11 : 325-335, 1995.
PubMed
16) Tikoo A, et al : An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem 269 : 23387-23390, 1994.
 
17) Kissil JL, et al : Merlin, the product of the NF2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell 12 : 841-849, 2003.
PubMed
18) Hirokawa Y, et al : A clue to the therapy of neurofibromatosis type 2 : NF2/merlin is a PAK1 inhibitor. Cancer J 10 : 20-26, 2004.
 
19) He H, et al : Signal therapy for RAS-induced cancers in combination of AG879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Cancer J 7 : 191-202, 2001.
PubMed
20) Sasakawa Y, et al : Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 64 : 1079-1090, 2002.
PubMed
21) Glass TL, et al : Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. Neuro Oncol 2 : 151-158, 2000.
PubMed
22) Batchelor TT, et al : Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28 : 2817-2823, 2010.
PubMed
23) Plotkin SR, et al : Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol 5 : 487-491, 2008.
PubMed
24) Ammoun S, et al : Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res 68 : 5236-5245, 2008.
PubMed
25) Wong HK, et al : Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 70 : 3483-3493, 2010.
PubMed
P.212 掲載の参考文献
1) Mizuguchi M : Neuropathology of tuberous sclerosis. Brain Dev (Tokyo) 23 : 516-522, 2001.
 
2) Mizuguchi M, Hino O : Neuropathology. In : Tuberous Sclerosis Complex : From Basic Science to Clinical Phenotypes (ed by Culatolo EP), p 264-278, Mac Keith Press, Tokyo, 2003.
 
3) 水口雅 : 結節性硬化症. Clinical Neuroscience 23 : 256-257, 2005.
 
4) Lopes MB, et al : Immunohistochemical characterization of subependymal giant cell astrocytomas. Acta Neuropathol (Berl) 91 : 368-375, 1996.
PubMed
5) Mizuguchi M : Abnormal giant cells in the cerebral lesions of tuberous sclerosis complex. Congenital Anomalies (Kyoto) 47 : 2-8, 2007.
PubMed
6) Henske EP, et al : Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 59 : 400-406, 1996.
PubMed
7) Mizuguchi M, et al : Loss of tuberin from cerebral tissues with tuberous sclerosis and astrocytoma. Ann Neurol 40 : 941-944, 1996.
PubMed
8) Arai Y, et al : Loss of the TSC2 product tuberin in subependymal giant-cell tumors. Acta Neuropathol (Berl) 98 : 233-239, 1999.
PubMed
9) Mizuguchi M, et al : Simultaneous loss of hamartin and tuberin from the cerebrum, kidney and heart with tuberous sclerosis. Acta Neuropathol (Berl) 99 : 503-510, 2000.
PubMed
10) Tabuchi S, et al : Subependymal giant cell astrocytoma with positive tuberin expression-case report. Neurol Med Chir (Tokyo) 43 : 616-618, 2003.
PubMed
11) Jozwiak J, et al : Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol 9 : 73-79, 2008.
PubMed
12) 水口雅 : 結節性硬化症. 小児疾患の診断治療基準 (「小児内科」「小児外科」編集委員会編), 第3版, p664-665, 東京医学社, 2006.
 
13) Goh S, et al : Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 63 : 1457-1461, 2004.
PubMed
14) Franz DN, et al : Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59 : 490-498, 2006.
PubMed
15) Koenig MK, et al : Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 23 : 1238-1239, 2008.
PubMed
P.218 掲載の参考文献
1) Lonser R, et al : von Hippel-Lindau disease. Lancet 361 : 2059-2067, 2003.
PubMed
2) Zbar B, et al : Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8 : 348-357, 1996.
PubMed
3) Latif F, et al : Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 : 1317-1320, 1993.
PubMed
4) Maxwell PH, et al : The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 : 271-275, 1999.
PubMed
5) Kanno H, et al : Molecular genetic diagnosis of von Hippel-Lindau disease : analysis of five Jananese families. Jpn J Cancer Res 87 : 423-428, 1996.
 
6) Cybulski C, et al : Long polymerase chain reaction in detection of germline deletions in the von Hippel-Lindau tumor suppressor gene. Hum Genet 105 : 333-336, 1999.
 
7) Kanno H, et al : Spinal cord hemangioblastomas in von Hippel-Lindau disease. Spinal Cord 47 : 447-452, 2009.
PubMed
8) Kanno H, et al : Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 54 : 4845-4847, 1994.
 
9) Park DM, et al : von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med 4 : 333-341, 2007.
 
10) Kanno H, et al : Intraoperative power Doppler ultrasonography with a contrast-enhancing agent for intracranial tumors. J Neurosurg 102 : 295-301, 2005.
PubMed
11) Tago M, et al : Gamma knife surgery for hemangioblastomas. J Neurosurg (Suppl) 102 : 171-174, 2005.
PubMed
12) Kanno H, et al : Meningioma showing VHL gene inactivation in a patient with von Hippel-Lindau disease. Neurology 60 : 1197-1199, 2003.
 
13) Lonser R, et al : Tumors of the endolymphatic sac in von Hippel-Lindau disease. N Engl J Med 350 : 2481-2486, 2004.
PubMed
14) Shuin T, et al : Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinoma. Cancer Res 54 : 2852-2855, 1994.
 
15) Motzer RJ, et al : Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 : 16-24, 2006.
PubMed
P.221 掲載の参考文献
1) Rickert CH, Paulus W : Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst 17 : 503-511, 2001.
PubMed
2) Cohen KJ, et al : Pediatric glial tumors. Curr Treat Options Oncol 2 : 529-536, 2001.
PubMed
3) Kleihues P, et al : The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61 : 215-225 ; discussion 226-229, 2002.
 
4) Nakamura M, et al : p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11 : 159-168, 2001.
PubMed
5) Nakamura M, et al : Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G : C→A : T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22 : 1715-1719, 2001.
 
6) Nakamura M, et al : Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 59 : 539-543, 2000.
PubMed
7) Nakamura M, et al : Promoter hypermethylation of the PB1 gene in glioblastomas. Lab Invest 81 : 77-82, 2001.
 
8) Nakamura M, et al : Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab Invest 85 : 165-175, 2005.
PubMed
9) Sung T, et al : Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 10 : 249-259, 2000.
PubMed
10) Sure U, et al : Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol 56 : 782-789, 1997.
PubMed
11) Bredel M, et al : Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 5 : 1786-1792, 1999.
PubMed
12) Louis DN, et al : Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J Neuropathol Exp Neurol 52 : 507-515, 1993,
PubMed
13) Nakamura M, et al : Molecular pathogenesis of pediatric astrocytic tumors. Neuro Oncol 9 : 113-123, 2007.
PubMed
14) Nicholson HS, et al : Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors : a report from the Children's Oncology Group. Cancer 110 : 1542-1550, 2007.
 
15) Nakamura M, et al : Clinicopathological diagnosis of gliomas by genotype analysis. Brain Nerve 61 : 773-780, 2009.
PubMed
P.227 掲載の参考文献
1) Arnstein LH, et al : A case report and survey of brain tumors during neonatal period. J Neurosurg 8 : 315-319, 1951.
PubMed
2) Solitare GB, Krigman MR : Congenital intracranial neoplasm. A case report and review of the literature. J Neuropathol Exp Neurol 23 : 280-292, 1964.
PubMed
3) Jellinger K, Sunder-Plassmann M : Congenital intracranial tumors. Neuropaediatrie 4 : 46-63, 1973.
 
4) Wakai S, et al : Congenital brain tumors. Surg Neurol 21 : 597-609, 1984.
PubMed
5) Haddad SF, et al : Brain tumors occurring before 1 year of age : a retrospective reviews of 22 cases in an 11-year period (1977-1987). Neurosurgery 29 : 8-13, 1991.
 
6) Woodward PJ, et al : From the archives of the AFIP : a comprehensive review of fetal tumors with pathologic correlation. Radiographics 25 : 215-242, 2005.
PubMed
7) Buetow PC, et al : Congenital brain tumors : a review of 45 cases. AJR Am J Roentgeno1 155 : 587-593, 1990.
 
8) Isaacs H : Fetal brain tumors : a review of 154 cases. Am J Perinatol 26 : 453-466, 2009.
PubMed
9) Isaacs H Jr : I. Perinatal brain tumors : a review of 250 cases. Pediatr Neurol 27 : 249-261, 2002.
PubMed
10) Isaacs H Jr : II. Perinatal brain tumors : a review of 250 cases. Pediatr Neurol 27 : 333-342, 2002.
PubMed
11) Severino M, et al : Congenital tumors of the central nervous system. Neuroradiology 52 : 531-548, 2010.
PubMed
12) Bader JL, Miller RW : U. S. cancer incidence and mortality in the first year of life. Am J Dis Child 133 : 157-159, 1979.
PubMed
13) Oi S, et al : Congenital brain tumors in Japan (ISPN Cooperative Study) : Specific clinical features in neonates. Childs Nerv Syst 6 : 86-91, 1990.
PubMed
14) Jooma R, et al : Intracranial tumors in neonates : A report of seventeen cases. Surg Neurol 21 : 165-170, 1984.
PubMed
15) Di Rocco C, et al : Intracranial tumors of the first year of life : Acooperative survey of the 1986-1987 Education Committee of the ISPN. Childs Nerv Syst 7 : 150-153, 1991.
 
16) The committee of brain tumor registry of Japan : Report of brain tumor registry of Japan (1984-2000). Neurol Med Chir (Tokyo) 49, 2009.
 
17) Vazquez E, et al : Congenital tumours involving the head, neck and central nervous system. Pediatr Radiol 39 : 1158-1172, 2009.
PubMed
18) Vagner-Capodano AM, et al : Cytogenetic studies in 45 pediatric brain tumors. Pediatr Hematol Oncol 9 : 223-235, 1992.
PubMed
19) Kleihues P, et al : Morphological markers in neuro-oncology. Curr Topics Pathol 77 : 307-338, 1987.
 
20) FujiiY, et al : Chromosome analysis of brain tumors in children. Genes Chromosom Cancer 11 : 205-215, 1994.
 
21) Girschick HJ, et al : Cytogenetics and histopathologic studies of congenital supratentorial primitive neuroectodermal tumors : A case report. Pathol Oncol Res 7 : 67-71, 2001.
 
22) Pollack IF, et al : The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 57 : 304-309, 1997.
PubMed
23) Carstensen H, et al : A report of nine newborns with congenital brain tumours. Childs Nerv Syst 22 : 1427-1431, 2006.
PubMed
24) Jeibmann AS, et al : From glioblastoma to gangliocytoma : an unforeseen but welcome shift in biological behavior. J Neurosurg Pediatr 5 : 475-478, 2009.
PubMed
25) Shaffery ME, et al : Maturation of intracranial immature teratomas report of two cases. J Neurosurg 85 : 672-676, 1996.
 
26) Cai DX, et al : Medulloblastomas with extensive posttherapy neuronal maturation. Report of two cases. J Neurosurg 93 : 330-334, 2000.
 
27) Geyer JR, et al : Differentiation of a primitive neuroectodermal tumor into a benign ganglioglioma. J Neurooncol 14 : 237-241, 1992.
PubMed
28) Torres LF, et al : Intracerebral neuroblastoma. Report of a case with neuronal maturation and long survival. Acta Neuropathol (Berl) 68 : 110-114, 1985.
PubMed

IV 脳腫瘍の診断

P.239 掲載の参考文献
1) 興梠征典ほか : グリオーマのMRI所見 -星細胞系腫瘍を中心に-. 日本医放会誌 59 (5) : 170-175, 1999.
 
2) 興梠征典, 高橋睦正 : 脳腫瘍の画像診断 -最近の進歩を中心に-. Brain Medical 13 : 229-233, 2001.
 
3) 興梠征典ほか : 神経堤由来腫瘍の画像診断 -Neurosurgery Headline 6 神経堤由来組織の腫瘍性病変 (生塩之敬, 山浦晶編). p29-43, 三輪書店, 1999.
 
4) 前原忠行, 高橋睦正 (編) : 神経疾患のMRI, p 359-426, 南江堂, 1994.
 
P.243 掲載の参考文献
1) Okamoto K, et al : Diffusion-weighted echo-planar MR imaging in differential diagnosis of brain tumors and tumor-like conditions. Eur Radiol 10 : 1342-1350, 2000.
PubMed
2) Stadnik TWP, et al : Diffusion-weighted MR imaging of intracerebral masses : comparison with conventional MR imaging and histologic findings. AJNR Am J Neuroradiol 22 : 969-976, 2001.
 
3) Kono K, et al : The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol 22 : 1081-1088, 2001.
PubMed
4) Lu S, ey al : Diffusion-tensor MR imaging of intracranial neoplasia and associated peritumoral edema : introduction of the tumor infiltration index. Radiology 232 : 221-228, 2004.
 
5) Provenzale JM, et al : Peritumoral brain regions in gliomas and meningiomas : investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging. Radiology 232 : 451-460, 2004.
PubMed
6) Kamada K, et al : Combined use of tractography-integrated functional neuronavigation and direct fiber stimulation. J Neurosurg 102 : 664-672, 2005.
PubMed
7) Kamada K, et al : Functional monitoring for visual pathway using real-time visual evoked potentials and optic-radiation tractography. Neurosurgery 57 : 121-127, 2005.
PubMed
8) Kinoshita M, et al : Fiber-tracking does not accurately estimate size of fiber bundle in pathological condition : initial neurosurgical experience using neuronavigation and subcortical white matter stimulation. Neuroimage 25 : 424-429, 2005.
PubMed
9) Bagley IJ, et al : Gliomas : correlation of magnetic susceptibility artifact with histologic grade. Radiology 202 : 511-516, 1997.
 
10) Sehgal V, et al : Susceptibility-weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses. J Magn Reson Imaging 24 : 41-51, 2006.
 
11) Pinker K, et al : High-resolution contrast-enhanced, susceptibility-weighted MR imaging at 3T in patients with brain tumors : correlation with positron-emission tomography and histopathologic findings. AJNR Am J Neuroradiol 28 : 1280-1286, 2007.
PubMed
12) Hori M, et al : Three-dimensional susceptibility-weighted imaging at 3 T using various image analysis methods in the estimation of grading intracranial gliomas. Magn Reson Imaging 28 : 594-598, 2010.
PubMed
13) Hori M, et al : Precontrast and postcontrast susceptibility-weighted imaging in the assessment of intracranial brain neoplasms at 1.5 T. Jpn J Radiol 28 : 299-304, 2010.
PubMed
14) 荒木力 : balanced SSFP. 決定版 MRI完全解説, p 250-252, 秀潤社, 2008.
 
15) Amemiya S, et al : Cranial nerve assessment in cavernous sinus tumors with contrast-enhanced 3D fast-imaging employing steady-state acquisition MR imaging. Neuroradiology 51 : 467-470, 2009.
PubMed
P.248 掲載の参考文献
1) Nakada T, et al : High-resolution imaging with high and ultra high-field magnetic resonance imaging systems. Neuroreport 19 : 7-13, 2008.
 
2) Nakada T : Myths and truths in functional MRI : a basic guide for practitioners. Magn Reson Med Sci 1 : 89-107, 2002.
 
3) Haacke EM, et al : Susceptibility weighted imaging (SWI). Magn Reson Med 52 : 612-618, 2004.
PubMed
4) Fujii Y, et al : High-resolution T2 reversed magnetic resonance imaging on high magnetic field system. J Neurosurg 89 : 492-495, 1998.
PubMed
5) 藤井幸彦ほか : 脳神経学におけるヒト用超高磁場 (7T) 装置の現状と展望. 脳神経外科 38 : 107-116, 2010.
 
6) Nakada T, et al : Three-dimensional anisotropy contrast periodically rotated overlapping parallel lines with enhanced reconstruction (3DAC PROPELLER) on a 3.0T system : a new modality for routine clinical neuroimaging. J Neuroimaging 16 : 206-211, 2006.
PubMed
7) Nakada T, et al : Magnetic resonance axonography of the rat spinal cord. Neuroreport 5 : 2053-2056, 1994.
PubMed
8) Pipe JG, et al : Multishot diffusion-weighted FSE using PROPELLER MRI. Magn Reson Med 47 : 42-52, 2002.
PubMed
9) 藤井幸彦, 中田力 : 脳神経描出の進歩と術前画像診断. 脳神経外科ジャーナル 17 : 102-106, 2008,
 
10) Yoneoka Y, et al : Preoperative depiction of cavernous sinus invasion by pituitary macroadenoma using three-dimensional anisotropy contrast (3DAC) periodically rotated overlapping parallel lines with enhanced reconstruction (PROPELLER) on a 3.0T system. J Neurosurg 108 : 37-41, 2008.
 
11) Yoshimura J, et al : Adult cerebellopontine angle medulloblastoma originating in the pons mimicking focal brainstem tumor. J Neuroimaging 19 : 385-387, 2009.
 
12) Nakada T, et al : In vivo visualization of senile-plaque-like pathology in Alzheimer's disease patients by MR microscopy on a 7T system. J Neuroimag 18 : 125-129, 2008.
 
P.252 掲載の参考文献
1) Devos A, et al : Classification of brain tumours using short echo time 1H MR spectra. J Magn Reson 170 : 164-175, 2004.
PubMed
2) Meyerand ME, et al : Classification of biopsy-confirmed brain tumors using single-voxel MR spectroscopy. AJNR Am J Neuroradiol 20 : 117-123, 1999.
PubMed
3) Majos C, et al : Proton magnetic resonance spectroscopy (1H MRS) of human brain tumours : assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol 13 : 582-591, 2003.
PubMed
4) Hazany S, et al : Utilization of glutamate/creatine ratios for proton spectroscopic diagnosis of meningiomas. Neuroradiology 49 : 121-127, 2007.
PubMed
5) Majos C, et al : Utility of proton MR spectroscopy in the diagnosis of radiologically atypical intracranial meningiomas. Neuroradiology 45 : 129-136, 2003.
 
6) Ishimaru H, et al : Differentiation between high-grade glioma and metastatic brain tumor using single-voxel proton MR spectroscopy. Eur Radiol 11 : 1784-1791, 2001.
PubMed
7) Opstad KS, et al : Differentiation of metastases from high-grade gliomas using short echo time 1H spectroscopy. J Magn Reson Imaging 20 : 187-192, 2004.
PubMed
8) Tomoi M, et al : Alterations of lactate (+lipid) concentration in brain tumors with in vivo hydrogen magnetic resonance spectroscopy during radiotherapy. Invest Radiol 32 : 288-296, 1997.
PubMed
9) Huang MQ, et al : In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS. Acad Radiol 14 : 1531-1539, 2007.
PubMed
10) Chernov MF, et al : Early metabolic changes in metastatic brain tumors after Gamma Knife radiosurgery : 1H-MRS study. Brain Tumor Pathol 21 : 63-67, 2004.
PubMed
11) Kamada K, et al : Differentiation of cerebral radiation necrosis from tumor recurrence by proton magnetic resonance spectroscopy. Neurol Med Chir (Tokyo) 37 : 250-256, 1997.
PubMed
P.257 掲載の参考文献
1) Papanicolaou A, et al : Magnetoencephalographic mapPing of the language-specific cortex. J Neurosurg 90 : 85-93, 1999.
PubMed
2) Papanicolaou A, et al : Magnetoencephalography : a noninvasive alternative to the Wada procedure. J Neurosurg 100 : 867-876, 2004.
 
3) Hirata M, et al : Determination of language dominance with synthetic aperture magnetometry : comparison with the Wada test. Neuroimage 23 : 46-53, 2004.
PubMed
4) Kaneko Y, et al : Determination of language dominant hemisphere by magnetoencephalography-a comparison with Wada Test-. In : Biomagnetism : Interdisciplinary Research and Exploration(ed by Kakigi R, et al), p 154-156, Hokkaido University Press, 2008.
 
5) Kim JS, Chung CK : Language lateralization using MEG beta frequency desynchronization during auditory oddball stimulation with one-syllable words. Neuroimage 42 : 1499-1507, 2008.
PubMed
6) Eulitz C, et al : Oscillatory neuromagnetic activity induced by language and non-language stimuli. Cogn Brain Res 4 : 121-132, 1996.
PubMed
7) Hamalainen MS, Ilmoniemi RJ : Interpreting magnetic fields of the brain : minimum norm estimates. Med Biol Engl Comput 32 : 35-42, 1994.
 
P.264 掲載の参考文献
1) Terada H, Kamata N : Contribution of the combination of 201Tl SPECT and 99mTcO4- SPECT to the differential diagnosis of brain tumors and tumor-like lesions. A preliminary report. J Neuroradiol 30 : 91-94, 2003.
 
2) Taki S, et al : 201Tl SPET in the differential diagnosis of brain tumours. Nucl Med Commun 20 : 637-645, 1999.
PubMed
3) Tie J, et al : Differentiation of tumor recurrence from radiation necrosis in high-grade gliomas using 201Tl-SPECT. J Clin Neurosci 15 : 1327-1334, 2008.
PubMed
4) Akagi H, et al : Evaluation of thallium-201 SPECT/MRI image fusion in the postoperative follow-up of gliomas. Bull Osaka Med College 54 : 41-47, 2008.
 
5) Gomez-Rio M, et al : Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence. Eur J Nucl Med Mol Imaging 35 : 966-975, 2008.
PubMed
6) Morimoto D, et al : Transient uptake of thallium-201 into a cerebral infarction : a case report. J Nippon Med Sch 75 : 344-346, 2008.
PubMed
7) Soricelli A, et al : Technetium-99m-tetrofosmin uptake in brain tumors by SPECT : comparison with thallium-201 imaging. J Nucl Med 39 : 802-806, 1998.
PubMed
8) Yamamoto Y, et al : 99mTC-MIBI and 201Tl SPET in the detection of recurrent brain tumours after radiation therapy. Nucl Med Commun 23 : 1183-1190, 2002.
PubMed
9) NagamaChi S, et al : The Correlation between 99mTC-MIBI Uptake and MIB-1 as a nuclear proliferation marker in glioma ; a comparative study with 201Tl. Neuroradiology 43 : 1023-1030, 2001.
PubMed
10) Nishiyama Y, et al : Comparison of 99mTc-MIBI with 201Tl chloride SPET in patients with malignant brain tumours. Nucl Med Commun 22 : 631-639, 2001.
 
11) Shinoda J, et al : High 123I-IMP retention on SPECT image in primary central nervous system lymphoma. J Neurooncol 61 : 261-265, 2003.
PubMed
12) Tanaka F, et al : Presurgical identification of epileptic foci with iodine-123 iomazenil SPET : comparison with brain perfusion SPET and FDG PET. Eur J Nucl Med 24 : 27-34, 1997.
PubMed
P.270 掲載の参考文献
1) Warburg O : Metabolism of Tumors, Arnold and Constable, London, 1930.
 
2) Warburg O : On the origin of cancer cells. Science 123 : 309-314, 1956.
PubMed
3) Guerin C, et al : The glucose transporter and blood-brain barrier of human brain tumors. Ann Neurol 28 : 758-765, 1990.
PubMed
4) Di Chiro G, Fulham MJ : Virchow's shackles : can PET-FDG challenge tumor histology? AJNR 14 (3) : 524-527, 1993.
 
5) Lau EW, et al : Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci 17 (1) : 43-49, 2010.
 
6) Chen W, et al : Imaging proliferation in brain tumors with 18F-FLT PET : comparison with 18F-FDG. J Nucl Med 46 : 945-952, 2005.
PubMed
7) Valk PE, et al : Hypoxia in human gliomas : demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 33 : 2133-2137, 1992.
PubMed
8) 藤巻高光ほか : Gliomaの補助画像診断-PET検査の有用性. 脳神経外科ジャーナル 12 : 10-15, 2003.
 
9) 百瀬敏光 : PET-FDGを中心とした臨床応用 . 日本臨牀 63 (増刊号9) : 242-249, 2005.
Medical*Online
10) 篠浦伸禎, 百瀬敏光 : グリオーマのPET. 神経研究の進歩 43 : 385-394, 1999.
 
11) Fulham MJ, et al : Neuroimaging of juvenile pilocytic astrocytomas : an enigma. Radiology 189 : 221-225, 1993.
PubMed
12) Alexieu GA, et al : Glioma recurrence versus radiation necrosis : accuracy of current imaging modalities, J Neurooncol 95 : 1-11, 2009.
 
13) Isselbacher KJ : Sugar and amino acid transport by cells in culture-differences between normal and malignant cells. N Engl J Med 286 (17) : 929-933, 1972.
PubMed
14) Ernestus RI, et al : Polyamine metabolism in brain tumours : diagnostic relevance of quantitative biochemistry. J Neurol Neurosurg Psychiatry 71 (1) : 88-92, 2001.
PubMed
15) Singhal T, et al : 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 10 (1) : 1-18, 2008.
PubMed
16) Okita Y, et al : (11) C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma : A stereotactic image-histology comparison. Neuroimage 49 (4) : 2977-2982, 2010.
PubMed
17) Nariai T, et al : Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103 (3) : 498-507, 2005.
PubMed
18) Kubota R, et al : Methionine uptake by tumor tissue : a microautoradiographic comparison with FDG. J Nucl Med 36 (3) : 484-492, 1995.
 
19) Dethy S, et al : PET findings in a brain abscess associated with a silent atrial septal defect. Clin Neurol Neurosurg 97 (4) : 349-353, 1995.
 
P.277 掲載の参考文献
1) Mineura K et al : Long-term positron emission tomography evaluation of slowly progressive gliomas. Eur J Cancer 32A : 1257-1260, 1996.
PubMed
2) Mineura K et al : Indications for differential diagnosis of non-tumor CNS diseases from tumors. APET study. J Neuroimaging 7 : 8-15, 1997.
 
3) Mineura K et al : Blood flow and metabolism of central neurocytoma. A positron emission tomography study. Cancer 76 : 1224-1232, 1995.
PubMed
4) Mineura K, et al : Perfusion and metabolism in predicting the survival of patients with cerebral gliomas. Cancer 73 : 2386-2394, 1994.
PubMed
5) Takahashi Y, et al : Prognostic and therapeutic indicator of fiuoroboronophenylalanine positron emission tomography in patients with gliomas. Clin Cancer Res 9 : 5888-5895, 2003.
PubMed
P.282 掲載の参考文献
1) Ogawa T, et al : Clinical positron emission tomography for brain tumors : comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine. AJNR Am J Neuroradiol 17 : 345-353, 1996.
PubMed
2) 河井信行ほか : 脳腫瘍におけるメチオニンPET. 脳神経外科 36 : 847-859, 2008.
 
3) Herholz K, et al : 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50 : 1316-1322, 1998.
PubMed
4) Kracht LW, et al : Delineation of brain tumor extent with [11C]L-methionine positron emission tomography : local comparison with stereotactic histopathology. Clin Cancer Res 10 : 7163-7170, 2004.
PubMed
5) Hatakeyama T, et al : 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 35 : 2009-2017, 2008.
PubMed
6) Nojiri T, et al : Contribution of biological tumor parameters to the incorporation rate of L-[methyl-11C]methionine into astrocytomas and oligodendrogliomas. J Neurooncol 93 : 233-241, 2009.
 
7) Tsuyuguchi N, et al : Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery-in malignant glioma-. Ann Nucl Med 18 : 291-296, 2004.
PubMed
8) 河井信行ほか : PETによる脳腫瘍の再発と放射線壊死の鑑別. Clinical Neuroscience 27 : 824-827, 2009.
 
9) Pirotte B, et al : Integration of [11C] methionineっositron emission tomographic and magnetic resonance imaging for image-guided surgical resection of infiltrative low-grade brain tumor in children. Neurosurgery 57 (1 Suppl) : 128-139, 2005.
 
10) 三宅啓介ほか : 悪性脳腫瘍の外科的治療におけるPET検査の有用性について. 脳腫瘍の外科, p 234-241, メディカ出版, 2008.
 
11) Grosu A-L, et al : L- (methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiosurgery. Int J Radiat Oncol Biol Phys 63 : 64-74, 2005.
 
12) Ribom D, et al : Positron emission tomography 11C-methionine and survival in patients with low-grade gliomas. Cancer 92 : 1541-1549, 2001.
 
13) Nariai T, et al : Usefulness of L-[methyl-11C]methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103 : 498-507, 2005.
PubMed
14) Okubo S, et al : Correlation L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol 99 : 217-225, 2010.
 
15) 河井信行ほか : 脳腫瘍におけるフルオロチミジンPET. 脳神経外科 37 : 657-664, 2009.
 
P.287 掲載の参考文献
1) Ueki K et al : Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8 : 196-201, 2002.
PubMed
2) Ishii D, et al : Efficacy of temozolomide is correlated with lp loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. Neurol Med Chir (Tokyo) 47 (8) : 341-349, 2007.
 
3) Ohgaki H, et al : Genetic pathways to glioblastoma : a population-based study. Cancer Res 64 : 6892-6899, 2004.
PubMed
4) Singh SK et al : Identification of human brain tumor initiating cells. Nature 432 : 396-401, 2004.
PubMed
5) Yan H, et al : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 : 765-773, 2009.
PubMed
6) Zheng H, et al : p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455 : 1129-1133, 2008.
PubMed
7) Takano S, et al : Molecular therapeutic targets for glioma angiogenesis. J Oncol, 2010. (Article ID 351908)
 
8) Mukasa A, et al : Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci USA 107 (6) : 2616, 2010.
PubMed
9) Brandes AA, et al : MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26 : 2192-2197, 2008.
PubMed
10) Hegi ME, et al : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005.
PubMed
11) Natsume A, et al : IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 65 : 7573-7579, 2005.
PubMed
12) Silber JR, et al : O6-methylguanine-DNA methyltransferase activity in adult gliomas : relation to patient and tumor characteristics. Cancer Res 58 : 1068-1073, 1998.
PubMed
13) Liu L, et al : Targeted modulation of MGMT : clinical implications. Clin Cancer Res 12 : 328-331, 2006.
PubMed
14) Ueda R, et al : Identification of a human glioma antigen, SOX6, recognized by patients' sera. Oncogene 23 : 1420-1427, 2004.
PubMed
15) Yamanaka R : Cell-and peptide-based immunotherapeutic approaches for glioma. Trends Mol Med 14 : 228-235, 2008.
PubMed
P.291 掲載の参考文献
1) Wakao D, et al : Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma. Ann Hematol 81 (3) : 140-146, 2002.
PubMed
2) Janik JE, et al : Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. Blood 104 (10) : 3355-3357, 2004.
PubMed
3) Boehme V, et al : Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High -Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 18 (1) : 149-157, 2007.
 
4) Ferreri AJ, et al : Prognostic scoring system for primary CNS lymphomas : the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21 (2) : 266-272, 2003.
 
5) Hagberg H, et al : Serum beta 2-microglobulin in malignant lymphoma. Cancer 51 (12) : 2220-2225, 1983.
PubMed
6) Mavlight GM, et al : Diagnosis of leukemia or lymphoma in the central nervous system by beta 2-microglobulin determination. N Engl J Med 303 (13) : 718-722, 1980.
 
7) Kersten MJ, et al : Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. Blood 87 (5) : 1985-1989, 1996.
PubMed
8) Murase S, et al : Diagnostic utility of CSF soluble CD27 for primary central nervous system lymphoma in immunocompetent patients. Neurol Res 22 (5) : 434-442, 2000.
PubMed
P.296 掲載の参考文献
1) Mosenblum MK, et al : GCS germ cell tumours. In : Pathology & Genetics of Tumours of the Central Nervous System (ed by Louis DN, et al), p 197-204, IARC, Lyon, 2007.
 
2) Morinaga T, et al : Primary structures of human alpha-fetoprotein and its mRNA. Proc Natl Acad Sci USA : 4604-4608, 1983.
PubMed
3) Kamoto T, et al : Lectin-reactive alpha-fetoprotein (AFP-L3%) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors. Jpn J Clin Oncol 32 : 472-476, 2002.
PubMed
4) Krantz DA, et al : Screening for open neural tube defects. Clin Lab Med 30 : 721-725, 2010.
PubMed
5) Matsutani M, et al : Primary intracranial germ cell tumors : a clinical analysis of 153 histologically verified cases. J Neurosurg 86 : 446-455, 1997.
 
6) Sawamura Y, et al : Overview for management. In : Intracranial Germ Cell Tumors (ed by Sawamura Y, et al), p 169-191, Springer-Verlag, Wien, 1998.
 
7) Sugiyama K, et al : Morphologic features of human chorionic gonadotropin-or alpha-fetoprotein-producing germ cell tumors of the central nervous system : histological heterogeneity and surgical meaning. Brain Tumor Pathol 18 : 115-122, 2001.
PubMed
8) 日本泌尿器科学会 : 精巣腫瘍の腫瘍マーカーとして, 何が推奨されるか? 精巣腫瘍診療ガイドライン, p15-16, 金原出版, 2009.
 
9) Sawamura Y, et al : Induction chemotherapy followed by reduced-volume radiation therapy for newly diagnosed central nervous system germinoma. J Neurosurg 88 : 66-72, 1998.
PubMed
10) Inamura T, et al : Human chorionic gonadotrophin in CSF, not serum, predicts outcome in germinoma. J Neurol Neurosurg Psychiatry 66 : 654-657, 1999.
PubMed
11) Fujimaki T, et al : Levels of beta-human chorionic gonadotropin in cerebrospinal fluid of patients with malignant germ cell tumor can be used to detect early recurrence and monitor the response to treatment. Jpn J Clin Oncol 30 : 291-294, 2000.
PubMed
12) Takeshima H, Kuratsu J : A review of soluble c-kit (s-kit) as a novel tumor marker and possible molecular target for the treatment of CNS germinoma. Surg Neurol 60 : 321-325, 2003.
PubMed
13) Nakamura H, et al : C-kit expression in germinoma : an immunohistochemistry-based study. J Neurooncol 75 : 163-167, 2005.
PubMed
14) Miyanohara O, et al : Diagnostic significance of soluble c-kit in the cerebrospinal fluid of patients with germ cell tumors. J Neurosurg 97 : 177-183, 2002.
PubMed
P.302 掲載の参考文献
1) Libermann T, et al : Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313 : 144-147, 1985.
PubMed
2) Pefram M, et al : Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18 : 2241-2251, 1999.
 
3) Caimcross J, et al : Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90 : 1473-1479, 1998.
PubMed
4) Stupp R, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005.
PubMed
5) 菅野洋, 山本勇夫 : 脳腫瘍の遺伝子診断. 脳神経外科ジャーナル 12 : 466-475, 2003.
 
6) Scheurer M, et al : Polymorphism in interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. Clin Cancer Res 14 : 6640-6646, 2008.
PubMed
7) Kiuru A, et al : XRCC1 and XRCC3 variants and risk of glioma and meningioma. J Neurooncol 88 : 135-142, 2008.
PubMed
8) Rajaraman P, et al : DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol 12 : 37-48, 2010.
PubMed
9) Yang P, et al : Polymorphism in GLTSR1 and ERCC2 are associated with the development of oligodendrogliomas. Cancer 103 : 2363-2372, 2005.
PubMed
10) Wiltshire RN, et al : Comparative genomic hybridization analysis of astrocytomas : prognostic and diagnostic implications. J Mol Diagn 6 : 166-179, 2004.
PubMed
11) Yan H, et al : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 : 765-773, 2009.
PubMed
12) Jones DT, et al : Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68 : 8673-8677, 2008.
PubMed
13) Pfister S, et al : 0utcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27 : 1627-1636, 2009.
PubMed
14) Kanno H, et al : Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 54 : 4845-4847, 1994.
 
15) Turner J, et al : The many roles of microRNAs in brain tumor biology. Neurosurg Focus 28 : 1-7, 2010.
PubMed

V 脳腫瘍の治療

P.309 掲載の参考文献
1) Ushio Y, et al : Effect of surgical removal on survival and quality of life in patients with supratentorial glioblastoma. Neurol Med Chir 45 : 454-461, 2005.
PubMed
2) Pichlmeier U, et al : Resection and survival in glioblastoma multiforme : An RTOG recursive panitioning analysis of ALA study patients. Neuro Oncol 10 : 1025-1034, 2008.
PubMed
3) Fuller CD, et al : Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme. Radiat Oncol 2 : 26-32, 2007.
PubMed
4) Stupp R, et al : Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study : 5-year analysis of the EORrC-NCIC trial, Lancet Oncol 10 : 459-466, 2009.
 
5) Ushio Y, et al : Correlation of molecular genetic analysis of p53, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma. Front Biosci 8 : 281-288, 2003.
 
6) Kreisl TN, et al : Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27 : 740-745, 2009.
PubMed
7) Reardon DA et al : Cilengitide : an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 17 : 1225-1235, 2008.
PubMed
8) van den Bent MJ, et al : Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults : the EORTC 22845 randomised trial. Lancet 366 : 985-990, 2005.
PubMed
9) Cairncross JG, Macdonald DR : Successful chemotherapy for recurrent oligodendroglioma. Ann Neurol 23 : 360-364, 1988.
PubMed
10) Jaeckle KA, et al : Current strategies in treatment of oligodendroglioma : evolution of molecular signatures of response. J Clin Oncol 24 : 1246-1252, 2006.
PubMed
11) Packer RJ, et al : Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average -risk medulloblastoma. J Clin Oncol 24 : 4202-4208, 2006.
PubMed
12) Crowford JR, et al : Medulloblastoma in childhood : new biological advances. Lancet Neurol 6 : 1073-1085, 2007.
 
P.319 掲載の参考文献
1) The Committee of Brain Tumor Registry of Japan : Report of Brain Tumor Registry of Japan (1969-1993). Neurol Med Chir (Tokyo) 40 (Suppl) : 1-106, 2000.
 
2) The Committee of Brain Tumor Registry of Japan : Report of Brain Tumor Registry of Japan (1969-1996). Neurol Med Chir (Tokyo) 43 (Suppl) : 1-111, 2003.
 
3) The Committee of Brain Tumor Registry of Japan : Report of Brain Tumor Registry of Japan (1984-2000). Neurol Med Chir (Tokyo) 49 (Suppl) : 1-101, 2009.
 
4) 野村和弘 : 脳腫瘍全国統計の最新情報. 臨床神経科学 19 : 274-277, 2001.
 
5) Davis FG, et al : Centralized databases available for describing primary brain tumor incidence, survival, and treatment : Central Brain Tumor Registry of the United States ; Surveillance, Epidemiology, and End Results ; and National Cancer Data Base. Neuro Oncol 1 : 205-211, 1999.
 
6) Surawicz TS, et al ; the collaborating registries of the Central Brain Tumor Registry of the United States : Descriptive epidemiology of primary brain and CNS tumors : Results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro Oncol 1 : 14-25, 1999.
 
7) Barnholtz-Sloan JS, et al : Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973-1997. J Neurosurg 99 : 458-466, 2003.
PubMed
8) Davis FG, et al : Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type : an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 88 : 1-10, 1998.
 
9) Deorah S, et al : Trends in brain cancer incidence and survival in the United States : Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus 20 (4) : E1, 2006.
PubMed
10) Surawicz TS, et al : Brain tumor survival : results from the National Cancer Data Base. J Neurooncol 40 : 151-160, 1998.
 
P.323 掲載の参考文献
1) Milano MT, et al : Primary spinal cord glioma : a Surveillance, Epidemiology, and End Results database study. J Neurooncol 98 : 83-92, 2010.
PubMed
2) Tseng JH, Tseng MY : Survival analysis of 459 adult patients with primary spinal cancer in England and Wales : a population-based study. Surg Neurol 67 : 53-58, 2007.
 
3) Henning A, et al : Quantitative magnetic resonance spectroscopy in the entire human cervical spinal cord and beyond at 3T Magn Reson Med 59 : 1250-1258, 2008.
PubMed
4) Vargas MI, et al : Clinical applications of diffusion tensor tractography of the spinal cord. Neuroradiology 50 : 25-29, 2008.
PubMed
5) Ducreux D, et al : MR diffusion tensor imaging and fiber tracking in 5 spinal cord astrocytomas. AJNR Am J Neuroradiol 27 : 214-216, 2006.
PubMed
6) Duprez TP, et al : Intraoperative 3T MR imaging for spinal cord tumor resection : feasibility, timing, and image quality using a "twin" MR-operating room suite. AJNR Am J Neuroradiol 29 : 1991-1994, 2008.
PubMed
7) Marchan EM, et al : Long-term survival enhanced by cordectomy in a patient with a spinal glioblastoma multiforme and paraplegia. J Neurosurg Spine 7 : 656-659, 2007.
 
8) Raco A, et al : High-grade intramedullary astrocytomas : 30 years' experience at the Neurosurgery Department of the University of Rome "Sapienza". J Neurosurg Spine 12 : 144-153, 2010.
 
9) McGirt MJ, et al : Extent of surgical resection of malignant astrocytomas of the spinal cord : outcome analysis of 35 patients. Neurosurgery 63 : 55-60, 2008.
PubMed
P.327 掲載の参考文献
1) Maruyama K, et al : Proposed treatment strategy for cavernous sinus meningiomas : a prospective study. Neurosurgery 55 : 1068-1075, 2004.
PubMed
2) 河瀬斌 : 傍鞍部腫瘍の解剖と手術選択. 脳神経外科 25 : 681-688, 1997,
 
3) 甲村英二 : 傍鞍部髄膜腫. 脳神経外科エキスパート 頭蓋底 (佐伯直勝編), p76-83, 中外医学社, 2009.
 
4) 川原信隆 : 前床突起髄膜腫. NS Now テント上髄膜腫 アプローチから摘出まで (新井一編), p101-111, メジカルビュー社, 2008.
 
5) 齋藤清ほか : Petroclival meningiomaの手術-anterior petrosal approachの適応と限界-. 脳外誌 11 : 224-229, 2002.
 
6) Natarajan SK, et al : Petroclival meningiomas : multimodality treatment and outcomes at long-term follow-up. Neurosurgery 60 : 965-981, 2007.
PubMed
7) 齋藤清 : 錐体斜台部・錐体部髄膜腫の手術. NS Now 後頭蓋窩手術 これだけは知っておこう (大畑建治編), p146-156, メジカルビュー社, 2010.
 
8) Milker-Zabel S, et al : Fractionated stereotactic radiation therapy in the management of primary optic nerve sheath meningiomas. J Neuro-Oncol 94 : 419-424, 2009.
 
9) 齋藤清 : 前頭正中前半部の開頭. 最新脳神経外科手術 (三宅悦夫編), p17-22, 金芳堂, 2003.
 
10) 齋藤清 : 前頭蓋底の解剖と手術. 脳神経外科エキスパート 頭蓋底 (佐伯直勝編), p38-47, 中外医学社, 2009.
 
11) Pieper DR, Al-Mefty O : Management of intracranial meningiomas secondarily involving the infratemporal fossa : radiographic characteristics, pattern of tumor invasion, and surgical implications. Neurosurgery 45 : 231-238, 1999.
PubMed
12) Shrivastava RK, et al : Sphenoorbital meningiomas : surgical limitations and lessons learned in their long-term management. J Neurosurg 103 : 491-497, 2005.
PubMed
13) Rosenberg LA, et al : Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution. Int J Radiation Oncol Biol Physics 74 : 427-432, 2009.
 
14) Pasquier D, et al : Atypical and malignant meningioma : outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. Int J Radiation Oncol Biol Physics 71 : 1388-1393, 2008.
 
P.332 掲載の参考文献
1) Bonneville F, et al : Imaging of cerebellopontine angle lesions : an update. Part 1 : enhancing extra-axial lesions. Eur Radiol 17 : 2472-2482, 2007.
PubMed
2) Adachi K, et al : Cavernous angioma of the vestibular nerve : case report and literature review. Surg Neurol 70 : 82-86, 2008.
PubMed
3) Bonneville F, et al : Imaging of cerebellopontine angle lesions : an update. Part 2 : intra-axial lesions, skull base lesions that may invade the CPA region, and non-enhancing extra-axial lesions. Eur Radiol 17 : 2908-2920, 2007.
PubMed
4) Salpietro FM, et al : Cerebellopontine angle lipoma. Case report. J Neurosurg Sci 38 : 55-58, 1994.
PubMed
5) Gjuric M, Rudic M : What is the best tumor size to achieve optimal functional results in vestibular schwannoma surgery? Skull Base 18 : 317-325, 2008.
PubMed
6) Voss NF, et al : Meningiomas of the cerebellopontine angle. Surg Neurol 53 : 439-446, 2000.
PubMed
7) Schiefer TK, Link MJ : Epidermoids of the cerebellopontine angle : a 20-year experience. Surg Neurol 70 : 584-590, 2008.
PubMed
P.336 掲載の参考文献
1) Al-Mefty O, Teixeira A : Complex tumors of the glomus jugulare : criteria, treatment, and outcome. J Neurosurg 97 : 1356-1366, 2002.
PubMed
2) Linnoila RI, et al : Decreased expression of neuropeptides in malignant paragangliomas : an immunohistochemical study. Hum Pathol 19 : 41-50, 1988.
 
3) Borba LA, et al : Surgical management of glomus jugulare tumors : a proposal for approach selection based on tumor relationships with the facial nerve. J Neurosurg 112 : 88-98, 2010.
PubMed
4) Liu JK, et al : The combined transmastoid retro-and infralabyrinthine transjugular transcondylar transtubercular high cervical approach for resection of glomus jugulare tumors. Neurosurgery 59 (1 Suppl 1) : ONS115-125 ; discussion ONS115-125, 2006.
 
5) Lim M, et al : Efficacy and safety of stereotactic radiosurgery for glomus jugulare tumors. Neurosurg Focus 17 : E11, 2004.
PubMed
6) Cole JM, Beiler D : Long-term results of treatment for glomus jugulare and glomus vagale tumors with radiotherapy. Laryngoscope 104 : 1461-1465, 1994.
PubMed
7) Pollock BE : Stereotactic radiosurgery in patients with glomus jugulare tumors. Neurosurg Focus 17 : E10, 2004.
PubMed
8) Loether JS, et al : Second tumors after radiosurgery : tip of the iceberg or a bump in the road? Neurosurgery 52 : 1436-1440 : discussion 1440-1442, 2003.
 
9) Bulsara KR, et al : Microsurgical management of 53 jugular foramen schwannomas : lessons learned incorporated into a modified grading system. J Neurosurg 109 : 794-803, 2008.
PubMed
10) Sanna M, et al : Surgical management of jugular foramen schwannomas with hearing and facial nerve function preservation : a series of 23 cases and review of the literature. Laryngoscope 116 : 2191-2204, 2006.
PubMed
11) Martin JJ, et al : Cranial nerve preservation and outcomes after stereotactic radiosurgery for jugular foramen schwannomas. Neurosurgery 61 : 76-81 ; discussion 81, 2007.
 
12) Molony TB, et al : Meningiomas of the jugular foramen. Otolaryngol Head Neck Surg 106 : 128-136, 1992.
PubMed
13) Kawahara N, et al : Dumbbell type jugular foramen meningioma extending both into the posterior cranial fossa and into the parapharyngeal space : report of 2 cases with vascular reconstruction. Acta Neurochir (Wien) 140 : 323-330 ; discussion 330-331, 1998.
 
14) Ramina R, et al : Meningiomas of the jugular foramen. Neurosurg Rev 29 : 55-60, 2006.
PubMed
15) Sanna M, et al : Surgical management of jugular foramen meningiomas : a series of 13 cases and review of the literature. Laryngoscope 117 : 1710-1719, 2007.
PubMed
16) Maruyama K, et al : Proposed treatment strategy for cavernous sinus meningiomas : a prospective study. Neurosurgery 55 : 1068-1075, 2004.
PubMed
P.343 掲載の参考文献
1) Black PM, et al : Development and implementation of intraoperative magnetic resonance imaging and its neurosurgical applications. Neurosurgery 41 : 831-842, 1997.
PubMed
2) Tronnier VM, et al : Intraoperative diagnostic and interventional magnetic resonance imaging in neurosurgery. Neurosurgery 40 : 891-900, 1997.
PubMed
3) Roberts DW, et al : A frameless stereotaxic integration of computerized tomographic imaging and the operating microscope. J Neurosurg 65 : 545-549, 1986.
PubMed
4) Watanabe E, et al : Three-dimensional digitizer (neuronavigator) : new equipment for computed tomography-guided stereotaxic surgery. Surg Neurol 27 : 543-547, 1987.
PubMed
5) Nimsky C, et al : Quantification of, visualization of, and compensation for brain shift using intraoperative magnetic resonance imaging. Neurosurgery 47 : 1070-1080, 2000.
PubMed
6) Nimsky C, et al : Preoperative and intraoperative diffusion tensor imaging-based fiber tracking in glioma surgery. Neurosurgery 56 : 130-137, 2005.
PubMed
7) Nimsky C, et al : Intraoperative visualization for resection of gliomas : the role of functional neuronavigation and intraoperative 1.5T MRI. Neurol Res 28 : 482-487, 2006.
 
8) Muragaki Y, et al : Usefulness of intraoperative magnetic resonance imaging for glioma surgery. Acta Neurochir Suppl 98 : 67-75, 2006.
PubMed
9) Claus EB, et al : Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer 103 : 1227-1233, 2005.
PubMed
10) McClain CD, et al : Detection of unanticipated intracranial hemorrhage during intraoperative magnetic resonance image-guided neurosurgery. J Neurosurg 106 (5 Suppl) : 398-400, 2007.
 
11) 村垣善浩 : 術中MRI. NS NOW 5 グリオーマ その最新知見 (寺本明編), p104-111, メジカルビュー社, 2009.
 
12) Knauth M, et al : Surgically induced intracranial contrast enhancement : potential source of diagnostic error in intraoperative MR imaging. AJNR Am J Neuroradiol 20 : 1547-1553, 1999.
PubMed
13) Ozawa N, et al : Shift of the pyramidal tract during resection of the intraaxial brain tumors estimated by intraoperative diffusion-weighted imaging. Neurol Med Chir (Tokyo) 49 : 51-56, 2009.
PubMed
P.348 掲載の参考文献
1) Jantti V, et al : Single-sweep cortical somatosensory evoked potentials : N20 and evoked bursts in sevoflurane anaesthesia. Electroencephalogr Clin Neurophysiol 108 : 320-324, 1998.
PubMed
2) Nunez P : Electric fields of the brain. In : The Neurophysics of EEG, Oxford University Press, 1981.
 
3) Penfield W, Jasper H : Functional localization in the cerebral cortex. In : Epilepsy and the Functional Anatomy of the Human Brain, p 41-155, 1954.
 
4) Spehlmann R : Evoked Potential Primer Visual, Auditory and Somatosensory Evoked Potensials in Clinical Diagnosis, p 1-400, Butterworths, Boston, 1985.
 
5) Taniguchi M, et al : Modification of cortical stimulation for motor evoked potentials under general anesthesia : technical description. Neurosurgery 32 : 219-226, 1993.
PubMed
6) Kalkman CJ, et al : Improved amplitude of myogenic motor evoked responses after paired transcranial electrical stimulation during sufentanil/nitrous oxide anesthesia. Anesthesiology 83 : 270-276, 1995.
PubMed
7) Kamada K, et al : The motor-evoked potential threshold evaluated by tractography and electrical stimulation. J Neurosurg 111 : 785-795, 2009.
PubMed
8) Duffau H : Intraoperative direct subcortical stimulation for identification of the internal capsule, combined with an image-guided stereotactic system during surgery for basal ganglia lesions. Surg Neurol 53 : 250-254, 2000.
PubMed
9) Rutten GJ, et al : Development of a functional magnetic resonance imaging protocol for intraoperative localization of critical temporoparietal language areas. Ann Neurol 51 : 350-360, 2002.
PubMed
P.353 掲載の参考文献
1) Abbott A : Neuroscience : Opening up brain surgery. Nature 461 : 866-868, 2009.
PubMed
2) Sanai N, et al : Functional outcome after language mapping for glioma resection. N Engl J Med 358 : 18-27, 2008.
PubMed
3) Sahin NT, et al : Sequential processing of lexical, grammatical, and phonological information within Broca's area. Science 326 : 445-449, 2009.
 
4) Stummer W, et al : Extent of resection and survival in glioblastoma multiforme : identification of and adjustment for bias. Neurosurgery 62 : 564-576 ; discussion 564-576, 2008.
 
5) Wick W, et al : NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27 : 5874-5880, 2009.
 
6) 村垣善浩ほか : 覚醒下機能マッピングとモニタリングを用いた手術. 脳神経外科ジャーナル 17 : 38-47, 2008.
 
7) De Benedictis A, et al : Awake mapping optimizes the extent of resection for low-grade gliomas in eloquent areas. Neurosurgery 66 : 1074-1084 ; discussion 1084, 2010.
 
8) Bello L, et al : Intraoperative subcortical language tract mapping guides surgical removal of gliomas involving speech areas. Neurosurgery 60 : 67-80 ; discussion 80-82, 2007.
 
9) Quinones-Hinojosa A, et al : Preoperative correlation of intraoperative cortical mapping with magnetic resonance imaging landmarks to predict localization of the Broca area. J Neurosurg 99 : 311-318, 2003.
PubMed
10) Pouratian N, et al : Variability of intraoperative electrocortical stimulation mapping parameters across and within individuals. J Neurosurg 101 : 458-466, 2004.
PubMed
11) Ozawa N, et al : Identhication of the pyramidal tract by neuronavigation based on intraoperative diffusion-weighted imaging combined with subcortical stimulation. Stereotact Funct Neurosurg 87 : 18-24, 2009.
PubMed
12) 村垣善浩ほか : 覚醒下手術の注意点. No Shinkei Geka 38 : 427-435, 2010.
 
13) Ojemann JG, et al : Preserved function in brain invaded by tumor. Neurosurgery 39 : 253-258 ; discussion 258-259, 1996.
 
14) Duffau H, et al : Long term reshaping of language, sensory, and motor maps after glioma resection : a new parameter to integrate in the surgical strategy. J Neurol Neurosurg Psychiatry 72 : 511-516, 2002.
PubMed
15) Taylor MD, Bemstein M : Awake craniotomy with brain mapping as the routine surgical approach to treating patients with supratentorial intraaxial tumors : a prospective trial of 200 cases. J Neurosurg 90 : 35-41, 1999.
 
P.358 掲載の参考文献
1) Enchev Y : Neuronavigation : geneology, reality, and prospects. Neurosurg Focus 27 (3) E11, 2009.
PubMed
2) Maesawa S, et al : Clinical indications for high-field 1.5 T intraoperative magnetic resonance imaging and neuro-navigation for neurosurgical procedures. Review of initial 100 cases. Neurol Med Chir (Tokyo) 49 : 340-349, 2009.
PubMed
3) Maesawa S, et al : Intraoperative tractography and MEP monitoring in surgery for gliomas around the corticospinal tract. World Neurosurgery, manuscript accepted.
 
4) 渡辺洋平ほか : 新規に開発したレジストレーションアームを用いた術中レジストレーション法の提案. JJSCAS 11 : 467-471, 2009.
 
5) 林雄一郎ほか : 術中画像と術前画像の融合による脳神経外科画像誘導手術支援. J JSCAS 11 : 301-302, 2008.
 
6) Ito E, et al : Magnetically guided 3-dimensional virtual neuronavigation for neuroendoscopic surgery : technique and clinical experience. Neurosurgery 66 (6 Suppl Operative) : 342-353, 2010.
 
P.362 掲載の参考文献
1) Lacroix M, et al : A multivariate analysis of 416 patients with glioblastoma multiforme : prognosis, extent of resection, and survival. J Neurosurg 95 : 190-198, 2001.
 
2) 脳腫瘍全国集計調査委員 : 脳腫瘍全国集計調査報告 1984-2000, Neurologia medico-chirurgica, 49, 2009.
 
3) Sanai N, Berger MS : Glioma extent of resection and its impact on patient outcome. Neurosurgery 62 : 753-764, 2008.
PubMed
4) Mikuni N, et al : Surgical resection of an epileptogenic cortical dysplasia in the deep foot sensorimotor area : a case report. Epilepsy Behav 7 : 559-562, 2005.
 
5) Ojemann G, et al : Conical language localization in left, dominant hemisphere. An electrical stimulation mapping investigation in 117 patients. J Neurosurg 71 : 316-326, 1989,
 
6) Sanai N, et al : Functional outcome after language mapping for glioma resection. N Engl J Med 358 : 18-27, 2008.
PubMed
7) Mikuni N, et al : Fibers from the dorsal premotor cortex elicit moto卜evoked potential in a cortical dysplasia. Neuroimage 34 : 12-18, 2007.
 
8) Duffau H : New concepts in surgery of WHO grade II gliomas : functional brain mapping, connectionism and plasticity-a review. J Neurooncol 79 : 77-115, 2006.
 
9) Bello L, et al : Intraoperative subcortical language tract mapping guides surgical removal of gliomas involving speech areas. Neurosurgery 60 : 67-82, 2007.
PubMed
P.367 掲載の参考文献
1) Iseki H, et al : New possibilities for stereotaxis information-guided stereotaxis. Stereotact Funct Neurosurg 76 : 159-167, 2001.
PubMed
2) Muragaki Y, et al : Usefulness of intraoperative magnetic resonance imaging for glioma surgery. Acta Neurochir Suppl 98 : 67-75, 2006.
PubMed
3) Iseki H, et al : Advanced computer-aided intraoperative technologies for information-guided surgical management of gliomas : Tokyo Women's Medical University experience. Minim Invasive Neurosurg 51 : 285-291, 2008,
 
4) Omori S, et al : Robotic laser surgery with λ=2.8μm microlaser in neurosurgery. J Robotics Mechatronics 16 (2) : 122-128, 2004.
 
5) Nishizawa K et al : Development of surgical manipulator system "HUMAN" for clinical neurosurgery. Japan Medical Association Journal 49 (11. 12) : 335-344, 2006.
 
6) 伊関洋 : 異分野融合 (医工連携) -医療におけるprocess managementと医療のtraceability-. 栢森情報科学振興財団設立10周年記念フォーラム「情報科学のニューチャレンジ『身体性にせまる情報技術』」講演抜刷, p1-14, 2006.
 
P.374 掲載の参考文献
1) Oka K : Introduction of the videoscope in neurosurgery. Neurosurgery 62 : 337-340, 2008.
 
2) Oi S, et al : Frameless free-hand maneuvering of a small-diameter rigid-rod neuroendoscope with a working channel used during high-resolution imaging. Technical note. J Neurosurg 102 : 113-118, 2005.
PubMed
3) Yurtseven T, et al : Neuroendoscopic biopsy for intraventricular tumors. Minim Invasive Neurosurg 46 : 293-299, 2003.
PubMed
4) Kassam AB, et al : Completely endoscopic resection of intraparenchymal brain tumors. J Neurosurg 110 : 116-123, 2009.
PubMed
5) Joki T, et al : Neuroendoscopic placement of Ommaya reservoir into a cystic craniopharyngioma. Childs Nerv Syst 18 : 629-633, 2002.
PubMed
6) Ahmad F, et al : Endoscopic management of intraventricular brain tumors in pediatric patients : a review of indications, techniques, and outcomes. J Child Neurol 25 : 359-367, 2010.
PubMed
7) Shono T, et al : Results of a long-term follow-up after neuroendoscopic biopsy procedure and third ventriculostomy in patients with intracranial germinomas. J Neurosurg 107 : 193-198, 2007.
PubMed
8) Akai T, et al : Intra-parenchymal tumor biopsy using neuroendoscopy with navigation. Minim Invasive Neurosurg 51 : 83-86, 2008.
PubMed
9) Levine NB, et al : Endoscopic resection of colloid cysts : indications, technique, and results during a 13-year period. Minim Invasive Neurosurg 50 : 313-317, 2007.
PubMed
10) Bhatia R, et al : The management of hydrocephalus in children with posterior fossa tumours : the role of pre-resectional endoscopic third ventriculostomy. Pediatr Neurosurg 45 : 186-191, 2009.
PubMed
11) Romano A, et al : Endoscopic removal of a central neurocytoma from the posterior third ventricle. J Clin Neurosci 16 : 312-316, 2009.
PubMed
12) Fujimoto Y, et al : Neuroendoscopic palliation for large cystic craniopharyngioma in an elderly patient. Br J Neurosurg 21 : 618-621, 2007.
 
13) Kalmar AF, et al : Value of Cushing reflex as warning sign for brain ischaemia during neuroendoscopy. Br J Anaesth 94 : 791-799, 2005.
PubMed
14) Oertel J, et al : Ultrasonic aspiration in ncuroendoscopy : first results with a new tool. J Neurosurg 109 : 908-911, 2008.
PubMed
P.382 掲載の参考文献
1) Stummer W, et al : Extent of resection and survival in glioblastoma multiforme : identification of and adjustment for bias. Neurosurgery 62 : 564-576, 2008.
PubMed
2) Stummer W, et al : Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma : a randomised controlled multicentre phase III trial. Lancet Oncol 7 : 392-401, 2006.
PubMed
3) Kajimoto Y, et al : Use of 5-aminolevulinic acid in fluorescence-guided resection of meningioma with high risk of recurrence. Case report. J Neurosurg 106 : 1070-1074, 2007.
PubMed
4) Miyatake S, et al : Fluorescence of non-neoplastic, magnetic resonance imaging-enhancing tissue by 5-aminolevulinic acid : case report. Neurosurgery 61 : 1101-1104, 2007.
 
5) Huber RM, et al : 5-Aminolaevulinic acid (ALA) for the fluorescence detection of bronchial tumors. Diagn Ther Endosc 5 : 113-118, 1999.
PubMed
6) Zaak D, et al : Photodynamic diagnosis of prostate cancer using 5-aminolevulinic acid-first clinical experiences. Urology 72 : 345-348, 2008.
PubMed
7) Peng Q, et al : 5-Aminolevulinic acid-based photodynamic therapy clinical research and future challenges. Cancer 79 : 2282-2308, 1997.
PubMed
8) Stummer W, et al : Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 42 : 518-525, 1998.
PubMed
9) Stummer W, et al : Fluorescence-guided resections of malignant gliomas-an overview. Acta Neurochir Suppl 88 : 9-12, 2003.
PubMed
10) 梶本宜永, 黒岩敏彦 : 蛍光ガイド下手術 グリオーマ その最新知見 (寺本明編), NS NOW 5, p112-115, メディカルビュー社, 2009.
 
11) Kajimoto Y. et al : Fiber-optic spectroscopic detection of neoplasm by intraoperative fluorescence labeling. In : Developments in Neuroscience (ed by Watanabe K, et al), International Congress Series 1259, p 33-38, Elsevier, Tokyo, 2004.
 
12) LacroiX M, et al : A multivariate analysis of 416 patients with glioblastoma multiforme : prognosis, extent of resection, and survival. J Neurosurg 95 : 190-198, 2001.
 
13) Stupp R, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005.
PubMed
14) Pichlmeier U, et al : Resection and survival in glioblastoma multiforme : an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 10 : 1025-1034, 2008.
PubMed
P.387 掲載の参考文献
1) Stummer W, et al : Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma : a randomized controlled multicentre phase III trial. Lancet Oncol 7 : 392-401, 2006.
PubMed
2) 秋元治朗ほか : 浸潤先端をターゲットとしたグリオーマの手術. 脳腫瘍の外科 (甲村英二編), p8-14, メディカ出版, 2008.
 
3) Usuda J, et al : Outcome of photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways > 1.0cm in diameter. Clin Cancer Res 16 (7) : 2198-2204, 2010.
 
4) Matsumura H, et al : Uptake and retention of the photosensitizer mono-L-asparthyl chlorine e6 in experimental malignant glioma. Lasers Med Sci 23 : 237-245, 2008.
PubMed
5) Namatame H, et al : Photodynamic therapy of C6-implanted glioma cells in the rat brain employing second-generation photosensitizer talaporfin sodium. Photodiagnosis Photodyn Ther 5 : 198-209, 2008.
PubMed
6) Yamamoto Y, et al : Fibrin plugging as a cause of microcirculatory occlusion during photodynamic therapy. Lasers Med Sci 14 : 129-135, 1999.
PubMed
7) Madsen SJ, et al : Photodynamic therapy of newly implanted glioma cells in the rat brain. Lasers Surg Med 38 : 540-548, 2006.
PubMed
8) Bisland SK, et al : Metronomic photodynamic therapy as a new paradigm for photodynamic therapy : rationale and preclinical evaluation of technical feasibility for treating malignant brain tumors. Photochem Photobiol 80 : 22-30, 2004.
PubMed
9) Beck TJ, et al : Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg Med 39 (5) : 386-393, 2007.
PubMed
10) Stummer W, et al : Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA : case report. J Neurooncol 87 (1) : 103-109, 2007.
 
P.391 掲載の参考文献
1) Groothuis DR : The blood-brain and blood-tumor barriers : a review of strategies for increasing drug delivery. Neuro Oncol 2 : 45-59, 2000.
PubMed
2) Krauze MT, et al : Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 103 : 923-929, 2005.
PubMed
3) Bobo RH, et al : Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91 : 2076-2080, 1994.
PubMed
4) Jain RK : Delivery of novel therapeutic agents in tumors : physiological barriers and strategies. J Natl Cancer Inst 81 : 570-576, 1989.
PubMed
5) Valtonen S, et al : Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas : a randomized double-blind study. Neurosurgery 41 : 44-48, 1997.
PubMed
6) Bidros DS, et al : Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol 6 : 117-125, 2010.
PubMed
7) Laske DW, et al : Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3 : 1362-1368, 1997.
PubMed
8) Debinski W, et al : A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 270 : 16775-16780, 1995.
PubMed
9) Patel SJ, et al : Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma : initial experience in 51 patients. Neurosurgery 56 : 1243-1252, 2005.
PubMed
10) Kunwar S, et al : Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma : a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25 : 837-844, 2007.
 
11) Lidar Z, et al : Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma : a phase I/II clinical study. J Neurosurg 100 : 472-479, 2004.
PubMed
12) Saito R, et al : Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol 196 : 381-389, 2005.
PubMed
13) Sampson JH, et al : Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol 9 : 343-353, 2007.
PubMed
14) Saito R, et al : Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res 64 : 2572-2579, 2004.
PubMed
15) Lonser RR, et al : Successful and safe perfusion of the primate brainstem : in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 97 : 905-913, 2002.
PubMed
P.395 掲載の参考文献
1) Ling CC, et al : Conformal radiation treatment of prostate cancer using inversely planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys 35 : 721-730, 1996.
PubMed
2) Low DA : Quality assurance of intensity-modulated radiotherapy. Semin Radiat Oncol 12 : 219-228, 2002.
PubMed
3) Iuchi T, et al : Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys 64 : 1317-1324, 2006.
PubMed
4) Huang E, et al : Intensity-modulated radiation therapy for pediatric medulloblastoma : early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 52 : 599-605, 2002.
PubMed
5) Uy NW, et al : Intensity-modulated radiation therapy (IMRT) for meningioma. Int J Radiat Oncol Biol Phys 53 : 1265-1270, 2002.
PubMed
6) Tomita N, et al : Helical tomotherapy for brain metastases : dosimetric evaluation of treatment plans and early clinical results. Technol Cancer Res Treat 7 : 417-424, 2008.
PubMed
7) Shibamoto Y, et al : Incidence of brain atrophy and decline in mini-mental state examination score after whole-brain radiotherapy in patients with brain metastases : a prospective study. Int J Radiat Oncol Biol Phys 72 : 1168-1173, 2008.
PubMed
8) Ghia A, et al : Distribution of brain metastases in relation to the hippocampus : implications for neurocognitive functional preservation. Int J Radiat Oncol Biol Phys 68 : 971-977, 2007.
 
9) Barani U, et al : Neural stem cell-preserving extemal-beam radiotherapy of central nervous system malignancies. Int J Radiat Oncol Biol Phys 68 : 978-985, 2007.
 
P.400 掲載の参考文献
1) Glinski B : Postoperative hypofractionated radiotherapy versus conventionally fractionated radiotherapy in malignant gliomas. A preliminary report on a randomized trial. J Neurooncol 16 : 167-172, 1993.
 
2) Slotman BJ, et al : Hypofractionated radiation therapy in patients with glioblastoma multiforme : results of treatment and impact of prognostic factors. Int J Radiat Oncol Biol Phys 34 : 895-898, 1996.
PubMed
3) Kleinberg L, et al : Short course radiotherapy is an appropriate option for most malignant glioma patients. Int J Radiat Oncol Biol Phys 38 : 31-36, 1997.
PubMed
4) Hulshof MC, et al : Hypofractionation in glioblastoma multiforme. Radiother Oncol 54 : 143-148, 2000.
PubMed
5) Sultanem K, et al : The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme : preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys 58 : 247-252, 2004.
PubMed
6) Floyd NS, et al : Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 58 : 721-726, 2004.
PubMed
7) Iuchi T, et al : Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys 64 : 1317-1324, 2006.
PubMed
8) Panet-Raymond V, et al : Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme : a safety and efficacy analysis. Int J Radiat Oncol Biol Phys 73 : 473-478, 2009.
PubMed
9) Welsh JS, et al : Helical tomotherapy : an innovative technology and approach to radiation therapy. Technol Cancer Res Treat 1 : 311-316, 2002.
 
10) Miwa K, et al : Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme : insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry 75 : 1457-1462, 2004.
 
11) Kracht LW, et al : Delineation of brain tumor extent with [11C] L-methionine positron emission tomography : local comparison with stereotactic histopathology. Clin Cancer Res 10 : 7163-7170, 2004.
PubMed
12) Levivier M, et al : Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors : clinical experience and proposed classification. J Nucl Med 45 : 1146-1154, 2004.
PubMed
13) Stupp R, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005.
PubMed
14) Gonzalez J, et al : Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 67 : 323-326, 2007.
PubMed
15) Matsuo M, et al : Stereotactic radiosurgery for patients with newly diagnosed glioblastoma multiforme (GBM) : comparison with intra-operative radiotherapy and evaluation of prognostic factors. J Radiother Pract 6 : 143-152, 2007.
 
P.405 掲載の参考文献
1) Kondziolka D, et al : Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery 62 : 53-58, 2008.
PubMed
2) Pollock BE, et al : Stereotactic radiosurgery provides equivalent tumor control to Simpson Grade 1 resection for patients with small-to medium-size meningiomas. Int J Radiat Oncol Biol Phys 55 : 1000-1005, 2003.
PubMed
3) Patil CG, et al : Predictors of peritumoral edema after stereotactic radiosurgery of supratentorial meningiomas. Neurosurgery 63 : 435-440, 2008.
PubMed
4) Maruyama K, et al : Proposed treatment strategy for cavernous sinus meningiomas : a prospective study. Neurosurgery 55 : 1068-1075, 2004.
PubMed
5) Flickinger JC, et al : Acoustic neuroma radiosurgery with marginal tumor doses of 12 to 13 Gy. Int J Radiat Oncol Biol Phys 60 : 225-230, 2004.
PubMed
6) Fukuoka S, et al : Gamma knife radiosurgery for vestibular schwannomas. Prog Neurol Surg 22 : 45-62, 2009.
PubMed
7) Friedman RA, et al : Surgical salvage after failed irradiation for vestibular schwannoma. Laryngoscope 115 : 1827-1832, 2005.
PubMed
8) Pollock BE, et al : Patient outcomes after vestibular schwannoma management : a prospective comparison of microsurgical resection and stereotactic radiosurgery. Neurosurgery 59 : 77-85, 2006.
PubMed
9) Myrseth E, et al : Vestibular schwannoma : surgery or gamma knife radiosurgery? A prospective, nonrandomized study. Neurosurgery 64 : 654-661, 2009.
 
10) Castinetti F, et al : Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol 6 : 214-223, 2010.
PubMed
11) Rowe J, et al : Risk of malignancy after gamma knife stereotactic radiosurgery. Neurosurgery 60 : 60-65, 2007.
 
12) Souhami L, et al : Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme : report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60 : 853-860, 2004.
PubMed
13) Regis J, et al : Radiosurgery with the world's first fully robotized Leksell Gamma Knife Perfexion in clinical use : a 200-patient prospective, randomized, controlled comparison with the Gamma Knife 4C. Neurosurgery 64 : 346-355, 2009.
 
14) Williamson R, et al : Adverse radiation effects after radiosurgery may benefit from oral vitamin E and pentoxifylline therapy : a pilot study. Stereotact Funct Neurosurg 86 : 359-366, 2008.
PubMed
15) Wong ET, et al : Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol 26 : 5649-5650, 2008.
PubMed
P.409 掲載の参考文献
1) Chopra R, et al : Long-term follow-up of acoustic schwannoma radiosurgery with marginal tumor doses of 12 to 13 Gy. Int J Radiat Oncol Biol Phys 68 (3) : 845-851, 2007.
PubMed
2) Bhandare N, et al : Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys 76 (3 Suppl) : S50-57, 2010.
 
3) Sawamura Y, et al : Management of vestibular schwannoma by fractionated stereotactic radiotherapy and associated cerebrospinal fluid malabsorption. J Neurosurg 99 (4) : 685-692, 2003.
PubMed
4) Nishioka K, et al : Stereotactic radiotherapy for intracranial nonacoustic schwannomas including facial nerve schwannoma. Int J Radiat Oncol Biol Phys 75 (5) : 1415-1419, 2009.
PubMed
5) Kondziolka D, et al : Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery 62 (1) : 53-58 ; discussion 58-60, 2008.
 
6) Milker-Zabel S, et al : Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma : long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys 61 (3) : 809-816, 2005.
 
7) Korah MP, et al : Radiation therapy alone for imaging-defined meningiomas. Int J Radiat Oncol Biol Phys 76 (1) : 181-186, 2010.
PubMed
8) Milker-Zabel S, et al : Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base : long-term experience of a single institution. Int J Radiat Oncol Biol Phys 68 (3) : 858-863, 2007.
PubMed
9) Voges J, et al : Linear accelerator radiosurgery for pituitary macroadenomas : a7-year follow-up study. Cancer 107 (6) : 1355-1364, 2006.
 
10) Aoyama H, et al : Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radio-surgery alone for treatment of brain metastases : a randomized controlled trial. JAMA 295 (21) : 2483-2491, 2006.
 
11) Pirzkall A, et al : Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 16 (11) : 3563-3569, 1998.
PubMed
12) Nishihori T, et al : Three-dimensional conformal radiotherapy for astrocytic tumors involving the eloquent area in children and young adults. J Neurooncol 60 (2) : 177-183, 2002.
 
13) Werner-Wasik M, et al : Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer 77 (8) : 1535-1543, 1996.
 
P.415 掲載の参考文献
1) Adler Jr JR, et al : The Cyberknife : a frameless robotic system for radiosurgery. Stereotact Funct Neurosurg 69 : 124-128, 1997.
PubMed
2) Lunsford LD, et al : Stereotactic radiosurgery for arteriovenous malformation of the brain. J Neurosurg 75 : 512-524, 1997.
 
3) Wowra B, et al : Quality of radiosurgery for single brain metastases with respect to treatment technology : a matched-pair analysis. J Neurooncol 94 : 69-77, 2009.
PubMed
4) Kajiwara K, et al : Image-guided stereotactic radiosurgery with the CyberKnife for pituitary adenomas. Minim Invasive Neurosurg 48 : 91-96, 2005.
PubMed
5) Roberts BK, et al : Efficacy and safety of CyberKnife radiosurgery for acromegaly. Pituitary 10 : 19-25, 2007.
 
6) Adler JR Jr, et al : Visual field preservation after multisession cyberknife radiosurgery for perioptic lesions. Neurosurgery 62 (Suppl 2) : 733-743, 2008.
PubMed
7) Pham CJ, et al : Preliminary visual field preservation after staged CyberKnife radiosurgery for perioptic lesions. Neurosurgery 54 : 799-812, 2004.
PubMed
8) Mehta VK, et al : Image guided stereotactic radiosurgery for lesions in proximity to the anterior visual pathways : a preliminary report. Technol Cancer Res Treat 1 : 173-180, 2002.
 
9) Nishizaki T, et al : The role of cyberknife radiosurgery/radiotherapy for brain metastases of multiple or large-size tumors. Minim Invasive Neurosurg 49 : 203-209, 2006.
PubMed
10) Shimamoto S, et al : CyberKnife stereotactic irradiation for metastatic brain tumors. Radiat Med 20 : 299-304, 2002.
PubMed
11) Yoshikawa K, et al : CyberKnife stereotactic radiotherapy for patients with malignant glioma. Minim Invasive Neurosurg 49 : 110-115, 2006.
PubMed
12) Sato K, et al : Radiation necrosis and brain edema association with CyberKnife treatment. Acta Neurochir Suppl 86 : 513-517, 2003.
PubMed
13) Chang SD, et al : Staged stereotactic irradiation for acoustic neuroma. Neurosurgery 56 : 1254-1263, 2005.
PubMed
14) Ishihara H, et al : CyberKnife radiosurgery for vestibular schwannoma. Minim Invasive Neurosurg 47 : 290-293, 2004.
PubMed
15) Davey P, et al : A phase I/II study of salvage radiosurgery in the treatment of recurrent brain metastases. Br J Neurosurg 8 : 717-723, 1994.
 
P.419 掲載の参考文献
1) Kanai T, et al : Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys 44 : 201-210, 1999.
PubMed
2) Tsujii H, et al : Preliminary results of phase I/II carbon-ion therapy at the National Institute of Radiological Sciences. J Brachytherapy Int 13 : 1-8, 1997.
 
3) Tsujii H, et al : Overview of clinical experiences on carbon ion radiotherapy at NIRS. Radiother Oncol 73 : 41-49, 2004.
 
4) Tsujii H, et al : Clinical results of carbon ion radiotherapy at NIRS. J Radiat Res 48A : A1-13, 2007.
 
5) Mizoe J, et al : Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas : combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 69 : 390-396, 2007.
PubMed
6) Curran WJ, et al : Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85 : 704-710, 1993.
PubMed
7) Stupp R, et al ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups ; National Cancer Institute of Canada Clinical Trials Group : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005.
 
8) Hegi ME, et al : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005.
PubMed
9) Mahasittiwat P, et al : L- [Methyl-11C] methionine positron emission tomography for target delineation in malignant gliomas : impact on results of carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 70 : 515-522, 2008.
PubMed
10) Hasegawa A, et al : Outcomes of visual acuity in carbon ion radiotherapy : analysis of dose-volume histograms and prognostic factors. Int J Radiat Oncol Biol Phys 64 : 396-401, 2006.
PubMed
11) Catton C, et al : Chordoma : Long-term follow-up after radical photon irradiation. Radiother Oncol 41 : 67-72, 1996.
PubMed
12) Forsyth PA, et al : Intracranial chordomas : A clinicopathological and prognostic study of 51 cases. J Neurosurg 78 : 741-747, 1993.
 
13) Munzenrider JE, Liebsch NJ : Proton therapy for tumors of the skull base. Strahlenther Onkol 175 (2) : 57-63, 1999.
 
14) Hug EB, et al : Proton radiation therapy for chordomas and chondrosarcomas of the skull basa. J Neurosurg 91 : 432-439, 1999.
 
15) Noel G, et al : Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure. Strahlenther Onkol 179 : 241-248, 2003.
PubMed
P.426 掲載の参考文献
1) Wilson RR : Radiological use of fast protons. Radiology 47 : 487-491, 1946.
PubMed
2) Gerelchuluun A, et al : Induction of in-situ DNA double strand breaks and apoptosis by 200 MeV protons and 10 MV X-rays in human tumor cell lines. Int J Radiat Biol 2010. (in press)
 
3) Scott CB, et al : Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients : a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40 : 51-55, 1998.
PubMed
4) Fitzek MM, et al : Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme : results of a phase II prospective trial. J Neurosurg 91 : 251-260, 1999.
 
5) Mizumoto M, et al : Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys 77 : 98-105, 2010.
PubMed
6) Munzenrider JE, Liebsch NJ : Proton therapy for tumors of the skull base. Strahlenther Oncol 175 : 57-63, 1999.
 
7) Igaki H, et al : Clinical results of proton beam therapy for skull base chordoma. Int J Radiat Oncol Biol Phys 60 : 1120-1126, 2004.
PubMed
8) Hayashi Y, et al : Long-term results of proton beam radiotherapy for skull base chordomas. Skull Base 2010. (in press)
 
9) Kjellberg RN, et al : Bragg-peak proton-beam therapy for arteriovenous malformations of the brain. N Engl J Med 309 : 269-274, 1983.
PubMed
10) Weber DC, et al : Proton beam radiosurgery for vestibular schwannoma : tumor control and cranial nerve toxicity. Neurosurgery 53 : 577-586, discussion 586-588, 2003.
 
11) Bush DA, et al : Fractionated proton beam radiotherapy for acoustic neuroma. Neurosurgery 50 : 270-273, discussion 273-275, 2002.
 
12) Noel G, et al : Functional outcome of patients with benign meningioma treated by 3D conformal irradiation with a combination of photons and protons. Int J Radiat Oncol Biol Phys 62 : 1412-1422, 2005,
PubMed
13) Fitzek MM, et al : Combined proton and photon irradiation for craniopharyngioma : long-term results of the early cohort of patients treated at Harvard Cyclotron Laboratory and Massachusetts General Hospital. Int J Radiat Oncol Biol Phys 64 : 1348-1354, 2006.
PubMed
14) Macdonald SM, et al : Proton radiotherapy for pediatric central nervous system germ cell tumors : early clinical outcomes. Int J Radiat Oncol Biol Phys 2010 May 6. [Epub ahead of print]
 
15) MacDonald SM, et al : Proton radiotherapy for childhood ependymoma : initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys 71 : 979-986, 2008.
PubMed
P.430 掲載の参考文献
1) Barth RF, et al : Boron neutron capture therapy of cancer : current status and future prospects. Clin Cancer Res 11 : 3987-4002, 2005.
PubMed
2) Diaz AZ : Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J Neurooncol 62 : 101-109, 2003.
 
3) Chanana AD, et al : Boron neutron capture therapy for glioblastoma multiforme : interim results from the phase I/II dose-escalation studies. Neurosurgery 44 : 1182-1192, 1999.
PubMed
4) Skold K et al : Boron Neutron Capture Therapy for glioblastoma multiforme : advantage of prolonged infusion of BPA-f Acta Neurol Scand 122 : 58-62, 2009.
PubMed
5) Nakagawa Y, Hatanaka H : Boron neutron capture therapy. Clinical brain tumor studies. J Neurooncol 33 : 105-115, 1997.
PubMed
6) 小野公二ほか : BNCTによる悪性神経膠腫の治療成績. 臨床放射線 44 : 227-233, 1999.
 
7) Yokoyama K, et al : Analysis of boron distribution in vivo for boron neutron capture therapy using two different boron compounds by secondary ion mass spectrometry. Radiat Res 167 : 102-109, 2007.
PubMed
8) 宮武仲一ほか : 悪性グリオーマに対する非開頭硼素中性子捕捉療法. 日本臨牀 63 (増刊号9) : 447-451, 2005.
 
9) Kawabata S, et al : The early successful treatment of glioblastoma patients with modified boron neutron capture therapy. Report of two cases. J Neurooncol 65 : 159-165, 2003.
 
10) Kawabata S, et al : Boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res (Tokyo) 50 : 51-60, 2009.
PubMed
11) Yamamoto T, et al : Boron neutron capture therapy for newly diagnosed glioblastoma. Radiother Oncol 91 : 80-84, 2009.
PubMed
12) Miyatake S, et al : Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms : an efficacy study based on findings on neuroimages. J Neurosurg 103 : 1000-1009, 2005.
PubMed
13) Pellettieri L, et al : An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme. Acta Neurol Scand 117 : 191-197, 2008.
PubMed
14) Miyatake S, et al : Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol 91 : 199-206, 2009.
PubMed
15) Barth RF : Boron neutron capture therapy at the crossroads : challenges and opportunities. Appl Radiat Isot 67 : S3-6, 2009.
PubMed
P.436 掲載の参考文献
1) Slatkin DN, et al : Subacute neuropathological effects of microplanar beams of X-rays from a synchrotron wiggler. Proc Natl Acad Sci USA 92 : 8783-8787, 1995.
PubMed
2) Laissue JA et al : Neuropathology of ablation of rat gliosarcomas and contiguous brain tissues using amicroplanar beam of synchrotron-wiggler-generated X rays. Int J Cancer 78 : 654-660, 1998.
PubMed
3) Nariyama N, et al : Spectromicroscopic film dosimetry for high-energy microbeam from synchrotron radiation. Appl Radiat Isot 67 : 155-159, 2009.
PubMed
4) Kashino G, et al : Induction of DNA double-strand breaks and cellular migration through bystander effects in cells irradiated with the slit-type microplanar beam of the spring-8 synchrotron. Int J Radiat Oncol Biol Phys 74 : 229-236, 2009.
PubMed
5) Dilmanian FA, et al : Interlaced X-ray microplanar beams : a radiosurgery approach with clinical potential. Proc Natl Acad Sci USA 103 : 9709-9714, 2006.
 
6) Serduc R et al : First trial of spatial and temporal fractionations of the delivered dose using synchrotron microbeam radiation therapy. J Synchrotron Radiat 16 : 587-590, 2009.
PubMed
7) Dilmanian FA, et al : Response of rat intracranial 9L gliosarcoma to microbeam radiation therapy. Neuro Oncol 4 : 26-38, 2002.
PubMed
8) Serduc R, et al : Synchrotron microbeam radiation therapy for rat brain tumor palliation-influence of the microbeam width at constant valley dose. Phys Med Biol 54 : 6711-6724, 2009.
PubMed
P.446 掲載の参考文献
1) Jain R, et al : Treatment induced necrosis versus recurrent/progressing brain tumor : going beyond the boundaries of conventional morphologic imaging. J Neurooncol 100 : 17-29, 2010.
PubMed
2) Alexiou GA, et al : Glioma recurrence versus radiation necrosis : accuracy of current imaging modalities. J Neurooncol 95 : 1-11, 2009.
PubMed
3) Yang I, et al : Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy. Neurosurg Clin N Am 21 : 181-186, 2010.
PubMed
4) Brandsma D, van den Bent MJ : Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22 : 633-638, 2009.
PubMed
5) Miyatake S, et al : Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas. Neuro Oncol 11 : 430-436, 2009.
PubMed
6) Kumar AJ, et al : Malignant gliomas : MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment. Radiology 217 : 377-384, 2000.
PubMed
7) Dequesada IM, et al : Can standard magnetic resonance imaging reliably distinguish recurrent tumor from radiation necrosis after radiosurgery for brain metastases? A radiographic-pathological study, Neurosurgery 63 : 898-890, 2008.
PubMed
8) Barajas RF Jr, et al : Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 253 : 486-496, 2009.
PubMed
9) Jain R, et al : First-pass perfusion computed tomography : initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis. Neurosurgery 61 : 778-786, 2007.
PubMed
10) Ozsunar Y, et al : Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging. Acad Radiol 17 : 282-290, 2010.
PubMed
11) Asao C, et al : Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. AJNR Am J Neuroradiol 26 : 1455-1460, 2005.
PubMed
12) Sundgren PC, et al : Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magn Reson Imaging 24 : 1131-1142, 2006.
PubMed
13) Zeng QS, et al : Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J Neurooncol 84 : 63-69, 2007.
PubMed
14) Zeng QS, et al : Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Phys 68 : 151-158, 2007.
PubMed
15) Rock JP, et al : Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 54 : 1111-1117, 2004.
PubMed
16) Kracht LW, et al : Methyl- [11C] -1-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 30 : 868-873, 2003.
 
17) Becherer A, et al : Brain tumour imaging with PET : a comparison between [18F] fluorodopa and [11C] methionine. Eur J Nucl Med Mol Imaging 30 : 1561-1567, 2003.
PubMed
18) Ichinose T, et al : Discrepancy between [18F] fluorodeoxyglucose and 11C-methionine positron emission tomography findings in Sturge-Weber syndrome-case report. Neurol Med Chir (Tokyo) 43 : 461-464, 2003.
PubMed
19) Tsuyuguchi N, et al : Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery : is a differential diagnosis possible? J Neurosurg 98 : 1056-1064, 2003.
PubMed
20) Terakawa Y, et al : Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49 : 694-699, 2008. (doi : 10.2967/jnumed. 107.048082)
 
21) Spence AM, et al : NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'- [18F] fiuorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas : preliminary efficacy studies. Mol Imaging Biol 11 : 343-355, 2009.
PubMed
P.451 掲載の参考文献
1) 若林俊彦 : グリオーマ III. テモゾロミドとの多剤併用化学療法. 癌と化学療法 36 : 938-940, 2009.
 
2) Enting RH, et al : Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63 : 901-903, 2004.
PubMed
3) Verger E, et al : Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases : a phase II randomized trial. Int J Radiat Oncol Biol Phys 61 : 185-191, 2005.
PubMed
4) 竹島秀雄, 倉津純一 : 悪性脳腫瘍の化学療法. 脳神経外科 31 : 725-734, 2003.
 
5) Yoshimura J, et al : Intrathecal chemotherapy for refractory disseminated medulloblastoma. Childs Nerv Syst 24 : 581-585, 2008.
PubMed
6) Stupp R, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005.
PubMed
7) Wakabayashi T, et al : A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high grade gliomas (INTEGRA study). Jpn J Clin Oncol 38 : 715-718, 2008.
PubMed
8) Molinari C, et al : Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas : a descriptive study. Int J Mol Med 25 : 145-151, 2010.
PubMed
9) Caimcross G, Jenkins R : Gliomas with 1p/19q codeletion : a. k. a. oligodendroglioma. Cancer J 14 : 352-357, 2008.
 
10) Abrey LE, et al : Treatment for primary CNS lymphoma : the next step. J Clin Oncol 18 : 3144-3150, 2000.
PubMed
11) Matsutani M, et al : Combined chemotherapy and radiation therapy for central nervous system germ cell tumors : preliminary results of a Phase II study of the Japanese Pediatric Brain Tumor Study Group. Neurosurg Focus 5 (1) : e7, 1998.
 
12) Ushio Y, et al : Preliminary observation for a new treatment in children with primary intracranial yolk sac tumor or embryonal carcinoma. Report of five cases. J Neurosurg 90 : 133-137, 1999.
 
13) 中州庸子, 三矢幸一 : 転移性脳腫瘍の診断と治療. 癌と化学療法 37 : 204-210, 2010.
 
14) Dae-Young K, et al : Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of asolid tumor : Methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol 33 : 608-612, 2003.
 
15) Shibui S : Randomized controlled trial on malignant brain tumors-Articles of the Japan Clinical Oncology Group Brain Tumor Study Group-. Neurol Med Chir 44 : 220-221, 2004.
 
P.455 掲載の参考文献
1) Kondo T, et al : In vitro test for sensitivity of tumor to carcinostatic agents. Gann 57 : 113-121, 1966.
PubMed
2) Suto A, et al : MTT assay with reference to the clinical effect of chemotherapy. J Surg Oncol 42 : 28-32, 1989.
 
3) Mosmann T : Rapid colorimetric assay for cellular growth and survival : application to proliferation and cytotoxicity assays. J Immunol Methods 65 : 55-63, 1983.
PubMed
4) Hoffman RM : In vitro assays for chemotherapy sensitivity. Crit Rev Oncol Hematol 15 : 99-111, 1993.
PubMed
5) Bromidge TJ, et al : In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues-correlation with clinical course. Leukemia 12 : 1230-1235, 1998.
PubMed
6) Bosanquet AG, Bell PB : Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined DiSC assay methodology. Leuk Res 20 : 143-153, 1996.
PubMed
7) Bosanquet AG, et al : Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. Br J Haematol 106 : 71-77, 1999.
PubMed
8) Chin KV, et al : Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255 : 459-462, 1992.
PubMed
9) Aas T, et al : Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2 : 811-814, 1996.
PubMed
10) Hawkins DS, et al : Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56 : 892-898, 1996.
PubMed
11) Thottassery JV, et al : p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 94 : 11037-11042, 1997.
PubMed
12) Miyake K, et al : Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells : demonstration of homology to ABC transport genes. Cancer Res 59 : 8-13, 1999.
PubMed
13) Decleves X, et al : Role of ABC transporters in the chemoresistance of human gliomas. Curr Cancer Drug Targets 6 : 433-445, 2006.
PubMed
14) Hegi ME, et al : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005.
PubMed
15) Miyake K : The tailor-made chemotherapy for the human malignant brain tumors. In : New Perspectives in Cancer Research and Therapy (ed by Kuriyama S, Yoshiji H), p337-356, Research Signpost, Kerala, 2005.
 
P.463 掲載の参考文献
1) Aoki T, et al : Management of glioblastoma. Expert Opin Pharmacother 8 : 3133-3146, 2007.
PubMed
2) Wen PY, Kesari S : Malignant gliomas in adults. N Engl J Med 359 : 492-507, 2008.
PubMed
3) Walker MD, et al : An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5 : 1725-1731, 1979.
PubMed
4) Chang CH, et al : Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 52 : 997-1007, 1983.
 
5) Souhami L, et al : Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme : report of Radiation Therapy Oncology Group 93-05 protocol, Int J Radiat Oncol Biol Phys 60 : 853-860, 2004.
PubMed
6) Walker MD, et al : Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49 : 333-343, 1978.
 
7) Stupp R, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005.
PubMed
8) Neuradiab SNO 2008 abstract. [http://www.glassarttriaLcom/]
 
9) Celldex 2008 ASCO presentation. [http://www.celldextherapeutics.com/ (http://www.celldextherapeutics.com/pdf/ASCO_ACT%2011_poster6_presented%2005.30. 2009.pdf) ]
 
10) Merck KGaA 2007 ASCO presentation. [http://www.euroinvestor.co.uk/news/story.aspx?id=10469614]
 
11) Chen AM, et al : Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 69 (3) : 825-830, 2007.
PubMed
12) Aoki T, et al : Phase II study of nimustine, carboplatin, vincristine, and interferon-b with radiotherapy for glioblastoma multiforme : experience of the Kyoto Neuro-Oncology Group. J Neurosurg 105 : 385-391, 2006.
 
13) Combs SE, et al : Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. Int J Radiat Oncol Biol Phys 71 (4) : 999-1005, 2008.
PubMed
14) Caroli M, et al : Temozolomide in glioblastoma : results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol? J Neurooncol 84 : 71-77, 2007.
PubMed
15) Herrlinger U, et al : Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma : UKT-03. J Clin Oncol 24 (27) : 4412-4417, 2006.
PubMed
16) De Sanctis V, et al : Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme. Anticancer Drugs 17 (8) : 969-975, 2006.
PubMed
17) Buckner JC, et al : Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme : North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol 24 (24) : 3871-3879, 2006.
PubMed
18) Westphal M, et al : A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5 : 79-88, 2003.
 
19) Brandsma D, et al : Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9 (5) : 453-461, 2008.
PubMed
P.467 掲載の参考文献
1) Fouladi M, et al : Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945. Cancer 98 : 1243-1252, 2003.
PubMed
2) Gnekow AK, et al : Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy-report from the multicenter treatment study for children and adolescents with a low grade glioma-HIT-LGG 1996-of the Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr 216 : 331-342, 2004.
 
3) Packer RI, et al : Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86 : 747-754, 1997.
 
4) Prados MD, et al : Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol 32 : 235-241, 1997.
PubMed
5) Gururangan S, et al : Temozolomide in children with progressive low-grade glioma. Neuro Oncol 9 : 161-168, 2007.
PubMed
6) Lafay-Cousin L, et al : Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma : a Canadian Pediatric Brain Tumor Consortium experience. Cancer 112 : 892-899, 2008.
PubMed
7) Ater J, et al : Results of COG protocol A9952 : A randomized phase 3 study of two chemotherapy regimens for incompletely resected low-grade glioma in young children. Neuro Oncol 10 : 451-452, 2008.
 
8) Bouffet E, et al : Phase II study of weekly vinblastine in recurrent/refractory pediatric low-grade gliomas. Neuro Oncol 10 (3) : 450, 2008.
 
9) Lafay-Cousin L, et al : Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 103 : 2636-2642, 2005.
PubMed
10) Sposto R, et al : The effectiveness of chemotherapy for treatment of high grade astrocytoma in children : results of a randomized trial. A report from the Children's Cancer Study Group. J Neurooncol 7 : 165-177, 1989.
 
11) Finlay IJ, et al : Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol 13 : 112-123, 1995.
 
12) Nicholson HS, et al : Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors : a report from the Children's Oncology Group. Cancer 110 : 1542-1550, 2007.
 
13) Grovas AC, et al : Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme ; report from Children's Cancer Group. Med Pediatr Oncol 33 : 83-87, 1999.
 
14) Massimino M, et al : Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro Oncol 7 : 41-48, 2005.
PubMed
15) Pollack IF, et al : Phase I trial of imatinib in children with newly diagnosed brain stem and recurrent malignant gliomas. Neuro Oncol 9 : 145-160, 2007.
PubMed
P.472 掲載の参考文献
1) Stupp R et al ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups ; National Cancer Institute of Canada Clinical Trials Group : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005.
 
2) Hegi ME, et al : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005.
PubMed
3) Markert JM, et al : Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma : results of phase I trial. Gene Ther 7 : 867-874, 2000.
PubMed
4) Jiang H, et al : Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells : role of autophagic cell death. J Natl Cancer Inst 99 : 1410-1414, 2007.
PubMed
5) Parsons DW, et al : An integrated genomic analysis of human glioblastoma multiforme. Science 321 : 1807-1812, 2008.
PubMed
6) Iwadate Y, et al : Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats. Clin Cancer Res 11 : 3821-3827, 2005.
PubMed
7) Yoshida J, et al : Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human β-interferon gene using cationic liposomes. Hum Gene Ther 15 : 77-86, 2004.
 
P.477 掲載の参考文献
1) Markert JM, et al : Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma : results of a phase I trial. Gene Ther 7 : 867-874, 2000.
PubMed
2) Markert JM, et al : Phase lb trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17 : 199-207, 2009.
 
3) Rampling R, et al : Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7 : 859-866, 2000.
PubMed
4) Papanastassiou V, et al : The potential for efficacy of the modified (ICP 34.5-) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma : a proof of principle study. Gene Ther 9 : 398-406, 2002.
PubMed
5) Harrow S, et al : HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma : safety data and long-term survival. Gene Ther 11 : 1648-1658, 2004.
PubMed
6) Chiocca EA, et al : A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10 : 958-966, 2004.
PubMed
7) Forsyth P, et al : A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 16 : 627-632, 2008.
 
8) Freeman AI, et al : Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13 : 221-228, 2006.
PubMed
9) Msaouel P, et al : Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer : an overview. Curr Opin Mol Ther 11 : 43-53, 2009.
PubMed
10) Martuza RL, et al : Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252 : 854-856, 1991.
PubMed
11) Mineta T, et al : Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1 : 938-943, 1995.
 
12) Markert JM, et al : Genetically engineered HSV in the treatment of glioma : a review. Rev Med Virol 10 : 17-30, 2000.
PubMed
13) Todo T, et al : Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 98 : 6396-6401, 2001.
PubMed
14) Csatary LK, et al : MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 67 : 83-93, 2004.
PubMed
15) Parker JN, et al : Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6 : 558-569, 2009.
PubMed
P.482 掲載の参考文献
1) Ichikawa T, Chiocca EA : Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or-defective viral vector. Cancer Res 61 (14) : 5336-5339, 2001.
PubMed
2) Todo T, et al : Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 98 (11) : 6396-6401, 2001.
PubMed
3) Piao Y, et al : Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther 16 (3) : 256-265, 2009.
PubMed
4) Ino Y, et al : Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 12 (2) : 643-652, 2006.
PubMed
5) Ichikawa T, et al : Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res 61 (3) : 864-868, 2001.
PubMed
6) Forsyth P, et al : A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 16 (3) : 627-632, 2008.
 
7) Tyler MA, et al : Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther 16 (2) : 262-278, 2009.
PubMed
8) Kurozumi K, et al : Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99 (23) : 1768-1781, 2007.
PubMed
9) Kurozumi K, et al : Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 16 (8) : 1382-1391, 2008.
PubMed
10) Ikeda K, et al : Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 5 (8) : 881-887, 1999.
PubMed
11) Kim JH, et al : Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 98 (20) : 1482-1493, 2006.
PubMed
12) Aghi MK, et al : Hypoxia enhances the replication of oncolytic herpes simplex virus. Mol Ther 17 (1) : 51-56, 2009.
PubMed
13) Wakimoto H, et al : Human glioblastoma-derived cancer stem cells : establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 69 (8) : 3472-3481, 2009.
PubMed
14) Kambara H, et al : An oncolytic HSV-1 mutant expressing ICP34.5 under control of nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65 : 2832-2839, 2005.
PubMed
15) Yokoyama T, et al : Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Ther 15 (17) : 1233-1239, 2008.
PubMed
P.487 掲載の参考文献
1) Reardon DA, et al : Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23 : 9359-9368, 2005.
PubMed
2) Fine HA, et al : Thornton results from Phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 23 (S16) (1 Suppl) : 1504, 2005.
 
3) Vredenburgh JJ, et al : Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13 : 1253-1259, 2007.
PubMed
4) Mellinghoff IK, et al : Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 : 2012-2024, 2005.
PubMed
5) Galanis E, et al : Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme : a North central cancer treatment group study. J Clin Oncol 23 : 5294-5304, 2005.
 
6) Presta LG, et al : Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57 : 4593-4599, 1997.
PubMed
7) Lai A, et al : Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 27 : 15s, 2009 (suppl ; abstr 2000).
 
8) Gruber ML, et al : Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma : Update progression-free survival, overall survival, and toxicity. J Clin Oncol 27 : 15s, 2009 (suppl ; abstr 2017).
 
9) Friedman HS, et al : Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27 (28) : 4733-4740, 2009.
PubMed
P.493 掲載の参考文献
1) Mischel PS, Cloughesy T : Targeted molecular therapy of GBM. Brain Pathol 13 : 52-61, 2003.
PubMed
2) Rich JN, Bigner DD : Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3 : 430-446, 2004.
PubMed
3) Reardon DA, et al : Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24 : 1253-1265, 2006.
PubMed
4) Stupp R, et al : Chemoradiotherapy in malignant glioma : standard of care and future directions. J Clin Oncol 25 : 4127-4136, 2007.
PubMed
5) Mellinghoff IK, et al : Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (19) : 2012-2024, 2005.
 
6) Reardon DA, Wen PY : Therapeutic advances in the treatment of glioblastoma : rationale and potential role of targeted agents. Oncologist 11 : 152-164, 2006.
PubMed
7) Sathornsumetee S, et al : Molecular targeted therapy for malignant glioma. Cancer 100 : 13-24, 2007.
 
8) Huang TT, et al : Targeted therapy for malignant glioma patients : lessons learned and the road ahead. Neurotherapeutics 6 : 500-512, 2009.
PubMed
9) Mischel PS, et al : Molecular analysis of glioblastoma : pathway profiling and its implications for patient therapy. Cancer Biol Ther 2 : 242-247, 2003.
PubMed
10) Mischel PS, et al : DNA-microarray analysis of brain cancer : molecular classification for therapy. Nat Rev Neurosci 5 : 782-792, 2004.
PubMed
11) Chakravarti A, et al : Impact of molecular profiling on clinical trial design for glioblastoma. Curr Oncol Rep 9 : 71-79, 2007.
PubMed
12) Phillips HS, et al : Molecular subclasses of high-grade glioma predict prognosis, delineate a pattem of disease progression, and resemble stages in neurogenesis. Cancer Cell 9 : 157-173, 2006.
 
13) Cancer Genome Atlas Research Network : Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 : 1061-1068, 2008.
 
14) Cloughesy TF, et al : Antitumor activity of rapamycin in a Phase 1 trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5 : 139-151, 2008.
 
15) Weil RI : Incorporating molecular tools into early-stage clinical trials. PLoS Med 5 : 34-38, 2008.
 
P.504 掲載の参考文献
1) Stupp R, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005.
PubMed
2) Vredenburgh JJ, et al : Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25 : 4722-4729, 2007,
PubMed
3) Friedman HS, et al : Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27 : 4733-4740, 2009.
PubMed
4) Yung WK, et al : A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83 : 588-593, 2000.
PubMed
5) Yung WK, et al : Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17 : 2762-2771, 1999.
 
6) Nghiemphu P, et al : Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 10 : 355-360, 2008.
PubMed
7) Chamberlain MC, Johnston SK : Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 96 : 259-269. 2010.
PubMed
8) Kreisl TN, et al : Phase II trial of single agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27 : 740-745, 2009.
PubMed
9) Narayana A, et al : Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnoses high-grade glioma. Int J Radiat Oncol Biol Phys 72 : 383-389, 2008.
PubMed
10) Norden AD, et al : An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 92 : 149-155, 2009.
PubMed
11) Quant EC, et al : Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11 : 550-555, 2009.
PubMed
12) Torcuator RG, et al : The role of salvage reirradiation for malignant gliomas that progress on bevacizumab. J Neurooncol 97 : 401-407, 2010.
PubMed
13) Lai A, et al : Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme : interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71 : 1372-1380, 2008.
PubMed
14) Gomez-Manzano C, et al : VEGF trap induces antiglioma effect at different stages of disease. Neuro Oncol 10 : 940-945, 2008.
PubMed
15) Batchelor Tr, et al : AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 : 83-95, 2007.
 
16) van den Bent MJ, et al : End point assessment in gliomas : novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol 27 : 2905-2908, 2009.
 
17) Rieger J, et al : Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 99 : 49-56, 2010.
PubMed
18) Sorensen AG, et al : A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69 : 5296-5300, 2009.
PubMed
19) Bergers G, Hanahan D : Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 8 : 592-603, 2008.
PubMed
20) Takano S, et al : Molecular therapeutic targets for glioma angiogenesis. J Oncol 2010 : 351908, 2010. (doi : 10.1155)
 
21) Jain RK, et al : Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6 : 327-338, 2009.
PubMed
22) Takano S, et al : Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56 : 2185-2190, 1996.
PubMed
23) Rafat N, et al : Circulating endothelial progenitor cells in malignant gliomas. J Neurosurg 112 : 43-49, 2010.
PubMed
24) Smith ER, et al : Urinary biomarker predict brain tumor presence and response to therapy. Clin Cancer Res 14 : 2378-2386, 2008.
PubMed
25) Lucio-Eterovic AK, et al : Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 15 : 4589-4599, 2009.
PubMed
26) Takano S, et al : Detection of failure of bevacizumab treatment for malignant glioma based on urinary metalloproteinase activity. Brain Tumor Pathol, 2010. (in press)
 
27) Jouanneau E : Angiogenesis and gliomas : current issues and development of surrogate markers. Neurosurgery 62 : 31-52, 2008.
PubMed
28) Anderson JC, et al : New molecular targets in the angiogenic vessels of glioblastoma tumors. Expert Rev Mol Med 10 : e23, 2009.
 
29) Reardon DA, et al : Cilengitide : an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 17 : 1225-1235, 2008.
PubMed
30) Fish JE, Srivastava D : MicroRNAs : opening a new vein in angiogenesis research. Sci Signal 2 (52) : pe1, 2009. (doi : 10.1126)
 
31) Wurdinger T, et al : miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 14 : 382-393, 2008.
PubMed
32) Methieu V, et al : Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 10 : 1383-1392, 2008.
 
33) Kamiyama H, et al : Anti-angiogenic effects of Sn 38 (active metabolite of irinotecan) : inhibition of hypoxia-inducible factor 1 alpha (HIF-1α) /vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol 131 : 205-213, 2005.
 
34) Tuettenberg J, et al : Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. J Cancer Res Clin Oncol 135 : 1239-1244, 2009.
PubMed
35) Kong DS, et al : Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 12 : 289-296, 2010.
PubMed
36) Takano S, et al : Metronomic treatment of malignant glioma xenografts with irinotecan (CPT11) inhibits angiogenesis and tumor growth. J Neurooncol 99 : 177-185, 2010.
PubMed
37) Mashiko R, et al : Hypoxia-inducible factor 1α expression is a prognostic biomarker in patients with astrocytic tumors associated with necrosis on MR image. J Neurooncol, 2010. (doi : 10.1007) (in press)
 
38) Jain RK, et al : Angiogenesis in brain tumours. Nat Rev Neurosci 8 : 610-622, 2007.
PubMed
P.510 掲載の参考文献
1) de Groot JF, et al : Tumor invasion after treatment of glioblastoma with bevacizumab : radiographic and pathologic correlation in humans and mice. Neuro Oncol 12 : 233-242, 2010.
PubMed
2) Inoue S, et al : Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas. (submitted)
 
3) Maruo T, et al : Proteomics-based analysis of invasion-related proteins in malignant gliomas. (submitted)
 
4) Nakada M, et al : Molecular targets of glioma invasion. Cell Mol Life Sci 64 : 458-478, 2007.
PubMed
5) Tate MC, Aghi MK : Biology of angiogenesis and invasion in glioma. Neurotherapeutics 6 : 447-457, 2009.
PubMed
6) Nagano O, Saya H : Mechanism and biological significance of CD44 cleavage. Cancer Sci 95 : 930-935, 2004.
PubMed
7) Cox EA, Huttenlocher A : Regulation of integrin-mediated adhesion during cell migration. Microsc Res Tech 43 : 412-419, 1998.
PubMed
8) de Groot J, Milano V : Improving the prognosis for patients with glioblastoma : the rationale for targeting Src. J Neurooncol 95 : 151-163, 2009.
PubMed
9) Xie D, et al : Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res 64 : 1987-1996, 2004.
PubMed
10) Rao JS : Molecular mechanisms of glioma invasiveness : the role of proteases. Nat Rev Cancer 3 : 489-501, 2003.
PubMed
11) Nowicki MO, et al : Lithium inhibits invasion of glioma cells ; possible involvement of glycogen synthase kinase-3. Neuro Oncol 10 : 690-699, 2008.
PubMed
12) Beadle C, et al : The role of myosin II in glioma invasion of the brain. Mol Biol Cell 19 : 3357-3368, 2008.
 
13) Reardon DA, et al : Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26 : 5610-5617, 2008.
PubMed
14) Reardon DA, et al : Cilengitide : an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 17 : 1225-1235, 2008.
PubMed
15) Groves MD, et al : Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20 : 1383-1388, 2002.
PubMed
P.514 掲載の参考文献
1) Carpentier AF, Meng Y : Recent advances in immunotherapy for human glioma. Curr Opin Oncol 18 : 631-636, 2006.
PubMed
2) Kushen MC, et al : Current immunotherapeutic strategies for central nervous system tumors. Surg Oncol Clin N Am 16 : 987-1004, xii, 2007.
 
3) Rosenberg SA, et al : Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313 : 1485-1492, 1985.
PubMed
4) Dillman RO, et al : Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27 : 398-404, 2004.
PubMed
5) Yoshida S, et al : Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res 48 : 5011-5016, 1988.
PubMed
6) Ishikawa E, et al : Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 24 : 1861-1871, 2004.
PubMed
7) Holladay FP, et al : Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma. J Neurooncol 27 : 179-189, 1996.
PubMed
8) Plautz GE, et al : T-cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6 : 2209-2218, 2000.
PubMed
9) Sloan AE, et al : Adoptive immunotherapy in patients with recurrent malignant glioma : Preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus 9 : e9, 2000.
PubMed
10) Tsuboi K, et al : Effects of local injection of ex vivo expanded autologous tumor-specific T-lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res 9 : 3294-3302, 2003.
PubMed
11) Dudley ME, et al : Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 : 2346-2357, 2005.
 
12) Motohashi S, et al : A phase I study of in vitro expanded natural killer T-cells in patients with advanced and recurrent nonsmall cell lung cancer. Clin Cancer Res 12 : 6079-6086, 2006.
PubMed
13) Peres E, et al : High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors. Neuropediatrics 39 : 151-156, 2008.
PubMed
14) Ishikawa E, et al : Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci 98 : 1226-1233, 2007.
PubMed
15) Yamanaka R, et al : Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma : Results of a clinical phase I/II trial. Clin Cancer Res 11 : 4160-4167, 2005.
PubMed
P.519 掲載の参考文献
1) Oka Y, et al : Induction of WT1 (Wilms' tumor gene) -specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101 : 13885-13890, 2004.
PubMed
2) Izumoto S, et al : Phase II clinical trial of WT1 (Wilms tumor gene) peptide vaccination for patients with recurrent glioblastoma. J Neurosurg 108 : 963-971, 2008.
PubMed
3) Oka Y, et al : Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 51 : 99-107, 2000.
PubMed
4) Gao L, et al : Selective elimination of leukemic CD34 (+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95 : 2198-2203, 2000.
PubMed
5) Ohminami H, et al : HLA class I-restricted lysis of leukemia cells by a CD8 (+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95 : 286-293, 2000.
 
6) Li Z, et al : Identification of a WTl protein-derived peptide, WT1 as a HLA-A*0206-restricted, WT1-specific CTL epitope. Microbiol Immunol 52 : 551-558, 2008.
 
7) Oka Y, et al : Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 164 : 1873-1880, 2000.
PubMed
8) Oka Y, et al : Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 78 : 56-61, 2003.
PubMed
9) Tsuboi A, et al : Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol 86 : 414-417, 2007.
 
10) Iiyama T, et al : WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 51 : 519-530, 2007.
PubMed
11) Therasse P, et al : New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (3) : 205-216, 2000.
PubMed
12) Wong ET, et al : Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17 (8) : 2572-2578, 1999.
PubMed
13) Stupp R, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (10) : 987-996, 2006.
 
14) Fujiki F, et al : Identification and characterization of a WT1 (Wilms tumor gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. J Immunother 30 : 282-293, 2007.
PubMed
15) Chiba Y, et al : Effects of concomitant temozolomide and radiation therapies on WT1-specific T cells in malignant glioma. Jpn J Clin Oncol 40 (5) : 395-408, 2010.
PubMed
P.526 掲載の参考文献
1) Yu JS, et al : Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61 : 842-847, 2001.
PubMed
2) Yu JS, et al : Vaccination with tumor lysate pulsed dendritic cells elicits antigen specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64 : 4973-4979, 2004.
PubMed
3) Liau LM, et al : Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11 : 5515-5525, 2005.
PubMed
4) Liau LM, et al : Dendritic cell vaccination in combination with TLR-7 agonist, imiquimod following radio-chemotherapy for newly diagnosed glioblastoma. Proc Am Soc Clin Oncol 25 : 2021, 2007.
 
5) Rutkowski S, et al : Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 91 : 1656-1662, 2004.
PubMed
6) Kikuchi T, et al : Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50 : 337-344, 2001.
PubMed
7) Kikuchi T, et al : Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27 : 452-459, 2004.
PubMed
8) Yamanaka R et al : Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses : results of a clinical phase I/II trial. Br J Cancer 89 : 1172-1179, 2003.
PubMed
9) Yamanaka R, et al : Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma : results of a clinical phase I/II trial. Clin Cancer Res 11 : 4160-4167, 2005.
PubMed
10) Wheeler CJ, et al : Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68 : 5955-5964, 2008.
PubMed
11) De Vleeschouwer S, et al : Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14 : 3098-3104, 2008.
PubMed
12) Yamanaka R : Cellular and peptide based immunotherapeutic approaches for glioma. Trends Mol Med 14 (5) : 228-235, 2008.
PubMed
P.531 掲載の参考文献
1) Reardon DA, et al : Phase II trial of murine (131) I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20 (5) : 1389-1397, 2002.
 
2) Reardon DA, et al : Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors : phase II study results. J Clin Oncol 24 (1) : 115-122, 2006.
PubMed
3) Cokgor I, et al : Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131) I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F (ab') (2) : a case study. Cancer 91 (9) : 1809-1813, 2001.
 
4) Coakham HB, Kemshead JT : Treatment of neoplastic meningitis by targeted radiation using (131) I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients. J Neurooncol 38 (2-3) : 225-232, 1998.
PubMed
5) Kato Y, et al : GMab-1, a high-affinity anti-3'-isoLM1/3', 6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice. Biochem Biophys Res Commun 391 (1) : 750-755, 2010.
PubMed
6) Patel SJ, et al : Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma : initial experience in 51 patients. Neurosurgery 56 (6) : 1243-1252, 2005. (discussion 1252-1253)
 
7) Maza S, et al : First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro Oncol 11 (4) : 423-429, 2009.
PubMed
8) Ravic M : Intracavitary treatment of malignant gliomas : radioimmunotherapy targeting fibronectin. Acta Neurochir Suppl 88 : 77-82, 2003.
PubMed
9) Weaver M, Laske DW : Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM 107) for therapy of malignant gliomas. J Neurooncol 65 (1) : 3-13, 2003.
 
10) Loging WT, et al : Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Res 10 (9) : 1393-1402, 2000.
PubMed
11) Emrich JG, et al : Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients : ten-year synopsis of a novel treatment. Am J Clin Oncol 25 (6) : 541-546, 2002.
PubMed
12) Papanastassiou V, et al : Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody : feasibility, pharmacokinetics and dosimetry. Br J Cancer 67 (1) : 144-151, 1993.
PubMed
13) Kramer K, et al : Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol 25 (34) : 5465-5470, 2007.
PubMed

VI 小児脳腫瘍の治療

P.538 掲載の参考文献
1) Central Brain Tumor Registry of the US : Statistical report 2004-2006 : Primary brain tumors in the United States [http://www.cbtrus.org/2010-NPCR-SEER/CBTRUS-WEBREPORT-Final-3-2-10.pdf] (Accessed March 8, 2010).
 
2) Committee of Brain Tumor Registry of Japan : Report of Brain Tumor Registry of Japan, 12th ed (1984-2000). Neurol Med Chir (Tokyo) 49 (Suppl) : 14, 2009.
 
3) Kiehna EN, et al : Changes in attentional performance of children and young adults with localized primary brain tumor after conformal radiation therapy. J Clin Oncol 24 : 5283-5290, 2006.
 
4) Yule SM, et al : Low grade astrocytomas in the West of Scotland 1987-96 : treatment, outcome, and cognitive functioning. Arch Dis Child 84 : 61-64, 2001.
PubMed
5) Laughton SJ, et al : Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J Clin Oncol 26 : 1112-1118, 2008.
 
6) Bowers DC, et al : Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors : a report from the Childhood Cancer Survivor Study. J Clin Oncol 24 : 5277-5282, 2006.
PubMed
7) Neglia JP, et al : New primary neoplasms of the central nervous system in survivors of childhood cancer : a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 98 : 1528-1537, 2006.
PubMed
8) Taylor AJ, et al : Survival after second primary neoplasms of the brain or spinal cord in survivors of childhood cancer : results from the British Childhood Cancer Survivor Study. J Clin Oncol 27 : 5781-5787, 2009.
PubMed
P.543 掲載の参考文献
1) Tait DM, et al : Adjuvant chemotherapy for medulloblastoma : the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 26 : 464-469, 1990.
PubMed
2) Evans AE, et al : The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72 : 572-582, 1990.
PubMed
3) Krischer JP, et al : Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. J Neurosurg 74 : 905-909, 1991.
 
4) Thomas PR, et al : Low-stage medulloblastoma : final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 18 : 3004-3011, 2000.
PubMed
5) Packer RJ, et al : Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81 : 690-698, 1994.
PubMed
6) Packer RJ, et al : Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy : A Children's Cancer Group Study. J Clin Oncol 17 : 2127-2136, 1999.
 
7) Packer RJ, et al : Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24 : 4202-4208, 2006.
PubMed
8) Gajjar A, et al : Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96) : long-term results from a prospective, multicentre trial. Lancet Oncol 7 : 813-820, 2006.
PubMed
9) Gandola L, et al : Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol 27 : 566-571, 2009.
PubMed
10) Duffner PK, et al : Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328 : 1725」731, 1993.
 
11) Geyer JR, et al : Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors : a report from the Children's Cancer Group. J Clin Oncol 23 : 7621-7631, 2005.
 
12) Dhall G, et al : Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols. Pediatr Blood Cancer 50 : 1169-1175, 2008.
 
13) Rutkowski S, et al : Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352 : 978-986, 2005.
PubMed
14) Pizer BL, Clifford SC : The potential impact of tumour biology on improved clinical practice for medulloblastoma : progress towards biologically driven clinical trials. Br J Neurosurg 23 : 364-375, 2009.
PubMed
15) Polkinghorn WR, Tarbell NJ : Medulloblastoma : tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4 : 295-304, 2007.
PubMed
P.549 掲載の参考文献
1) Louis DN, et al : WHO Classification of Tumours of the Central Nervous System, p 69-80, WHO Press, Geneva, 2007.
 
2) Report of brain tumor registry of Japan (1984-2000), 12th ed. Neurol Med Chir 49 : S1-S96, 2009.
 
3) Pollack IF, et al : Intracranial ependymoma of childhood : long-term outcome and prognostic factors. Neurosurg 37 : 655-666, 1995.
 
4) Shim K-W, et al : The history of ependymoma management. Childs Nerv Syst 25 : 1167-1183, 2009.
PubMed
5) Merchant TE, et al : Conformal radiotherapy after surgery for paediatric ependymoma : a prospective study. Lancet Oncol 10 : 258-266, 2009.
PubMed
6) Little AS, Sheean T : The management of completely resected childhood intracranial ependymoma : the argument for observation only. Childs Nerv Syst 25 : 281-284, 2009.
PubMed
7) Grundy RG, et al : Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children : the UKCCSG/SIOP prospective study. Lancet Oncol 8 : 696-705, 2007.
PubMed
8) Zacharoulis S, et al : Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 49 : 34-40, 2007.
PubMed
9) Grill J, et al : Postoperative Chemotherapy without irradiation for ependymoma in children under 5 years of age : a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 19 : 1288-1296, 2001.
 
10) Conklin HM, et al : Predicting change in academic abilities after conformal radiation therapy for localized ependymoma. J Clin Oncol 26 : 3965-3970, 2008.
PubMed
11) Sangra M, et al. Management strategies for recurrent ependymoma in the paediatric population. Childs Nerv Syst 25 : 1283-1291, 2009.
PubMed
12) MacDonald SM, Yock TI : Proton beam therapy following resection for childhood ependymoma. Childs Nerv Syst 26 : 285-291, 2010.
PubMed
13) Krieger MD, McComb JG : The role of stereotactic radiotherapy in the management of ependymomas. Childs Nerv Syst 25 : 1269-1273, 2009.
PubMed
14) Evans AE, et al : Adjuvant chemotherapy of childhood posterior fossa ependymoma : cranio-spinal, irradiation with or without adjuvant CCNU, vincristine, and prednisone : a Children's Cancer Group study. Med Pediatr Oncol 27 : 8-14, 1996.
PubMed
15) Nicholson HS, et al : Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors : a report from the Children's Oncology Group. Cancer 110 : 1542-1550, 2007.
 
P.554 掲載の参考文献
1) Matsutani M, et al : Primary intracranial germ cell tumors : a clinical analysis of 153 histologically verified cases. J Neurosurg 86 : 446-455, 1997.
 
2) Jennings JL, et al : Intracranial germ-cell tumors : natural history and pathogenesis. J Neurosurg 63 (2) : 155-167, 1985.
 
3) Yamini B, et al : Initial endoscopic management of pineal region tumors and associated hydrocephalus ; clinical series and literature review. J Neurosurg (Pediatrics 5) 100 : 437-441, 2004.
 
4) Romann DD, et al : Neuropsychological effect of cranial radiation : current knowledge and future directions. Int J Radiat Oncol Biol Phys 31 : 983-998, 1995.
 
5) Mishima K, et al : Fluorescence detection of CNS germ cell tumors with 5-aminolevulinic acid. Neuro Oncol 7 : 530, 2005.
 
6) Wellons JC, et al : Neuroendoscopic findings in patients with intracranial germinomas correlating with diabetes insipidus. J Neurosurg (Pediatrics 5) 100 : 430-436, 2004.
 
7) Bamberg M, et al : Radiation therapy for intracranial germinoma : results of the German cooperative prospective trials MAKEI 83/86/89. J Clin Oncol 17 : 2585-2592, 1999.
PubMed
8) Matsutani M : Treatment of intracranial germ cell tumors : the second phase II study of Japanese GCT Study Group. Neuro Oncol 10 : 420, 2008.
 
9) Logothetis CJ, et al : The growing teratoma syndrome. Cancer 50 : 1629-1635, 1982.
PubMed
10) Kato T, et al : Occult neurohypophyseal germinomas in patients presenting with central diabetes insipidus. Neurosurg Focus 5 : 1-6, 1998.
PubMed
11) Sudo A, et al : Uptake on 11C-methionine positron emission tomographic scan of basal ganglia germinoma with cerebral hemiatrophy. AJNR Am J Neuroradiol 24 : 1909-1911, 2003.
PubMed
12) Cho J, et al : Low-dose craniospinal irradiation as a definitive treatment for intracranial germinoma. Radiother Oncol 91 (1) : 75-79, 2009.
PubMed
13) Shikama N, et al : Lack of benefit of spinal irradiation in the primary treatment of intracranial germinoma : a multiinstitutional, retrospective review of 180 patients. Cancer 104 (1) : 126-134, 2005.
PubMed

VII 高齢者脳腫瘍の治療

P.560 掲載の参考文献
1) The Committee of Brain Tumor Registry of Japan : Report of brain tumor registry of Japan (1984-2000), 12th ed. Neurol Med Chir (Tokyo) 49 (Suppl) : 2009.
 
2) 河内正人, 生塩之敬 : 脳腫瘍. 高齢者例の特徴. Clinical Neuroscience 19 : 1034-1036, 2001.
 
3) Godfrey JB, Caird FI : Intracranial tumors in the elderly ; diagnosis and treatment. Age Ageing 13 : 152-158, 1984.
PubMed
4) Kuratsu J, et al : Incidence and clinical features of asymptomatic meningiomas. J Neurosurg 92 : 766-770, 2000.
PubMed
5) Pietila TA, et al : Brain tumor surgery in geriatric patients ; A critical analysis in 44 patients over 80 years. Surg Neurol 52 : 259-264, 1999.
PubMed
6) Laumer R, et al : Intensive therapy of elderly patients in neurosurgery ; Specifics of the postoperative phase in advanced age. Fortschr Med 110 : 241-244, 1992.
PubMed
7) Asano K, et al : Risk factors for postoperative systemic complications in elderly patients with brain tumors. J Neurosurg 111 : 258-264, 2009.
PubMed
8) Keime-Guibert F, et al : Radiotherapy for glioblastoma in the elderly. N Engl J Med 356 : 1527-1535, 2007.
PubMed
9) Stupp R, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005.
PubMed
P.564 掲載の参考文献
1) Curran WJ Jr, et al : Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85 (9) : 704-710, 1993.
PubMed
2) Brandes AA, et al : Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma : correlation with MGMT promoter methylation status. Cancer 115 (15) : 3512-3518, 2009.
PubMed
3) Combs SE, et al : Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys 70 (4) : 987-992, 2008.
PubMed
4) Keime-Guibert F, et al : Radiotherapy for glioblastoma in the elderly. N Engl J Med 356 (15) : 1527-1535, 2007.
PubMed
5) Minniti G, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 88 : 97-103, 2008.
PubMed
6) Minniti G, et al : Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol 91 : 95-100, 2009.
PubMed
7) Roa W, et al : Abbreviated course of radiation therapy in older patients with glioblastoma multiforme : a prospective randomized clinical trial. J Clin Oncol 22 : 1583-1588, 2004.
PubMed
8) Report of brain tumor registry of Japan (1984-2000), 12th edition. Neurol Med Chir (Tokyo) 49 (Suppl), 2009.
 
9) Stupp R, et al : Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on surviva1 in glioblastoma in a randomised phase III study : 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10 (5) : 459-466, 2009.
 
P.569 掲載の参考文献
1) Caroli M, et al : Surgery for intracranial meningiomas in the elderly : a clinical-radiological grading system as a predictor of outcome. J Neurosurg 102 : 290-294, 2005.
PubMed
2) Sacko O, et al : Intracranial meningioma surgery in the ninth decade of life. Neurosurgery 61 : 950-955, 2007.
PubMed
3) Jung HW, et al : Long-term outcome and growth rate of subtotally resected petroclival meningiomas : experience with 38 cases. Neurosurgery 46 (3) : 567-575, 2000.
PubMed
4) Van Havenbergh T, et al : Natural history of petroclival meningiomas. Neurosurgery 52 (1) : 55-64, 2003.
PubMed
5) Takanashi M, et al : Gamma knife radiosurgery for skull-base meningiomas. Prog Neurol Surg 22 : 96-111, 2009.
PubMed
6) Benbow SJ, et al : Pituitary tumours presenting in the elderly : management and outcome. Clin Endocr 46 : 657-660, 1997.
PubMed
7) Hong J, et al : Clinical analysis of 103 elderly patients with pituitary adenomas : transsphenoidal surgery and follow-up. J Clin Neurosci 15 (10) : 1091-1095, 2008.
PubMed
8) Turner HE, et al : Pituitary tumours in the elderly : a 20 year experience. Eur J Endocrinol 140 (5) : 383-389, 1999.
PubMed
9) 中村一仁ほか : 超高齢非機能性下垂体腺腫に対する外科治療 No Shinkei Geka 35 (4) : 371-375, 2007.
 
10) 佐藤篤ほか : 急速な視力視野障害を呈した80歳の頭蓋咽頭腫に対して可及的摘出術と放射線療法が奏効した1例. No Shinkei Geka 33 (12) : 1183-1189, 2005.
 
11) Bakkouri WE, et al : Conservative management of 386 cases of unilateral vestibular schwannoma : tumor growth and consequences for treatment. J Neurosurg 110 (4) : 662-669, 2009.
PubMed
12) Nagano O, et al : Transient expansion of vestibular schwannoma following stereotactic radiosurgery. J Neurosurg 109 (5) : 811-816, 2008.
PubMed
13) Battaglia A, et al : Comparison of growth patterns of acoustic neuromas with and without radiosurgery. Otol Neurotol 27 (5) : 705-712, 2006.
PubMed
14) Ferroli P, et al : Advanced age as a contraindication to microvascular decompression for drug-resistant trigeminal neuralgia : evidence of prejudice. Neurol Sci 31 : 23-28, 2010.
PubMed
15) Amichetti M, et al : Proton therapy in chordoma of the base of the skull : a systematic review. Neurosurg Rev 32 : 403-416, 2009.
PubMed
P.573 掲載の参考文献
1) Kuratsu J, Ushio Y : Epidemiological study of primary intracranial tumours in elderly people. J Neurol Neurosurg Psychiatry 63 : 116-118, 1997.
 
2) Awad IA et al : Intracranial meningiomas in the aged : surgical outcome in the era of computed tomography. Neurosurgery 24 : 557-560, 1989.
PubMed
3) Umansky F, et al : Surgical outcome in an elderly population with intracranial meningioma. J Neurol Neurosurg Psychiatry 55 : 481-485, 1992.
 
4) Gijtenbeek JM, et al : Surgery for intracranial meningiomas in elderly patients. Clin Neurol Neurosurg 95 : 291-295, 1993.
PubMed
5) Black P, et al : Meningioma surgery in the elderly : a case-control study assessing morbidity and mortality. Acta Neurochir 140 : 1013-1016 ; discussion 1016-1017, 1998.
 
6) Buhl R, et al : Results in the operative treatment of elderly patients with intracranial meningioma. Neurosurg Rev 23 : 25-29, 2000.
PubMed
7) D'Andrea G, et al : Thirty-seven cases of intracranial meningiomas in the ninth decade of life : our experience and review of the literature. Neurosurgery 56 : 956-961 ; discussion 956-961, 2005.
 
8) Bateman BT, et al : Meningioma resection in the elderly : nationwide inpatient sample, 1998-2002. Neurosurgery 57 : 866-872 ; discussion 866-872, 2005.
 
9) Sacko O, et al : Intracranial meningioma surgery in the ninth decade of life. Neurosurgery 61 : 950-954 ; discussion 955, 2007.
 
10) Cohen-Inbar O, et al : Meningiomas in the elderly, the surgical benefit and a new scoring system. Acta Neurochir 152 : 87-97 ; discussion 97, 2010.
 
11) Tucha O, et al : Effects of surgery on cognitive functioning of elderly patients with intracranial meningioma. Br J Neurosurg 15 : 184-188, 2001.
PubMed
12) Drummond KJ, et al : Meningiomas : updating basic science, management, and outcome. Neurologist 10 : 113-130, 2004.
PubMed

VIII 転移性脳腫瘍

P.581 掲載の参考文献
1) Schouten LJ, et al : Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94 : 2698-2705, 2002.
 
2) Gavrilovic IT, Posner JB : Brain metastases : epidemiology and pathophysiology. J Neurooncol 75 : 5-14, 2005.
PubMed
3) 国立がん研究センターがん対策情報センター : がんの統計 [http://ganjoho.ncc.go.jp/professional/statics/index.html].
 
4) Weber GF : Molecular mechanisms of metastasis. Cancer Lett 270 : 181-190, 2008.
PubMed
5) Marshall JC, et al : The Nm23-H1 metastasis suppressor as a translational target. Eur J Cancer 46 : 1278-1282, 2010.
PubMed
6) Kitamura T, Taketo MM : Keeping out the bad guys : gateway to cellular target therapy. Cancer Res 67 : 10099-10102, 2007.
PubMed
7) Robinson PD, et al : Methodology used to develop the AANS/CNS management of brain metastases evidence-based clinical practice parameter guidelines. J Neurooncol 96 : 11-16, 2010.
PubMed
8) Gaspar L, et al : Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials, Int J Radiat Oncol Biol Phys 37 : 745-751, 1997.
PubMed
9) Samson DJ, et al : Evidence for management for small cell lung cancer : ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 : 314S-323S, 2007.
PubMed
10) Gaspar LE, et al : The role of whole brain radiation therapy in the management of newly diagnosed brain metastases : a systematic review and evidence-based clinical practice guideline. J Neurooncol 96 : 17-32, 2010.
PubMed
11) Patchel RA, et al : A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322 : 494-500, 1990.
 
12) Vecht CJ, et al : Treatment of single brain metastasis : radiotherapy alone or combined with neurosurgery? Ann Neurol 33 : 583-590, 1993.
 
13) Mintz AH, et al : A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78 : 1470-1476, 1996.
PubMed
14) Patchel RA, et al : Postoperative radiotherapy in the treatment of single metastases to the brain : a randomized tria1. JAMA 280 : 1485-1489, 1998.
 
15) Kalkanis SN, et al : The role of surgical resection in the management of newly diagnosed brain metastases : a systematic review and evidence-based clinical practice guideline. J Neurooncol 96 : 33-43, 2010.
PubMed
16) Muacevic A, et al : Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain : a randomized controlled multicentre phase III trial. J Neurooncol 87 : 299-307, 2008.
 
P.585 掲載の参考文献
1) DeAngelis LM, et al : Radiation-induced dementia in patients cured of brain metastases. Neurology 39 : 789-796, 1989.
PubMed
2) Asai A, et al : Subacute brain atrophy after irradiation therapy for malignant brain tumor. Cancer 63 : 1962-1974, 1989.
PubMed
3) Chang EL, et al : Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation : a randomised controlled trial. Lancet Oncol 10 : 1037-1044, 2009.
 
4) Serizawa T, et al : Gamma knife treatment for multiple metastatic brain tumors compared with whole-brain radiation therapy. J Neurosurg (Suppl 3) 93 : 32-36, 2000.
 
5) Serizawa T, et al : Gamma knife radiosurgery for metastatic brain tumors from lung cancer. Comparison between small cell cancer and non-small cell cancer. J Neurosurg (Suppl 5) 97 : 484-488, 2000.
 
6) Serizawa T, et al : Gamma knife surgery for brain metastases : indications for and limitations of a local treatment protocol. Acta Neurochir (Wien) 147 : 721-726, 2005.
PubMed
7) Serizawa T, et al : Gamma knife surgery for metastatic brain tumors from lung cancer without prophylactic whole brain radiation therapy. In : Radiosurgery (ed by Kondziolka D), p 186-198, Karger, Basel, 2006.
 
8) Serizawa T, et al : Gamma knife surgery for metastatic brain tumor without prophylactic whole brain radiation therapy : results in 1000 consecutive cases. J Neurosurg 105 : 86-90, 2006,
 
9) Serizawa T, et al : Gamma knife surgery for metastatic brain tumors. A 2-institute study in Japan. J Neurosurg 109 : 118-121, 2008.
PubMed
10) Serizawa T : Metastatic brain tumors : lung cancer. In : Japanese Experience with Gamma Knife Radiosurgery (ed by Yamamoto M), p 142-153, Karger, Basel, 2008.
 
11) Yamamoto M, et al : Gamma knife radiosurgery for numerous brain metastases : Is this a safe treatment? Int J Radiat Oncol Biol Phys 53 (5) : 1279-1283, 2002.
 
12) Aoyama H, et al : Stereotactic radiosurgery plus whole brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases : a randomized controlled trial. JAMA 295 (21) : 2483-2491, 2006.
PubMed
13) Higuchi Y, et al : Three-staged stereotactic radiotherapy without whole brain irradiation for large metastatic brain tumors. Int J Radiat Oncol Biol Phys 74 (5) : 1543-1548, 2009.
PubMed
14) Serizawa T, et al : Gamma knife surgery for 1-10 brain metastases without prophylactic wholebrain radiation therapy ; analysis of cases meeting the Japanese prospective multi-institute study (JLGK0901) inclusion criteria. J Neurooncol 98 (2) : 163-167, 2010.
 
P.592 掲載の参考文献
1) Adler JR Jr, et al : Image-guided robotic radiosurgery. Neurosurgery 44 (6) : 1299-1306 ; discussion 1306-1307, 1999.
 
2) Kawachi T, et al : Reference dosimetry condition and beam quality correction factor for CyberKnife beam. Med Phys 35 (10) : 4591-4598, 2008.
PubMed
3) Chang SD, et al : Clinical experience with image-guided robotic radiosurgery (the Cyberknife) in the treatment of brain and spinal cord tumors. Neurol Med Chir (Tokyo) 38 (11) : 780-783, 1998.
PubMed
4) Tuniz F, et al : Multisession cyberknife stereotactic radiosurgery of large, benign cranial base tumors : preliminary study. Neurosurgery 65 (5) : 898-907 ; discussion 907, 2009.
 
5) http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
PubMed
6) Jagannathan J, et al : Stereotactic radiosurgery for pituitary adenomas : a comprehensive review of indications, techniques and long-term results using the Gamma Knife. J Neurooncol 92 (3) : 345-356, 2009.
PubMed
7) degli Uberti EC, et al : Review of Cortina criteria for the diagnosis of acromegaly. J Endocrinol Invest 28 (11 Suppl International) : 70-72, 2005.
 
8) Shih HA, Loeffier JS : Radiation therapy in acromegaly. Rev Endocr Metab Disord 9 (1) : 59-65, 2008.
 
9) Veeravagu A, et al : The role of radiosurgery in the treatment of craniopharyngiomas. Neurosurg Focus 28 (4) : E11, 2010.
PubMed
10) Kano H, et al : Stereotactic radiosurgery for pituitary metastases. Surg Neurol 72 (3) : 248-255 ; discussion 255-256, 2009.
 
P.596 掲載の参考文献
1) 成田善孝 転移性脳腫瘍治療の問題点と手術適応. 脳神経外科ジャーナル 16 (11) : 820-827, 2007.
 
2) NCCN : Central nervous system cancers. In : Clinical Practice Guidelines in Oncology-v.1.2010, 2010. [http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf]
 
3) Andrews DW, et al : Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases : phase III results of the RTOG 9508 randomised trial. Lancet 363 (9422) : 1665-1672, 2004.
 
4) Neuwelt EA : Mechanisms of disease : the blood-brain barrier. Neurosurgery 54 (1) : 131-140, 2004. (discussion 41-42)
 
5) Drappatz J, Wen PY : Chemotherapy and targeted molecular therapies for brain metastases. Expert Rev Neurother 6 (10) : 1465-1479, 2006.
PubMed
6) van den Bent MJ : The role of chemotherapy in brain metastases. Eur J Cancer 39 (15) : 2114-2120, 2003.
PubMed
7) Walbert T, Gilbert MR : The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol 14 (4) : 299-306, 2009.
PubMed
8) Abrey LE, et al : A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53 (3) : 259-265, 2001.
 
9) Christodoulou C, et al : Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12 (2) : 249-254, 2001.
PubMed
10) Giorgio CG, et al : Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer : phase II study. Lung Cancer 50 (2) : 247-254, 2005.
PubMed
11) Clayton AJ, et al : Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91 (4) : 639-643, 2004.
PubMed
12) Shmueli E, et al : Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 40 (3) : 379-382, 2004.
PubMed
13) Lin NU, et al : Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15 (4) : 1452-1459, 2009.
PubMed
14) Sutherland S, et al : Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases-the UK experience. Br J Cancer 102 (6) : 995-1002, 2010.
PubMed
15) Ceresoli GL, et al : Gefitinib in patients with brain metastases from non-small-cell lung cancer : a prospective trial. Ann Oncol 15 (7) : 1042-1047, 2004.
PubMed
16) Chiu CH, et al : Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 47 (1) : 129-138, 2005.
PubMed
17) Porta R, et al : Brain metastases from lung cancer responding to erlotinib : the importance of EGFR mutation. Eur Respir J, 2010.
PubMed
18) Ushio Y, et al : Chemotherapy of brain metastases from lung carcinoma : acontrolled randomized study. Neurosurgery 28 (2) : 201-205, 1991.
 
19) Guerrieri M, et al : A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 46 (1) : 107-111, 2004.
PubMed
20) Antonadou D, et al : Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20 (17) : 3644-3650, 2002.
PubMed
21) Verger E, et al : Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases : a phase II randomized trial. Int J Radiat Oncol Biol Phys 61 (1) : 185-191, 2005.
PubMed
22) Robinet G, et al : Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer : Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 12 (1) : 59-67, 2001.
PubMed
23) Groves MD : New strategies in the management of leptomeningeal metastases. Arch Neurol 67 (3) : 305-312, 2010.
PubMed
24) Hitchins RN, et al : A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5 (10) : 1655-1662, 1987.
PubMed
25) Boogerd W, et al : Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 67 (6) : 1685-1695, 1991.
PubMed
26) Sandberg DI, et al : Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47 (1) : 49-54, 2000. (discussion 54-55)
 
27) Boogerd W, et al : The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer : a randomised study. Eur J Cancer 40 (18) : 2726-2733, 2004.
PubMed
28) Jackman DM, et al : Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24 (27) : 4517-4520, 2006.
 
29) Clarke JL, et al : High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99 (2) : 283-286, 2010.
PubMed
30) Ferrario C, et al : Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol 20 (4) : 792-795, 2009.
PubMed
31) Mir O, et al : High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 19 (11) : 1978-1980, 2008.
 
32) Glantz MJ, et al : A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5 (11) : 3394-3402, 1999.
PubMed
33) Glantz MJ, et al : Practice parameter : anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54 (10) : 1886-1893, 2000.
PubMed
34) Filley CM, Kleinschmidt-DeMasters BK : Toxic leukoencephalopathy. N Engl J Med 345 (6) : 425-432, 2001.
PubMed
35) 日本神経学会マニュアル作成委員会 : 白質脳症重篤副作用疾患別対応マニュアル, 2006. [http://www.mhlw.go.jp/topics/2006/11/tp1122-1c.html]
 
P.602 掲載の参考文献
1) Chamberlain MC : Neoplastic meningitis. Neurologist 12 : 179-187, 2006.
PubMed
2) Kesari S, Batchelor TT : Leptomeningeal metastases. Neurol Clin North Am 21 : 25-66, 2003.
 
3) Glantz MJ, et al : Cerebrospinal fluid cytology in patients with cancer : minimizing false-negative results. Cancer 82 : 733-739, 1998.
PubMed
4) Chamberlain MC, et al : A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro Oncol 3 : 42-45, 2001.
PubMed
5) Chamberlain MC, Junk L : Defining patients at risk for neoplastic meningitis : what parameters can be used to determine who should be treated? Expert Rev Neurother 4 (Suppl 4) : S3-10, 2004.
 
6) Freiberg MH, et al : Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 82 : 923-930, 1998.
 
7) Nagai A, et al : Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with Ieptomeningeal metastasis. Clin Chim Acta 329 : 53-60, 2003.
 
8) Stockhammer G, et al : Vascular endothelial growth factor in CSF : a biological marker for carcinomatous meningitis. Neurology 54 : 1670-1676, 2000.
PubMed
9) Groves MD, et al : A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 10 : 208-215, 2008.
PubMed
10) Lin NU, et al : Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15 : 1452-1459, 2009.
PubMed
11) Shapiro WR, et al : Treatment modalities for leptomeningeal metastases. Semin Oncol 36 (Suppl 2) : S46-54, 2009.
 
12) Strong JM, et al : Pharmacokinetics of intraventricular and intravenous N, N', N"-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res 46 : 6101-6104, 1986.
 
13) Grossman SA, et al : Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11 : 561-569, 1993.
 
14) Platini C, et al : Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 7 : 778-780, 2006.
PubMed

IX 多施設共同試験

P.608 掲載の参考文献
1) Cairncross JG, et al : Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90 : 1473-1479, 1998.
PubMed
2) Stupp R, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005.
PubMed
3) Takakura K, et al : Effect of ACNU and radiotherapy on malignant glioma. J Neurosurg 64 : 53-57, 1986.
PubMed
4) 永井政勝ほか : 悪性脳腫瘍に対するBRM療法の進歩. 癌と化学療法 18 : 188-194, 1991.
Medical*Online
5) Stewart LA, et al : Chemotherapy in adult high-grade glioma : asystematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 : 1011-1018, 2002.
 
6) Wick W, et al : NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27 : 5874-5880, 2009.
 
P.615 掲載の参考文献
1) Hegi ME, et al : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005.
PubMed
2) Friedman HS, et al : Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst 84 : 1926-1931, 1992.
PubMed
3) van den Bent MJ, et al : Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma : EORTC brain tumor group study 26034. J Clin Oncol 27 : 1268-1274, 2009.
PubMed
4) Vredenburgh JJ, et al : Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25 : 4722-4729, 2007.
PubMed
5) Friedman HS, et al : Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27 : 4733-4740, 2009.
PubMed
6) Raymond E, et al : Phase II study of imatinib in patients with recurrent gliomas of various histologies : a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 26 : 4659-4665, 2008.
 
7) Reardon DA, et al : Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 101 : 1995-2004, 2009.
PubMed
8) Galanis E, et al : Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme : a North Central Cancer Treatment Group Study. J Clin Oncol 23 : 5294-5304, 2005.
 
9) Lustig R, et al : Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol 10 : 1004-1009, 2008.
PubMed
10) Westphal M, et al : A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5 : 79-88, 2003.
 
11) Yamanaka R, et al : Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma : results of a clinical phase I/II trial. Clin Cancer Res 11 : 4160-4167, 2005.
PubMed
12) Sampson JH, et al : An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 8 : 2773-2779, 2009.
PubMed
13) Perry JR, et al : Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma : RESCUE study. J Clin Oncol 28 : 2051-2057, 2010.
PubMed
P.626 掲載の参考文献
1) 佐々木光ほか : 神経膠腫における遺伝子診断と個別化治療. 脳神経外科 36 : 355-369, 2008.
 
2) The committee of brain tumor registry of Japan : Report of brain tumor registry of Japan (1984-2000), 12th ed. Neurol Med Chir (Tokyo) 49 (Suppl) : 2009.
 
3) Cairncross JG, et al : Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma : Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24 : 2707-2714, 2006.
 
4) van den Bent MJ, et al : Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas : a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol 24 : 2715-2722, 2006.
 
5) Wick W, et al : NOA-04 randomised phase III trial of sequential radiochemotherapy of anaplastic gliomas with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27 : 5874-5880, 2009.
PubMed
6) http://www.nccn.org/
 
7) Abrey LE, et al : Oligodendroglioma Study Group : Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 9 : 314-318, 2007.
 
8) 佐々木光ほか : 神経膠腫の遺伝子診断に基づくテーラーメイド治療. 脳神経外科速報 20 : 66-71, 2010.
 
9) van den Bent MJ, et al : MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors : A report from EORTC brain tumor group study 26951. J Clin Oncol 27 : 5881-5886, 2009.
 
10) van den Bent MJ, et al : IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors : A report of the EORTC brain tumor group. Clin Cancer Res 16 : 1597-1604, 2010.
 
11) Brandes AA, et al : Survival following adjuvant PCV or temozolomide for anaplastic astrocytomas. Neuro Oncol 8 : 253-260, 2006.
PubMed
12) Vogelbaum MA, et al : Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas : RTOG BR0131. Neuro Oncol 11 : 167-175, 2009.
PubMed
13) Stupp R, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005.
PubMed
14) 山本精一郎 : 統計家から臨床医へのメッセージ. Lesson 5 個別化治療の研究デザイン. Respirar 5 : 12-14, 2006 (株式会社協和企画/提供 : 大鵬薬品工業株式会社).
 
15) Dubbink HJ, et al : IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73 : 1792-1795, 2009.
PubMed
16) Mason WP, Cairncross JG : The expanding impact of molecular biology on the diagnosis and treatment of gliomas. Neurology 71 : 365-373, 2008.
PubMed
17) Ino Y, et al : Molecular subtypes of anaplastic oligodendrogliomas : implications for patient management at diagnosis. Clin Cancer Res 7 : 839-845, 2001.
PubMed
18) Kaloshi G, et al : Temozolomide for low-grade gliomas. Neurology 68 : 1831-1836, 2007.
PubMed
19) Hegi ME, et al : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005.
PubMed
20) Weller M, et al : MGMT promoter methylation in malignant gliomas : ready for personalized medicine? Nat Rev Neurol 6 : 39-51, 2010.
PubMed
P.633 掲載の参考文献
1) Brada M, et al : Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14 : 1715-1721, 2003.
PubMed
2) Buckner JC, et al : Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma : efflcacy and associations with chromosomal abnormalities. J Clin Oncol 21 : 251-255, 2003.
PubMed
3) Cairncross JG, Macdonald DR : Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23 : 360-364, 1988.
PubMed
4) Douw L, et al : Cognitive and radiological effects of radiotherapy in patients with low-grade glioma : long-term follow-up. Lancet Neurol 8 : 810-818, 2009.
PubMed
5) Dubbink HJ, et al : IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73 : 1792-1795, 2009.
PubMed
6) Duffau H : Awake surgery for nonlanguage mapping. Neurosurgery 66 : 523-528 ; discussion 528-529, 2010.
 
7) Eyre HJ, et al : A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas : a Southwest Oncology Group study. J Neurosurg 78 : 909-914, 1993.
 
8) Jackson RJ, et al : Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 3 : 193-200, 2001.
PubMed
9) Kaloshi G, et al : Temozolomide for low-grade gliomas : predictive impact of 1p/19q loss on response and outcome. Neurology 68 : 1831-1836, 2007.
PubMed
10) Karim AB, et al : A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma : European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36 : 549-556, 1996.
PubMed
11) Levin N, et al : Progressive low-grade oligodendrogliomas : response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106 : 1759-1765, 2006.
PubMed
12) Louis DN ; International Agency for Research on Cancer : World Health Organization : WHO Classification of Tumours of the Central Nervous System, International Agency for Research on Cancer, Lyon, 2007.
PubMed
13) Mason WP, et al : Low-grade oligodendroglioma responds to chemotherapy. Neurology 46 : 203-207, 1996.
PubMed
14) Pace A, et al : Temozolomide chemotherapy for progressive low-grade glioma : clinical benefits and radiological response. Ann Oncol 14 : 1722-1726, 2003.
PubMed
15) Pignatti F, et al : Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20 : 2076-2084, 2002.
PubMed
16) Pouratian N, et al : Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol 82 : 281-288, 2007.
PubMed
17) Pouratian N, Schiff D : Management of low-grade glioma. Curr Neurol Neurosci Rep 10 : 224-231, 2010.
PubMed
18) Ricard D, et al : Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 61 : 484-490, 2007.
PubMed
19) Shaw E, et al : Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma : initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20 : 2267-2276, 2002.
 
20) Shaw EG, et al : Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802 : Radiation therapy (RT) versus RT+ procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). J Clin Oncol 26 (Suppl) : 2006, 2008.
 
21) Smith JS, et al : Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26 : 1338-1345, 2008.
 
22) Smith JS, et al : Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18 : 636-645, 2000.
PubMed
23) Stege EM, et al : Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103 : 802-809, 2005.
PubMed
24) van den Bent MJ, et al : Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults : the EORTC 22845 randomised triaL Lancet 366 : 985-990, 2005.
PubMed
25) van den Bent MJ, et al : Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy : EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14 : 599-602, 2003.
PubMed
26) van den Bent MJ, et al : Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors : the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21 : 2525-2528, 2003.
 
27) Arakawa Y, et al : The role of radical resection for low-grade glioma. A view from biological nature. Brain Tumor Surgery 12 : 15-21, メディカ出版, 2008.
 
P.639 掲載の参考文献
1) Evans AE, et al : The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 75 : 572-582, 1990.
 
2) Tait DM, et al : Adjuvant chemotherapy for medulloblastoma : the first multi-center control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 26 : 464-469, 1990.
 
3) Bailley CC, et al : Prospective randomized trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the German Society of Paediatric Oncology (GPO) : SIOP II. Med Pediatr Oncol 25 : 166-178, 1995.
 
4) Thomas PR, et al : Low-stage medulloblastoma : final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 18 : 3004-3011, 2000.
PubMed
5) Kuhl J, et al : Preradiation chemotherapy of children and young adults with malignant brain tumors : results of the German pilot trial HIT '88/'89. Klin Padiatr 210 : 227-233, 1998.
 
6) Packer RJ, et al : Treatment of children with medulloblastomas with reduced-dose craniospinal radiation and adjuvant chemotherapy : AChildren's Cancer Group Study. J Clin Oncol 17 : 2127-2136, 1999.
 
7) Kortmann RD, et al : Postoperative neo-adjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood : results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46 : 269-279, 2000.
 
8) Taylor RE, et al : Results of a randomized study of pre-radiation chemotherapy (carboplatin, vincristine, cyclophosphamide, etoposide) with radiotherapy alone in Chang stage M0/M1 medulloblastoma (SIOP/UKCCSG PNET-3). Med Pediatr Oncol 37 : 191, 2001.
 
9) Packer RJ, et al : Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24 : 4202-4208, 2006.
PubMed
10) Gajjar A, et al : Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96) : long-term results from a prospective, multicentre trial. Lancet Oncol 7 : 813-820, 2006.
PubMed
11) Wolff JE, et al : Resection not so important after all? Analysis of the choroid plexus tumor SIOP study. Neuro Oncol 12 : ii49, 2010.
 
P.645 掲載の参考文献
1) Ferreri AJ, et al : Prognostic scoring system for primary CNS lymphomas : the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21 : 266-272, 2003.
 
2) Abrey LE, et al : Primary central nervous system lymphoma : the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24 : 5711-5715, 2006.
 
3) Hayakawa T, et al : Primary central nervous system lymphoma in Japan-a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan. J Neurooncol 19 : 197-215, 1994.
 
4) Nelson DF, et al : Non-Hodgkin's lymphoma of the brain : can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG) : RTOG 8315. Int J Radiat Oncol Biol Phys 23 : 9-17, 1992.
PubMed
5) Schultz C, et al : Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas : initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 14 : 556-564, 1996.
PubMed
6) Mead GM, et al : A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma : cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 89 : 1359-1370, 2000.
PubMed
7) O'Brien P, et al : Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18 : 519-526, 2000.
 
8) DeAngelis LM, et al : Combination chemotherapy and radiotherapy for primary central nervous system lymphoma : Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20 : 4643-4648, 2002.
 
9) Poortmans PM, et al : High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma : European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21 : 4483-4488, 2003.
PubMed
10) Ferreri AJ, et al : High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma : a randomised phase 2 trial. Lancet 374 : 1512-1520, 2009.
PubMed
11) Batchelor T, et al : Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy : a report of NABTT 96-07. J Clin Oncol 21 : 1044-1049, 2003.
PubMed
12) Hoang-Xuan K, et al : Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years : a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21 : 2726-2731, 2003.
 
13) Pels H, et al : Primary central nervous system lymphoma : results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21 : 4489-4495, 2003.
PubMed
14) Angelov L, et al : Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma : a multi-institutional experience. J Clin Oncol 27 : 3503-3509, 2009.
PubMed
15) Shah GD, et al : Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25 : 4730-4735, 2007.
PubMed
P.649 掲載の参考文献
1) Patchell RA, et al : A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322 (8) : 494-500, 1990.
 
2) Vecht CJ, et al : Treatment of single brain metastasis : radiotherapy alone or combined with neurosurgery? Ann Neurol 33 : 583-590, 1993.
 
3) Patchell RA, et al : Postoperative radiotherapy in the treatment of single brain metastases to the brain. JAMA 280 : 1485-1489, 1998.
 
4) O'Neill BP, et al : A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys 55 : 1169-1176, 2003.
 
5) Rades D, et al : Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1-3 brain metastases : results of a matched pair analysis. Eur J Cancer 45 (3) : 400-404, 2009.
PubMed
6) Andrews DW, et al : Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases : phase III results of the RrOG9508 randomised trial. Lancet 363 : 1665-1672, 2004.
 
7) Aoyama H, et al : Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases. A randomized controlled trial. JAMA 295 (21) : 2483-2491, 2006.
PubMed
8) Aoyama H, et al : Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 68 (5) : 1388-1395, 2007.
PubMed
9) Chang EL, et al : Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation : a randomised controlled trial. Lancet Oncol 10 (11) : 1037-1044, 2009.
PubMed

X 特論

P.656 掲載の参考文献
1) 鈴木匡子 : 高次脳機能障害の診方. 臨床神経学 49 : 83-89, 2009.
 
2) 鈴木匡子 : 言語優位半球の決定法. 神経研究の進歩 47 : 771-780, 2003.
 
3) Gaillard WD, et al : fMRI language task panel improves determination of language dominance. Neurology 63 : 1403-1408, 2004.
PubMed
4) Seghier ML : Laterality index in functional MRI : methodological issues, Magn Reson Imaging 26 : 594-601, 2008.
PubMed
5) Hirata M, et al : Language dominance and mapping based on neuromagnetic oscillatory changes : comparison with invasive procedures. J Neurosurg 112 : 528-538, 2010.
PubMed
6) 鈴木匡子 : 大脳皮質刺激によるマッピング. Annual Review 2009 神経 (柳澤信夫ほか編), p35-41, 中外医学社, 2009.
 
7) Taylor MD, Bernstein M : Awake craniotomy with brain mapping as the routine surgical approach to treating patients with supratentorial intraaxial tumors : a prospective trial of 200 cases. J Neurosurg 90 : 35-41, 1999.
 
8) Whittle IR, et al : Brain dysfunction following 'awake' craniotomy, brain mapping and resection of glioma. Br J Neurosurg 17 : 130-137, 2003.
PubMed
9) Duffau H, et al : Usefulness of intraoperative electrical subcortical mapping during surgery for low-grade gliomas located within eloquent brain regions : functional results in a consecutive series of 103 patients. J Neurosurg 98 : 764-778, 2003.
 
10) Brell M, et al : Factors influencing surgical complications of intra-axial brain tumours. Acta Neurochir (Wien) 142 : 739-750, 2000.
PubMed
11) Sawaya R, et al : Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42 : 1044-1055, 1998.
 
12) Duffau H, et al : Contribution of intraoperative electrical stimulations in surgery of low grade gliomas : a comparative study between two series without (1985-96) and with (1996-2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry 76 : 845-851, 2005.
 
P.660 掲載の参考文献
1) Gruney JG, et al : Social outcomes in the Childhood Cancer Survivor Study cohort. J Clin Oncol 27 : 2390-2395, 2009.
 
2) Zeltzer LK, et al : Psychological status in childhood cancer survivors : a report from the Childhood Cancer Survivor Study. J Clin Oncol 27 : 2396-2404, 2009.
PubMed
3) 石田也寸志 : 小児脳腫瘍の晩期障害. 日小児会誌 108 : 368-379, 2004.
 
4) Sugiyama K, et al : Quality of life of extremely long-time germinoma survivors mainly treated with radiotherapy. Prog Neurol Surg 23 : 130-139, 2009.
PubMed
5) de Boer AGEM, et al : Adult survivors of childhood cancer and unemployment. Cancer 107 : 1-11, 2006.
 
6) Bull KS, et al : Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma : a follow-up study in PNET 3 trial survivors on behalf of the CCLG (formerly UKCCSG). J Clin Oncol 25 : 4239-4245, 2007.
 
7) Katz ER, et al : Health-related quality of life. In : Cancer in Adolescents and Young Adults (ed by Bleyer WA, Barr WD), p 387-400, Springer, Berlin, 2007.
 
8) 福原俊一 : いまなぜQOLか-患者立脚型アウトカムとしての位置づけ. 臨床のためのQOL評価ハンドブック (池上直己ほか編), p2-7, 医学書院, 2001.
 
9) Kennedy C, Glaser A : Quality of survival. In : Brain and Spinal Tumors of Childhood (ed by Walker DA, et al), p 493-514, Oxford University Press, CA, 2004.
 
10) Kobayashi K, Kamibeppu K : Measuring quality of life in Japanese children : Development of the Japanese version of PedsQL(TM). Pediatr Int 52 : 80-88, 2010.
 
11) Sato I, et al : Development of the Japanese version of Pediatric Quality of Life Inventory Brain Tumor Module. Health Qual Life Outcomes 8 : 38, 2010.
PubMed
12) Fukuhara S, et al : Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 51 : 1037-1044, 1998.
PubMed
13) Kobayashi K, et al : A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C 30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 34 : 810-815, 1998.
 
14) Osoba D, et al : The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5 : 139-150, 1996.
PubMed
P.665 掲載の参考文献
1) Uchitomi Y, Yamawaki S : Truth-telling practice in cancer care in Japan. Ann N Y Acad Sci 809 : 290-299, 1997.
PubMed
2) Horikawa N, et al : Changes in disclosure of information to cancer patients in a general hospital in Japan. Gen Hosp Psychiatry 22 (1) : 37-42, 2000.
 
3) 内田幹人ほか : 悪性脳腫瘍の告知に関する, 患者家族へのアンケート調査. 山梨医学 33 : 32-35, 2005.
 
4) 成田善孝ほか : 悪性神経膠腫患者に対する告知・終末期医療の現状報告 -日本脳腫瘍学会会員へのアンケート調査報告-. 脳神経外科 37 (10) : 973-981, 2009.
 
5) Oken D : What to tell cancer patients. A study of medical attitudes. JAMA 175 (13) : 1120-1128, 1961.
 
6) Novack DH, et al : Changes in physician's attitude toward telling the cancer patient. JAMA 241 : 897-900, 1979.
 
7) 星野一正 : 医療の倫理, 岩波書店, 1991.
 
8) Sullivan RJ, et al : Truth-telling and patient diagnoses. J Med Ethics 27 (3) : 192-197, 2001.
PubMed
9) Davies E, Higgison U : Communication, information and support for adults with malignant cerebral glioma : a systematic literature review. Support Care Cancer 11 (1) : 21-29, 2003.
 
10) Davies E, et al : Malignant cerebral glioma-II : Perspectives of patients and relatives on the value of radiotherapy. BMJ 313 (7071) : 1512-1516, 1996.
PubMed
11) Salander P, et al : The creation of protection and hope in patients with malignant brain tumours. Soc Sci Med 42 (7) : 985-996, 1996.
PubMed
12) Giovagnoli AR : Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumour. J Neurol Neurosurg Psychiatry 67 (3) : 358-363, 1999.
PubMed
13) Anderson SI, et al : Mood disorders in patients after treatment for primary intracranial tumours. Br J Neurosurg 13 (5) : 480-485, 1999.
PubMed
14) Davies E, Bannon M : Opportunities for improving the quality of care in malignant cerebral glioma. J Neurol Neurosurg Psychiatry 66 (5) : 693, 1999.
PubMed
P.670 掲載の参考文献
1) 内冨庸介ほか : サイコオンコロジー. リエゾン精神医学とその治療学 (山脇成人編), p51-106, 中山書店, 2009.
 
2) 明智龍男 : サイコオンコロジー. 現代医学 53 : 59-65, 2005.
Medical*Online
3) 清水研ほか : 悪性腫瘍とうつ病. 成人病と生活習慣病 36 : 268-272, 2006.
 
4) 保坂隆ほか : 癌患者にみられる代表的な精神症状とその対策. コンセンサス癌治療 (岩井壽夫編), p8-19, へるす出版, 2008.
 
5) Poggi G, et al : Brain tumors in children and adolescents : cognitive and psycological disorders at different ages. Psychooncology 14 : 386-395, 2005.
 
6) Wellisch D, et al : Predicting major depression in brain tumor patients. Psychooncology 11 : 230-238, 2002.
PubMed
7) Weitzner MA, Meyers CA : Cognitive functioning and quality of life in malignant glioma patients : a review of the literature. Psychooncology 6 : 169-177, 1997.
PubMed
8) 嶋本正弥ほか : がんとうつ. 心療内科 9 : 391-395, 2005.
 
9) Akizuki N, et al : Development of an Impact Thermometer for use in combination with the Distress Thermometer as a brief screening tool for adjustment disorders and/or major depression in cancer patients. J Pain Symptom Manage 29 : 91-99, 2005.
PubMed
10) 岡村仁 : 精神症状とリハビリテーション. MB Med Reha 60 : 23-28, 2005.
 
11) 大田哲生 : 脳腫瘍, 脳転移. 癌のリハビリテーション (辻哲也ほか編), p82-93, 金原出版, 2006.
 

書評

最近チェックした商品履歴

Loading...